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Abstract 
 
clear cell Renal Cell Carcinoma (ccRCC) is the most prevalent subtype of Kidney 
Cancer and is the eighth most common cancer in the United Kingdom. Historically, 
the disease has been characterised by the biallelic loss of VHL gene and loss-of-
heterozygosity of chromosome 3p. Inactivation of the VHL gene leads to 
constitutive up-regulation of the HIF family of transcription factors, thereby leading 
to a hypoxia response transcription signature. Recent studies have led to the 
identification of recurrent mutations in genes involved in chromatin remodelling and 
histone methylation. Increasing evidence has also been presented to show genetic 
intratumour heterogeneity (ITH) for this disease. These observations have led to 
important questions regarding disease etiology and the impact of ITH on disease 
biology as well as prognosis. This thesis investigates high throughput “omics” 
datasets and a comprehensive integrative analysis is performed of the genetic 
changes and transcriptome expression levels for ccRCC. Computational methods 
ranging from survival statistics, analyses of co-alteration and mutual exclusivity 
patterns for genetic alterations, gene expression analyses, to network algorithms 
have been used as part of this work to elucidate both ccRCC biology and pathology. 
To validate biomarkers, which could provide independent prognostic information in 
the clinic, published ccRCC prognostic biomarkers are investigated in an 
independent patient cohort published by the Cancer Genome Atlas (TCGA). The 
ITH of the most promising marker is then investigated in a multiregion biopsy 
dataset to guide biomarker optimisation. Furthermore, the functional consequences 
of cancer gene mutations as well as copy number events are interpreted by 
integrating them with gene expression data and by employing state of the art 
computational network algorithms. 
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Chapter 1. Introduction 
The past few decades have witnessed some of the largest advances in diagnosing, 
understanding and thereby treating complex diseases. With the increasing average 
age of the population, the rate of incidence of diseases such as Alzheimer’s and 
cancer have risen dramatically; however, there have been corresponding 
improvements in patient care and treatment. Combined with this is the advent of 
newer technologies such as next generation sequencing (NGS), including DNA and 
RNA sequencing, which facilitate an improved measure of such diseases at various 
levels. Computational methods have further enabled analyses of this dearth of data. 
Through the work presented in this thesis, I have attempted to unravel the 
biological mechanisms underlying clear cell Renal Cell Carcinoma (ccRCC) and 
underpin important prognostic markers for this cancer. In this chapter, a 
background of ccRCC, both in terms of biology and prognosis, as well as an 
introduction to the analytical methods used for this study are presented.  
 
1.1 A thesis justified 
1.1.1 Cancer and its hallmarks 
Cancer is a complex multifaceted disease characterised essentially by eight 
properties, namely: sustaining proliferative signalling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, 
activating invasion and metastasis, reprogramming of energy metabolism and 
evading immune destruction. Together the above properties are commonly known 
Chapter 1 Introduction 
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as the hallmarks of cancer (Hanahan and Weinberg, Hanahan and Weinberg). 
Although monoclonal in origin, cancers acquire numerous genetic and epigenetic 
changes facilitated by a background of genomic instability (Burrell et al.). Such 
changes are acquired both at onset as well as throughout the development of the 
disease and thus lead to the evolution of the cancer cell in a manner similar to 
Darwinian evolution.  
 
Decades of research have enabled the characterisation of mutations in several 
genes, which are central in causing and progressing cancer (‘Cancer Genes’), and 
the pathways through which these genes may act. However, since cancer can be 
considered to be a consequence of malfunctions within complex cellular systems, 
our understanding of the disease is by no means complete (Hornberg et al.). 
Through recent advances in DNA sequencing technologies, knowledge of the 
genetic alterations in cancer is accumulating rapidly allowing the descriptive 
analysis of cancer genomes at unprecedented speeds and at nucleotide resolution. 
This has led to the discovery of multiple new cancer genes, which are recurrently 
mutated (Dalgliesh et al., Varela et al., Wood et al., The Cancer Genome Atlas 
Research Network, International Cancer Genome et al.) 
 
However, a typical solid tumour harbours tens to hundreds of non-synonymous 
somatic mutations, and it is now apparent that this mutational landscape is highly 
heterogeneous. This heterogeneity is characterized by only a few commonly 
mutated genes in each cancer type, which have been referred to as ‘mountains’ on 
the mutational landscape, and a much larger number of infrequently mutated genes 
or ‘hills’, which are only found in a small percentage of tumours of a particular type 
(Wood et al.). Furthermore, there are multiple levels of heterogeneity; inter-patient, 
intra-patient and intratumour. Inter-patient heterogeneity exists at the level where 
even within cancer of the same type, patients exhibit differences in terms of both 
biology and prognosis, for example, in breast cancer, based on gene expression, 
patients can be classified into at least four broad subtypes, namely basal (triple 
negative breast cancer (TNBC)), HER2+, and luminal A and B subtypes.  Luminal 
A and B are estrogen positive cancers, with luminal A having the best prognosis. 
True to its name, HER2+ has overexpression of the HER2 growth enhancing 
protein. These are slow growing tumours and respond well to treatment. The Basal 
Chapter 1 Introduction 
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or TNBC subtype is triple negative for estrogen, progestin receptors and HER2. 
This is the most aggressive subtype, and is unresponsive to treatment. Extending 
on this, intra-patient heterogeneity is explained by the differences in the primary 
and the metastatic tumour sites; these include morphological and genetic 
differences, and differences in terms of tumour aggressiveness and proliferation. 
Intratumour heterogeneity is then explained by difference between regions within 
the same tumour mass (Gerlinger et al., Gerlinger et al.) (Figure 1.1).  
 
 
 
Figure 1.1: The different levels of tumour heterogeneity 
This figure depicts tumour heterogeneity at different levels. At the top level, 
phenotypic and genotypic diversity between patients within the same cancer type is 
referred to as Intertumour or Inter-patient heterogeneity in the population. Within 
the same patient, we can observe heterogeneity between tumours from different 
sites, example primary and metastatic sites, which is referred to as Intra-patient 
heterogeneity and ultimately heterogeneity can be seen at the intratumour level. 
Multiple sites within the same tumour biopsy can show variations both at the 
genetic and non-genetic levels. Figure modified with permission from ((Burrell et 
al.), Nature Publishing Group). 
 
 
Although the existence of high levels of intra-tumour heterogeneity now appears to 
be well established, little is known as to the exact advantages this provides 
tumours (Stratton). However, it is postulated that heterogeneous mutations may 
provide tumour cells with specific advantages. Such advantages at the cellular level 
may increase the fitness of tumours under specific environmental conditions, 
leading to cancer progression, drug resistance and eventually patient death. The 
Chapter 1 Introduction 
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big question facing the research community is how can the high volume of primary 
information, collected at both the genetic and phenotypic levels, be integrated to 
help cancer patients? 
 
To an extent, recent developments in the high-throughput technologies have 
lessened the difficulties in monitoring the systemic changes occurring during 
cancer cell progression. Computational algorithms have become indispensable for 
the integration of different types of ‘omics’ datasets, such as sequencing, mRNA 
expression and protein interaction data. Moreover, since cellular systems are 
perturbed both during the onset and development of cancer, and the behavioural 
change of tumour cells usually involves a broad range of dynamic variations, 
computational approaches developed for network analysis are becoming especially 
useful for providing insights into the mechanism behind tumour development and 
metastasis. These ideas are embodied in this work. 
 
1.1.2 clear cell Renal Cell Carcinoma  
Renal Cell Carcinoma is by far the most common form of kidney cancer, with about 
9 in 10 cases of kidney cancer being renal cell carcinoma (Motzer et al.). It is 
comprised of a set of different histologies, out of which the clear cell subtype 
(ccRCC) is most prevalent (60%-80%), followed by papillary and chromophobe 
subtypes (Kovacs et al., Thoenes et al.). Characteristically, ccRCCs are defined as 
cancer cells with clear cytoplasms and nested clusters of cells surrounded by 
dense endothelial networks (Jonasch et al.).  ccRCC is one of the 10 most common 
cancers in both men and women (Rini and Atkins).  ccRCC incidence has 
increased progressively in the past 30 years (Figure 1.2), which could be in part 
attributed to development in diagnostic techniques; however, there has been little 
corresponding improvement in survival (Brannon et al.). As yet, surgery for 
localised disease is the only curative therapy. Treatment of metastatic disease is 
even more challenging; with 5-year survival rates for patients with metastatic 
disease being less than 10% (Motzer et al.).  
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Figure 1.2: ccRCC incidence and mortality within the UK 
Graphs depicting the incidence and mortality rates for ccRCC, during the 1970’s-
2012 in the UK for both males and females. Data presented by Cancer Research 
UK and adapted from the CRUK website.  
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Historically, ccRCC has been characterised by biallelic inactivation of the von 
Hippel Landau (VHL) gene, which can be found in approximately 85% of ccRCCs 
(An and Rettig). VHL is located on chromosome 3p25 and its biallelic inactivation 
occurs via loss of chromosome 3p along with either somatic mutations in the VHL 
gene or promoter hypermethylation (An and Rettig, Gossage et al.). Inactivation of 
the VHL gene leads to stabilisation of the hypoxia response pathway, which in turn 
leads to increased levels of tumour angiogenesis. Recent work has also shown the 
inactivation of other tumour suppressor genes such as PBRM1, SETD2, KDM5C 
and BAP1 (Dalgliesh et al., Guo et al., van Haaften et al., Varela et al., The Cancer 
Genome Atlas Research Network, Sato et al., Scelo et al.). Intriguingly all these 
genes function as histone and/or chromatin modifiers. Thus ccRCC seems to be a 
metabolically and epigenetically controlled cancer (The Cancer Genome Atlas 
Research Network). In addition to the loss of chromosome 3p, other aberrations 
have also been reported as recurrent events in ccRCC (Klatte et al., Kroeger et al., 
Gunawan et al.): gains of 5q (Gunawan et al.), 8q (Klatte et al., Monzon et al.), 12 
(Elfving et al.) and losses of 8p (Elfving et al.), 9p (Sanjmyatav et al., Klatte et al., 
La Rochelle et al., Moch et al., Brunelli et al.) and 14q (Kroeger et al., Monzon et 
al.). Moreover, along with this inter-patient heterogeneity, recent work has shown 
substantial genetic intratumour heterogeneity in ccRCC through exome sequencing 
of several regions from the same tumour as well as somatic copy number 
alterations (SCNAs) profiling (Gerlinger et al., Gerlinger et al., Martinez et al.); all of 
which is likely to influence clinical outcome, and provides a possible explanation for 
the slow progress in development of effective therapies for ccRCC.  
 
To summarise, much work has been done on studying ccRCC in terms of 
sequencing (Dalgliesh et al., Guo et al., van Haaften et al., Varela et al., The 
Cancer Genome Atlas Research Network, Sato et al., Scelo et al.), copy number 
analysis (Beroukhim et al.), analysing gene expression data to classify patients into 
different subgroups (Brannon et al., Zhao et al., Beleut et al.) and studying patient 
biology and survival patterns amongst patients (Jones et al., Vasselli et al., Zhao et 
al., Zhao et al.). This has led to the identification of key genetic events; however 
their biological effects and their impact on cancer cell fitness are largely unknown 
(with the exception perhaps of the VHL gene). Although incremental work over the 
past two decades has increased our knowledge of the disease, there is still the 
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need to understand the mechanisms that not only lead to induction of the cancer 
but also allow it to proliferate and resist treatment. The implications of previous 
findings are further limited due to the extensive amounts of both inter-patient and 
intratumour heterogeneity.  These observations mandate further research in the 
field of ccRCC biology. Large-scale tumour profiling efforts from the Cancer 
Genome Atlas (TCGA, (The Cancer Genome Atlas Research Network)) and 
International Cancer Genome Consortium (ICGC (International Cancer Genome et 
al.)), have made it possible to analyse larger cohorts of patients and unravel 
tumour mechanisms. A detailed analysis of ccRCC dataset profiled by the TCGA 
forms the base of the work presented here. 
 
In this thesis, the aim is to present a comprehensive and integrated molecular 
analyses, analysing somatic mutation, copy number alteration as well as 
transcriptomics data, to shed light on key driver events for cancer progression and 
evolution, find prognostic biomarkers and elucidate biological mechanisms 
underlying ccRCC by interpreting the analyses of TCGA dataset. Moreover, the 
conclusions drawn from this cohort are related to an in-house multiregion ccRCC 
dataset (Swanton Laboratory) to gain insights into what drives ITH in ccRCC by 
defining the variable phenotypes established through genetic ITH. 
 
1.2 clear cell Renal Cell Carcinoma: what is known and where 
the field stands 
1.2.1 Genetics  
While mutations in the VHL gene (both somatic or germline) and loss of 
heterozygosity (LOH) of chromosome 3p is observed in over 90% of ccRCC cases, 
thereby marking these two events as the major players of this disease as well as 
the necessary precursors, recent studies have identified somatic mutations in other 
genes including PBRM1, BAP1 and SETD2 as well as recurrent somatic copy 
number alterations. In this section, the VHL gene axis of ccRCC biology is 
reviewed followed by a review of the other recurrent ccRCC associated alterations.   
 
The VHL gene and Hypoxia inducible factors (HIFs) 
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The VHL gene is a tumour suppressor that lies on chromosome 3p25. It was first 
characterised in 1993 (Latif et al.), which led to the identification of families with 
VHL disease. The VHL disease is a hereditary disorder, which predisposes patients 
to various benign and malignant neoplasms including ccRCC. Typically patients 
with VHL disease inherit a germline-mutated copy of the VHL gene and 
subsequently acquire a somatic alteration or loss of the second VHL allele (Latif et 
al.). Soon after, VHL was also seen to be the main driver event in sporadic ccRCC 
cohorts as well, where loss of function was taking place by either somatic mutation 
or promoter hypermethylation in up to 80-90% of the cohort (Gnarra et al., 
Nickerson et al., Shuin et al., Duan et al., Pause et al., Kibel et al., The Cancer 
Genome Atlas Research Network, Sato et al., Scelo et al.).  Thus the VHL gene is 
a classic example of a ‘two-hit’ tumour suppressor gene, where one copy of the 
gene is lost via deletion or chromosomal arm loss and the second copy is 
inactivated via somatic mutation or hypermethylation (Brugarolas, Linehan et al.).  
 
The VHL gene product (pVHL) has various roles, the most important being its 
function as the substrate recognition module of an E3 ubiquitin ligase complex. 
This complex targets the hypoxia inducible factor (HIFα) and facilitates its oxygen-
dependent ubiquitination. This has been well characterised in relationship to 
ccRCC (Keefe et al.). When the VHL gene is activated, it targets the HIFs for 
polyubiquitinilation and degradation. However, when the VHL gene is inactivated, 
HIFs are stabilised and the cell is under the condition of hypoxia. Under hypoxic 
conditions, HIF translocates to the nucleus and up-regulates a variety of genes 
including vascular endothelial growth factor (VEGF) and Erythropoietin (EPO) 
(Gordan and Simon), which enable the cell to adapt to hypoxic conditions.  The up-
regulation of VEGF accounts for the highly vascular nature of this disease 
(Brannon and Rathmell). Furthermore, HIF also targets various metabolism related 
genes, which mediates the global metabolic shift of ccRCCs (Keefe et al.).  Major 
targets include Glut1, which is a glucose transporter and rate-limiting enzymes 
involved in glycolysis (hexokinase, phosphofructokinase, lactate dehydrogenase) 
(Osthus et al., Kim et al., Semenza). HIF translocation also leads to expression of 
pyruvate dehydrogenase kinases, thereby suppressing the entry of pyruvate into 
the citric acid cycle (Kim et al.) (Figure 1.3). 
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Figure 1.3: Regulation of HIF via the VHL protein. 
In the absence of pVHL, the VHL protein – Elongin complex is disrupted, which 
then cannot target the degradation of HIF. Accumulation of HIF in turn leads to 
activation of downstream targets such as VEGF, PDGF and Glut1. Figure 
reproduced with permission from (Linehan et al.). 
 
 
However, recent work has demonstrated that despite large-scale VHL gene loss 
and correlation with ccRCC, HIF deregulation is not uniform in all patients. It has 
been postulated that different mutation types may contribute differently to HIF1α 
and HIF2α regulation (the two most prominent members of the HIF family) (Lee et 
al., Rathmell et al.). Further work has shown that depending on whether tumours 
are expressing both HIF1 and HIF2 (H1H2) or only HIF2 (H2), differences can be 
seen in terms of c-myc transcription factor activity (Gordan et al.) and tumour 
metabolism. Further, Dalgliesh et al. (Dalgliesh et al.) suggest that H2 tumours may 
have certain nonsense mutations that puts them under selective pressure to lose 
HIF1 expression. 
 
The estimates for VHL gene mutations in sporadic ccRCC cohorts vary greatly 
between studies (Yoshida et al., Banks et al., Gnarra et al., Brauch et al., The 
Cancer Genome Atlas Research Network, Sato et al., Scelo et al.), with as high as 
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90% loss being reported (Nickerson et al.).  While the importance of VHL gene 
mutation as a precursor event for ccRCC is well established, its efficacy as a 
biomarker still remains questionable (Brannon and Rathmell, Lee et al.).  
 
Somatic mutations profile  
The advent of next generation sequencing technologies facilitated the possibility of 
sequencing larger cohorts of patients to look for other majorly mutated genes in 
ccRCC. In 2009, van Haaften et al. (van Haaften et al.), performed sequencing of 
the genes involved in histone methylation in different human cancers (n=1390) 
including 419 ccRCCs. This study proposed the histone lysine demethylase gene 
UTX/KDM6A as a novel ccRCC gene. UTX is located on chromosome Xp11.2 and 
encodes a histone H3 lysine 27 (H3K27) demethylase. Studies in model organisms, 
have suggested that the UTX gene plays a role in cell cycle progression, affecting 
proliferation as well as cell fate (Wang et al., Herz et al.). Moreover, reintroducing 
UTX into cancer cells showed decrease in cell proliferation further supporting its 
role in ccRCC tumourigenesis (van Haaften et al.).  
 
Following this, another study (Dalgliesh et al.), presented results from the selected 
sequencing of coding exons of 3544 genes in 101 ccRCC cases. They followed up 
60 genes in another 246 cases of ccRCCs. Their results not only supported the 
potential role of UTX/KDM6A in ccRCC tumourigenesis but further highlighted 
recurrent mutations in major chromatin and histone modifying genes including SET 
Domain Containing 2 (SETD2), Lysine (K)-Specific Demethylase 5C 
(JARID1C/KDM5C) and Lysine (K)-Specific Methyltransferase 2D (MLL2) genes. 
All these genes have been seen to be mutated in many other cancers such as 
pancreatic, prostate and breast cancers (Rydzanicz et al.). Another gene, 
Neurofibromin 2 (NF2), which is a regulator of multiple receptor tyrosine kinases 
and activates pathways such as Ras/Raf/MEK/ERK, PI3K/AKT and mTORC1, was 
also seen to be recurrently mutated in this cohort. NF2 has been shown to be a 
potential tumour suppressor involved in mitogenic signalling and cell proliferation 
(Zhou and Hanemann, 2012). Independent studies have confirmed recurrent 
mutations in SETD2 (Duns et al.) and JARID1C/KDM5C genes (Guo et al.).  Down-
regulation of JARID1C has further been shown to promote tumour growth in 
xenograft models (Niu et al.). Recent work by our collaborators has suggested 
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SETD2 to be promoting tumourigenesis through potentially suppressing replication 
stress and coordinating DNA damage repair pathways (Kanu et al.). 
 
Subsequently, Varela et al. (Varela et al.), performed exome sequencing for 7 
ccRCC cases, identifying recurrent mutations in the Polybromo 1 (PBRM1) gene. 
This observation was followed up in a mixed RCC cohort of 257 cases, 227 of 
which were ccRCC. The PBRM1 gene was seen to be mutated in 41% of the cases 
in this cohort. PBRM1 encodes the BAF180 protein, which is part of the SWI/SNF 
chromatin-remodelling complex (Reisman et al.). This complex is involved in 
multiple processes such as replication, transcription (Burrows et al.), DNA repair, 
cell proliferation (Burrows et al., Xia et al.) and chromosome stability (Xue et al., 
Vries et al.). The observation that PBRM1 is the second most frequently mutated 
gene in ccRCC has since been verified in various independent study cohorts (Duns 
et al., Pena-Llopis et al., Kapur et al.). While mutations in PBRM1 have been 
shown to have better patient prognosis than those with mutations in the BAP1 gene 
(Kapur et al.), loss of PBRM1 protein expression nevertheless correlates with 
advanced tumour stage, low tumour grade and a relatively poor patient prognosis 
(Pawlowski et al.).  
 
Guo et al. (Guo et al.) performed whole exome sequencing of 10 ccRCC samples, 
which identified 282 somatic mutations in over 234 genes. They further queried for 
genes identified in cosmic and cancer gene census to be associated with ccRCC 
and combined them with their identified genes, to compile a list of ~1100 genes 
which were screened for in 88 cases. This identified 23 genes as frequently 
mutated in ccRCC, confirming previous finding of frequent mutations in VHL, 
PBRM1, SETD2, KDM5C and additionally identified genes associated in the 
ubiquitin mediated proteolysis pathway (UMPP) to be mutated in ccRCC. These 
genes included BAP1, SYNE2, SPTBN4, RYR1, AHNAK, ZNF804A, TSC1, 
SHANK1, LRRK2, FMN2, FAM11B and ASB15. Further targeted sequencing of 
135 genes involved in UMPP showed mutation in 50% of the analysed tumours in 
at least one of these genes, including VHL (27%), BAP1 (8%), CUL7 (3%) and 
BTRC (2%).  The BAP1 gene has since then been shown to be of particular 
interest in independent ccRCC cohorts (Duns et al., Pena-Llopis et al., Kapur et al., 
The Cancer Genome Atlas Research Network) as well as other cancers (Rydzanicz 
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et al.). It encodes a ubiquitin carboxy-terminal hydrolase/BRCA1-associated protein 
(BAP1), and is implicated in DNA damage response, cell cycle regulation and cell 
growth (Matsuoka et al., Yu et al.).  
 
All the above studies were either targeted towards selected genes or were done on 
smaller cohorts. However in 2013, two studies were published showing whole 
exome sequencing (WES) data for a large cohort of ccRCC cases. The first study 
(Sato et al.), performed genome and exome sequencing; whole exome sequencing 
was done for ~110 cases. The top significantly mutated genes were VHL, PBRM1, 
BAP1 and SETD2. Furthermore, they also identified recurrent mutations in the 
Transcription Elongation Factor B (SIII), Polypeptide 1 (TCEB1) gene, which leads 
to HIF accumulation by disrupting the binding of the C-VHL gene product with 
elongin. 
 
The second study was published by the TCGA (The Cancer Genome Atlas 
Research Network), which comprises the biggest study cohort for ccRCC cases to 
date. Over 400 cases were undertaken for WES, clinical follow-up, SNP-array 
analysis and RNA-Sequencing (RNA-Seq). This analysis underlined recurrent 
mutations in the chromatin machinery in ccRCC and underscored ccRCC being a 
metabolic and chromatin regulation controlled cancer. 
 
The most recent study (Scelo et al.), includes a cohort of ~100 ccRCC cases of 
either European or British origin. Whole genome sequencing was performed for 94 
cases out of which 25 were from the United Kingdom. Non-synonymous mutations 
were detected in 583 genes and the top 5 most frequent genes identified included 
VHL, PBRM1, SETD2, BAP1 and Zinc finger homeobox 4 (ZFHX4) gene. This 
study was important in highlighting that ccRCC mechanisms may differ in diverse 
populations. This has been discussed in more detail in Chapter 3.  
 
A few striking features emerged from all these studies. The first is the emergence 
of recurrent mutations of chromatin and histone modifying genes, namely PBRM1, 
SETD2 and KDM5C (Figure 1.4). The second remarkable feature is that PBRM1, 
SETD2 and BAP1 all share proximity to the 3p25 locus which is where the VHL 
gene also resides. Most mutations in these genes are loss of function mutations 
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and this combined with the fact that 3p LOH occurs in over 90% of ccRCC cases, 
results in the complete inactivation of these genes when mutated. While all these 
genes show recurrence in terms of being mutated in various ccRCC cohorts from 
different origins, their importance in terms of cancer progression and prognosis still 
remains to be shown.  
 
 
 
Figure 1.4: Major chromatin regulators in ccRCC 
Major chromatin regulators altered by somatic mutations and somatic copy number 
alterations (SCNAs) in ccRCC are depicted. SETD2 is involved in trimethylation of 
H3K36, UTX/KDM6A is a H3K27 demethylase, KDM5C is a H3K4 demethylase 
and PBRM1 is part of the SWI/SNF complex. Figure reproduced with permission 
from ((Jonasch et al.), American Association for Cancer Research). 
 
 
Chromosomal aberrations 
Chromosomal aberrations include both numerical changes (duplications or 
deletions) of parts of or whole chromosome as well as structural rearrangements of 
chromosomes. 
 
Besides somatic mutations described above and 3p LOH, there are multiple other 
genetic aberrations which maybe supplementing ccRCC from development to 
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progression. Molecular cytogenetic methods such as fluorescent in-situ 
hybridisation (FISH), array based comparative genomic hybridisation (CGH) and 
more recently, single nucleotide polymorphism (SNP) based arrays have led to 
advancements in detecting recurring chromosomal aberrations for ccRCC at higher 
resolution and at genome wide levels (Rydzanicz et al.).  
 
Loss of chromosome 3p spanning the VHL locus is an example of a hallmark 
somatic copy number alteration (SCNA) in ccRCC and has been described in 
various studies (Junker et al., 2003, Chen et al., Klatte et al.). Interestingly, two 
large-scale studies have described 3p LOH to be associated with a relatively good 
patient prognosis. In the first study (Klatte et al.), cytogenetic analysis was used to 
look for recurrent gains and losses in ccRCC and they assessed Cancer Specific 
Survival (CSS) to analyse the association of these aberrations with patient 
prognosis. Another study (Kroeger et al.) compared patients with loss of 3p or with 
loss of 14q and patients with loss of both these chromosomes with each other. 
Here too they observed that while patients with loss of only 3p had better prognosis, 
patients with loss of 14q had poorer survival in comparison and patients with loss of 
both had the worst prognosis.  
 
The second most recurrent SCNA for ccRCC is gain of chromosome 5q (Gunawan 
et al., Junker et al., 2003, The Cancer Genome Atlas Research Network). In the 
TCGA publication (The Cancer Genome Atlas Research Network), using focal 
amplifications, the authors narrowed the amplification down to 5q35 focal region, 
with 60 putative target genes including genes involved in histone modification 
(EZH2), stress response (STC2), cell adhesion and migration (VCAN). All these 
genes are over-expressed in ccRCC. In addition, using cytogenetic analysis 
Gunawan et al. (Gunawan et al.) described the focal region 5q31-qter to be 
associated with CSS, where patients with 5q gain had relatively better survival than 
those without.  
 
Multiple groups have discussed the loss of chromosome 9p as an important 
recurrent SCNA in ccRCC and its association with poor prognosis has been 
observed in various independent study cohorts (Moch et al., Sanjmyatav et al., 
Klatte et al., La Rochelle et al., Brunelli et al.). All these studies described loss of 
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the whole p-arm of chromosome 9, apart from (Sanjmyatav et al.), where loss of 
two particular focal regions namely 9p21.3p24.1 and 9q32q33.1 was described to 
be associated with poor prognosis. 
 
Besides deletions of chromosomes 3p and 9p, Klatte et al. (Klatte et al.), also 
described other recurrent gains and losses. Losses of chromosome 4p and 14q 
were each associated with poor patient prognosis. 
 
Sanjmyatav et al. described some other SCNAs (Sanjmyatav et al.) detected using 
CGH arrays and Fluorescent in-situ hybridisation (FISH). They studied CSS in 
patients and observed gain of 7q36.3 region to be associated with poor patient 
survival. Gain of focal region 20q11.21q13.32 was also identified to be associated 
with poor patient prognosis. 
 
Gain of the q-arm of chromosome 8 has been described by two groups to be 
associated with poor patient survival. Klatte et al. (Klatte et al.), used cytogenetics 
to identify recurrently altered chromosomes in ccRCC, and then studied CSS to 
identify 8q gain to be associated with poor prognosis. The second group (Monzon 
et al.) used SNP arrays to identify 8q gains in ccRCC patient, reasserting the above 
observation. They studied overall survival for their patient cohort. In the same study, 
the authors described loss of chromosome 14q to also be associated with poor 
patient prognosis.  
 
Other ccRCC recurrent SCNAs in ccRCC include deletion of chromosomes 1p, 4q 
(Beroukhim et al., Girgis et al.), 6q (Toma et al.), 8p (Chen et al., Toma et al., 
Girgis et al.), and amplification of chromosomes 7q (Beroukhim et al., Girgis et al.) 
and 12q (Girgis et al.). 
 
To further our understanding of associations of SCNAs with cancer, the algorithm 
GISTIC was developed (Beroukhim et al., Mermel et al.). GISTIC identifies genes 
targeted by SCNAs that drive cancer growth. The algorithm estimates the 
background rates for each category and defines the boundaries of SCNA regions, 
by separating SCNA profiles into underlying arm-level and focal alterations. 
Beroukhim et al. (Beroukhim et al.) used GISTIC on a cohort of 90 ccRCCs and 
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identified gains of 1q, 2q, 5q, 7q, 8q,12p and 20q and losses of 1p, 3p, 4q, 
6q,8p,9p and 14q of to be associated with ccRCC.  
 
All SCNAs discussed above have potential tumour suppressors and oncogenes 
located on them, and further studies that analyse the effect of these SCNAs at the 
gene expression and functional levels should provide insights into ccRCC 
tumourigenesis. 
 
1.2.2 Transcriptomics 
Gene expression profiling is a very powerful tool when studying cellular phenotypes. 
Indeed multiple studies analysing mRNA expression, have been able to elucidate 
gene associated with ccRCC at the phenotypic level. Using microarray data 
analyses, a study (Tun et al.) has shown genes associated with three major 
pathways, namely loss of normal renal function, down-regulated metabolism and 
immune activation to be reflective of the ccRCCs. These findings were verified in 
another independent study (Zhou et al.). A recent study using RNA-Sequencing 
data from 537 patients profiled by TCGA, identified 186 differentially expressed 
genes after multiple testing correction with |log fold change | > 5 (Yang et al.). 
Moreover, expression levels for multiple genes have also been shown to associate 
with patient outcome. For example, high levels of CD31, EDNRB and TSPAN7 
have shown to correlate with better prognosis (Wuttig et al.). A three-gene 
signature based on the expression levels VCAM1, EDNRB and RGS5 has been 
shown to predict ccRCC prognosis effectively and higher levels of these genes too 
correlate with better prognosis (Yao et al.).  
 
Furthermore, similar to other cancer types, clustering of patients based on 
transcriptional signatures has revealed multiple molecular subgroups in ccRCC. 
Such analyses are done primarily with two objectives in mind. The first being to be 
able to classify patients into discernible subgroups and a second closely related 
objective is to be able to distinguish between these subgroups, not only in terms of 
biological signatures but also in terms of patient prognosis. Most such studies start 
as unsupervised clustering analyses (Zhao et al., Kosari et al., Vasselli et al., 
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Takahashi et al., Brannon et al., Beleut et al.). These studies use gene expression 
analysis to form an understanding of the dataset such as, number of subgroups 
and genes differentially regulated between subgroups. Subsequently, a 
superimposed question is asked, such as how to maximise patient prognosis, 
enabling a more supervised analysis to be performed. There have been two 
landmark studies showing the existence of at least two major subgroups in ccRCC 
with differences in biology as well as prognosis (Zhao et al., Brannon et al.). These 
studies are discussed in further details in Section 1.2.7.  
 
1.2.3 DNA methylation, microRNA profiling, Tissue Microarrays (TMAs), and 
plasma serum protein analysis 
Other than those discussed above, other methodologies are available to detect 
alterations and biomarkers for ccRCC. While these methodologies do not form part 
of the work covered in this thesis, they are briefly outlined below.  
 
DNA methylation 
DNA methylation is a cellular mechanism frequent utilised by cells for epigenetic 
silencing of genes. For ccRCCs, methylation of the VHL promoter region is seen 
frequently as an alternative method of silencing the gene instead of somatic 
mutations (Herman et al., Clifford et al.). Promoter methylation of the DLEC1 
tumour suppressor gene was shown to be associated with advanced tumour stage 
and grade (Zhang et al.). Significant correlation was also observed between 
methylation of SCUBE3 and increased risk of death or relapse for RCC (Morris et 
al.). In the TCGA publication (The Cancer Genome Atlas Research Network), the 
authors identified 289 genes epigenetically silenced in at least 5% of cases. For 
example, the UQCRH gene was observed to be hypermethylated in about 36% of 
the tumours, a gene previously been proposed to be a tumour suppressor gene.  
 
MicroRNA expression 
MicroRNAs (miRNA) are 21-23 nucleotide long segments of single-strand non-
coding RNAs. They have been implicated in tumour development as well as 
progression. Since a single miRNA targets the expression of many genes, aberrant 
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expression of miRNAs can be an effective mechanism for epigenetic regulation. A 
number of studies have been undertaken to ascertain the ability of miRNAs to 
distinguish RCCs from normal cells or between RCC histologies (Chow et al., 
Huang et al., Juan et al., Petillo et al.). Two studies were undertaken to assess 
miRNAs associated with metastasis, and their analysis suggested that miR-10b, 
miR-29a and miR-30a characterise metastatic potential (Junker et al.). Recent work 
has shown the overexpression of miR-210 in ccRCCs and while miR-210 positive 
patients had a higher chance of disease recurrence and shorter overall survival in 
univariate analysis, the statistical significance of this classification was lost when 
adjusted for tumour size and stage (Samaan et al.).  
 
Tissue microarrays 
Tumour protein expression levels can be efficiently assessed using Tissue 
microarrays (TMAs). TMAs from 800 ccRCCs were analysed for genes in pathways 
reported to be controlled by VHL and PTEN genes. Improved prognosis was 
observed for tumours that stained positive for p7 and CAIX (stage T2 and T3 
tumours) (Dahinden et al.). In another study of 308 ccRCC patients, high nuclear 
HIF2α was shown to be associated with smaller tumour size and lower Fuhrman 
grades while high cytoplasmic HIF2α correlated with lymph node and distant 
metastasis as well as higher Fuhrman grades (Kroeger et al.).  
 
Plasma serum proteins 
Due to the ease of sampling, plasma serum proteins form an attractive category of 
biomarkers. Compared to tumour biopsies, a blood test is relatively simpler, as well 
as less invasive for the patients. Potential biomarkers for response to the drug 
sunitinib in metastatic RCC (mRCC) patients have been identified. Those 
responding had low levels of TNFα (tumour necrosis factor α) and MMP9 (matrix 
mettalloproteinaise-9) (Perez-Gracia et al.). Tumour response has also been seen 
to be correlated with changes in serum levels of VEGF, sVEGFR-s and sVEGFR-3 
levels (Deprimo et al.). In another study, sVEGFR-3 and VEGF-C serum levels 
were shown to be associated with longer progression free survival and response 
rate in bevacizumab-refractory mRCCs (Rini et al.). While these serum proteins 
have been shown to have potential predictive power, they all still need to be 
validated in independent cohorts.   
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1.2.4 ccRRCs and the PIK3CA/mTOR pathway 
Beside the VHL/HIF pathway, the PIK3CA/mTOR pathway is also a prominent in 
ccRCCs, indeed it is classified as the second major pathway recurrently altered in 
ccRCC. The mammalian target of rapamycin (mTOR) protein has been identified 
as part of two complexes (mTORC1 and mTORC2) in humans (Oosterwijk et al.). 
mTORC1 has been shown to play a role in cell growth regulation and metabolism 
(Jonasch et al.). mTORC1 has been shown to suppress autophagy (He and 
Klionsky, Sancak et al.) and regulating mitochondrial functions (Blagosklonny and 
Hall), but its most important role is to promote protein translation which is mediated 
through phosphorylation of S6K and the eukaryotic initiation factor 4E-binding 
protein 1 (Ma and Blenis). As suggested by its name, mTORC1 is inhibited by 
rapamycin and its analogues and it controls the regulation of HIF1 (Zhong et al., 
Brugarolas et al., Thomas et al.). Upstream regulation of the mTOR pathway is 
controlled by the PTEN gene. Mutations in PTEN are rare in ccRCC (The Cancer 
Genome Atlas Research Network); however, deregulation of the PIK3CA/mTOR 
pathway can be seen in 17-28% of the cases if mutations across different genes in 
pathway as well as ITH are taken into consideration (The Cancer Genome Atlas 
Research Network, Gerlinger et al.).  
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Figure 1.5: the mTORC1 pathway in ccRCC 
Figure depicts the HIF and mTORC pathway connections. HIF expression is 
blocked under hypoxia in a TSC1/TSC2 and REDD1 dependent manner. 
  
1.2.5 Intratumour heterogeneity 
So far, this introduction has concentrated on the evidence of extensive genetic and 
phenotypic heterogeneity at the inter-patient level. Recent work in multiple cancers 
has also revealed existence of this heterogeneity within individual tumour samples, 
so called intra-tumour heterogeneity (ITH) (Gerlinger et al., Gerlinger et al., Nik-
Zainal et al., Shah et al., Ding et al., Yachida et al., Sottoriva et al., Thirlwell et al., 
Campbell et al., Bashashati et al., Navin et al.). ITH is being increasingly perceived 
as a major challenge for the implementation of personalised cancer medicine. 
Branched cancer evolution analogous to Darwinian evolution, may lead to multiple 
distinct clones which may co-exist in a tumour mass and result in varying degree of 
ITH (Navin and Hicks).  
 
Using single biopsies to sample such heterogeneous tumours may lead to 
undervaluing the extent of this heterogeneity. The analysis of multiple tumour 
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regions from individual ccRCCs has identified substantial ITH, indicating that cells 
within a single tumour do not all share the same mutations, rather subgroups of 
tumour cells differ in their mutation spectrum (Gerlinger et al., Gerlinger et al.). The 
authors identified extensive genetic intra-tumour heterogeneity by whole exome 
sequencing of multiple regions i.e. multiple biopsies from the same tumour. 
According to these studies, approximately 50% of the mutations found in any one 
biopsy are not shared with other biopsies from the same patient. They showed that 
the ancestral relationship between the mutations in different regions from a patient 
could be represented in the form of a phylogenetic tree. The trunk of such a tree 
represents the clonal or ubiquitous mutations for a single tumour, i.e. mutations that 
are present in all malignant cells assessed, for example VHL (Figure 1.6). The 
branches represent shared or private mutations to a particular region i.e. the 
subclonal mutations. The mutational timing can be approximated from such a tree 
on the basis of the distance between subclonal mutations and the mutations is the 
most recent common ancestor; thus truncal mutations occur before the mutations 
on the branches. Spatially separated subclones harbouring distinct driver mutations 
and somatic copy number aberrations (SCNAs) were present within primary 
tumours and between primary tumours and metastases (Gerlinger et al., Gerlinger 
et al., Martinez et al.). Phylogenetic reconstruction revealed branched evolution, 
demonstrating that multiple subclones were evolving simultaneously within 
individual tumours. Assessment of a validated prognostic gene expression 
signature (Brannon et al.) showed expression of the good prognosis ccA signature, 
or poor prognosis ccB signature, in different tumour regions within the same 
patient (Gerlinger et al.).  
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Figure 1.6: Branched evolution in ccRCC development 
Figure depicts a tree to show the branched evolution as observed by sequencing 
multiple regions from individual tumour biopsies (Gerlinger et al.). Examples are 
shown for mutations in genes (red), representing clonal and subclonal mutations.  
 
 
Furthermore, some of the major somatic mutations and SCNAs discussed above 
such as mutations in SETD2 and BAP1 genes and deletions of chromosome 9p 
and 14q were observed to be subclonal events (Gerlinger et al.). These studies 
have shown that while the clonal or ubiquitous events in ccRCC are consistent 
(VHL, 3p loss), there is still diversity in terms of patient outcomes. These 
observations support the hypothesis discussed previously, that subclonal events 
play a major role in tumour progression, and may increase the fitness of tumours 
under specific environmental conditions, leading to cancer progression, drug 
resistance and eventually patient death. 
 
While quantitative analyses on mutation timing are beyond the scope of the work 
presented here, the qualitative impact of ITH, at both the biological and prognostic 
levels for ccRCC, are described in a number of places in this thesis.  
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1.2.6 Staging, prognosis and management of disease 
Tumour stage describes the progress of the tumour cells. The American Joint 
Committee on Cancer (AJCC) tumour node metastasis (TNM) staging system has 
been the most widely adopted system for ccRCC. It classifies tumours with a 
combined stage between I-IV using three values. T gives the size of the primary 
tumour and extent of invasion, N describes if the tumour has spread to regional 
lymph nodes and M is indicative of distant metastasis. The exact method of 
combination of these three factors to give an overall stage has been explained in 
detail in Figure 2.1.  
 
In terms of prognosis, Stage I patients have the best prognosis with 5 year survival 
rates of ~80-95%. The survival rates progressively worsen with stage, with Stage II 
patients having survival rates of ~80% and Stage III ~60%. Even with advances in 
targeted therapies, Stage IV patients have survival rates of just over two years 
(Jonasch et al.). 
 
At the time of diagnosis, about three quarters of the ccRCC cases, present with 
localised disease and with no evidence of metastasis (Jonasch et al.). Partial 
(partial kidney removal) or radical (complete surgical removal) nephrectomy 
remains the gold standard for treatment of localised disease. Different clinical trials 
have discussed and compared the merits of both these methods and results 
favoured partial nephrectomy since it preserves kidney function.  
 
1.2.7 Clinical prognosis and molecular biomarkers 
As discussed in the previous section, the clinical behaviour of ccRCCs is highly 
variable, ranging from slow-growing localised tumours to aggressive metastatic 
disease. ccRCCs are resistant to both chemotherapy and radiotherapy, with 
surgery (nephrectomy) for localised disease, being the only suitable treatment. 
Prognostic markers in routine clinical use include tumour stage and histologic 
grade, necrosis and blood tests aimed at measuring levels of lactate 
dehydrogenase, haemoglobin, platelets, and calcium levels. Other markers include 
prior nephrectomy, symptoms, and performance status (Motzer et al., Heng et al., 
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Tang et al., Sorbellini et al.). Multiple prognostic models and nomograms have 
been developed that evaluate and incorporate a combination of these factors. The 
Mayo clinic’s SSIGN model is based on the stage, size, grade and the extent of 
necrosis (Ficarra et al., Frank et al.); while the University of California, Los Angeles 
integrated staging system (UISS) quantifies stage, tumour grade and performance 
status (Zisman et al., Han et al.).  Another widely used model is the Leibovich score, 
which incorporates tumour size, stage, grade, necrosis and regional lymph node 
status to predict relapse of disease after radical nephrectomy (Leibovich et al.). A 
recent review (Lane and Kattan) compared the utility of these models. However, 
the accuracy of predictions for each individual patient remains limited.  
 
Molecular prognostic markers are thus important to guide therapeutic intervention 
and follow-up strategies. Traditionally molecular biomarkers have been researched 
at the level of gene expression, for example, in breast cancer a gene expression 
panel to classify patients into prognostic groups is commercially available and has 
been adopted in clinical practice (Glas et al.).  Multiple biomarker studies have 
been published for ccRCC, finding recurrent somatic mutations, SCNAs as well as 
gene expression signatures to be clinically associated with ccRCC. The first few 
clinical studies concentrated on finding association between the VHL gene 
mutations and patient prognosis. Two groups, both analysing loss of function 
(insertions/deletions and nonsense) mutations in the VHL gene, described patients 
with loss of function mutations to have a poor prognosis when compared to those 
who did not have these mutations (Schraml et al., Kim et al.). In addition, a third 
group (Yao et al.) studied VHL gene alterations, which included both mutation as 
well as hypermethylation events, and assessed the association of these with CSS, 
finding that patients with VHL gene alterations had better prognosis than those 
without. However, this association was seen only for Stage I-III cases. It has been 
shown that non-synonymous mutations in BAP1 gene are associated with poor 
survival in ccRCC when compared to patients with PBRM1 mutations (Kapur et al.). 
Further, other groups have validated the association of BAP1 gene with poor 
prognosis in independent cohorts (Hakimi et al., The Cancer Genome Atlas 
Research Network, Sato et al.). Mutations in other key genes such as the SETD2 
gene have been described to be associated with poor patient prognosis (Hakimi et 
al., Sato et al.).  
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As described in section 1.2.1, several recurrent SCNAs have been observed to be 
associated with ccRCC prognosis. Some examples include deletion of 3p, 4p, 8p, 
9p, 14q and 19 (Klatte et al., Kroeger et al., Elfving et al., Sanjmyatav et al., La 
Rochelle et al., Moch et al., Brunelli et al., Antonelli et al.), and amplification of 5q, 
7q, 8q and 20q chromosomes (Gunawan et al., Sanjmyatav et al., Klatte et al., 
Monzon et al., Elfving et al.).  
 
In terms of studying gene expression signatures, high expression levels of CD31, 
EDNRB and TSPAN7 have been described to be associated with better prognosis 
(Wuttig et al.). Using microarray data and hierarchical clustering Zhao et al. (Zhao 
et al.), showed the existence of two main subgroups of ccRCC differing in terms of 
prognosis. These two subgroups could be further divided into five subgroups 
differing in terms of gene expression. They also developed a panel of 259 genes 
that could be used to stratify patients into good and poor prognosis groups. Another 
landmark study in 2010 (Brannon et al.), showed that ccRCC patients could be 
divided into two molecular subtypes, ccA and ccB, where ccB patients had a worse 
prognosis as compared to ccA patients. This group also used microarray data and 
using logical analysis of data (LAD) analysis devised a panel of 120 probes (110 
genes) to classify patients into ccA and ccB subgroups. A recent publication by 
Bostrom et al. (Bostrom et al.), showed the association of a TGFβ pathway 
expression signature with ccRCC prognosis. Here the authors showed that patients 
with higher TGFβ activity had a poorer survival prognosis than those with lower 
activity.  
 
While all these publications have shown clinical association of various molecular 
signatures with patient prognosis, most associations have not been independently 
validated. Even those that have been validated have not entered clinical practice. 
Neither have these biomarkers been compared with each other to identify lead 
candidates for further development. This leads to the question as to which of these 
predictors are independently associated with patient prognosis and do they 
influence each other? Furthermore, as discussed in section 1.2.5, most of these 
alterations have been observed to be subclonal; thus ITH with spatially separated 
subclones can lead to sampling biases that may contribute to the lack of clinically 
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qualified biomarkers in ccRCC. Such observations raise questions regarding how 
biomarker discovery strategies can be improved in heterogeneous tumours.  
 
1.2.8 Therapy and targets 
The increase in our understanding of the genetic factors underlying ccRCC, has 
translated to improvements in target identification and therapies. The 
understanding of VEGF and mTOR being central to ccRCC biology, led to the 
implementation of multiple antiangiogenic drugs (sunitinib, sorafenib, pazopanib, 
everolimus, and bevacizumab plus interferon-α) for ccRCC treatment (Junker et al.). 
VEGF targeted therapies produce a more robust Response Evaluation Criteria in 
Solid Tumours (RECIST) - response than cytokine therapy (Jonasch et al.). 
However, response rates vary between 10-50% depending upon the VEGF 
inhibitor used. mTOR-targeted therapy rates are reported to be more modest, 
although mTOR and VEGF-targeted therapies haven’t been compared within the 
same cohorts (Jonasch et al.).  
 
While the response rates for targeted therapies are impressive (Rini and Atkins), 
there are uncertainties regarding specific targeting of RCC cells (Huang et al., 
2010a).  Furthermore not only toxicity due to these drugs still remains an obvious 
concern (van der Veldt et al.), resistance mechanisms have also been observed to 
develop to both these targets (Huang et al., Rini and Atkins). Moreover, at least in 
part, it has been argued that both treatment response and toxicity maybe reflective 
of the underlying genetic makeup of the patients. Multiple studies have evaluated 
this (van Erp et al., van der Veldt et al., Garcia-Donas et al., Xu et al.) and the data 
suggest that there might be differential clinical benefits depending on the genotype 
of the patient and if such hypothesis could be confirmed, future studies could 
benefit and provide more tailored and personalised cancer treatments.  
 
1.3 Survival modelling 
As discussed in section 1.2.7, it is imperative to assess and identify biomarkers, 
either diagnostic or prognostic. The primary interest in such an analysis is to study 
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the effect of a risk factor or treatment with respect to cancer progression. In survival 
modelling, the data is referred to as ‘time to event’ data. The objective here is to 
analyse the time that passes before an event occurs due to one or more covariates. 
This type of data has three main characteristics. Firstly, the dependent variable or 
response is defined as the waiting time until the occurrence of a well-defined event, 
for example, death. Secondly, there are certain observations, which are ‘censored’, 
i.e. there are certain cases in the data cohort, for whom the event of interest has 
not occurred at the time the data were analysed; or there is loss of information 
regarding these cases, the reason of which may be known or unknown. Lastly, the 
objective of such an analysis is to assess or to control the effect of predictors or 
explanatory variables on the waiting time. Computationally, there can be multiple 
ways to address the above, including but not limited to linear regression models, 
decision trees and support vector machines. However, due to the unique 
characteristics of this problem, the modelling of this data requires modelling of two 
specific functions namely the survival and hazard functions and sophisticated tests 
such as logrank tests (Bland and Altman) and Cox regression analysis (Cox). 
These methods have been developed specifically for this purpose and are the tests 
used as part of this thesis.  
 
1.3.1 The Survival and Hazard functions 
The two main functions that model survival data are the survival and hazard 
functions. The survival function, or the survival probability S(t), gives the probability 
of the survival of an individual from the original time to a future time t. This 
describes the survival experience of the cohort under consideration.  
 
The hazard function h(t), however, is the probability of the individual to have the 
event at the given time t. It represents the instantaneous rate of event for an 
individual, who has also reached or survived to time t. It is different from the 
survival function in the respect that while the survival function estimates the 
probability of not having the event, the hazard focuses on the probability of the 
event occurrence (Clark et al.).  
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Mathematically the relationship between the hazard and survival functions can be 
represented as (Clark et al.): 
 
 1.1 
 
 
1.3.2 Censoring 
Censoring is an important constraint in survival analysis. In a survival analysis, not 
all patients reach the endpoint of interest till the end of the study period. Therefore 
‘survival’ times are unknown for these individuals. This phenomenon is called 
censoring and such individuals are censored when analysing survival data. There 
are three cases in which a patient may be censored: 1) the patient did not reach 
the endpoint of interest by the end of the study period – for example, if death due to 
disease is the endpoint of interest, patients alive at the end of the study will fall into 
this category. 2) Loss of follow-up during the study period – this could happen due 
to various reasons such as the will of the patient to provide further information. 3) 
The patient experiences a different event than the endpoint of interest, which 
renders further follow up impossible – following from the previous example, in this 
case could be death due to causes other than the disease under consideration.  
 
The above examples all come under what is known as ‘right’ censoring since the 
event (if it occurred) is beyond the timeline of the follow up period. However if there 
was a scenario where while we knew when the event occurs, the time from when it 
began is unknown, this falls under the category of ‘left’ censoring. Most survival 
data include right-censored cases, and for the purpose of this thesis, that is the 
censoring under use. Lastly, a very important consideration is that the censoring 
should be uninformative. This means that there is equal probability of the censored 
cases to have the event as there is of those cases that did have the event; i.e. the 
censoring does not carry any prognostic information (Clark et al.).  
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1.3.3 Methods for estimating and comparing survival times 
A few typical errors in survival analysis include, counting only the event frequencies 
i.e. only assessing if the event occurred or not with no thought to the time to event 
or considering how long the patients were observed. Another mistake could be to 
exclude patients, for whom the event did not occur from the analysis, and lastly to 
assume that the time of censoring is equivalent to event time; i.e. no distinction is 
made whether the patient is recorded as ‘event’ or ‘censored’ (Zwiener et al.). Thus 
special methods are required to avoid these mistakes.  
 
The Kaplan Meier (KM) method (Bland and Altman) is the most common method 
used to estimate the survival function. It is a non-parametric method, which 
estimates the survival probability from observed survival times taking both 
censored and uncensored observations into account. Mathematically, the KM 
estimator calculates the probability of survival at time point t from the probability of 
being alive at time point t-1, where t0 = 0 and S(0) =1, i.e. at the beginning of time 
there is 100% survival probability.  
 
However, often in studies assessing survival, there is a need to compare the 
survival of two or more groups; for example in a drug trial, the survival of patients 
on the drugs would be compared to the placebo group. While the KM estimator 
would assess the survival of each group, it does not provide a comparison. There 
are different tests available to perform these comparisons. Another important point 
of consideration is the effect of covariates. The survival of an individual may be the 
consequence of multiple factors, which can be assessed using multivariate models. 
In the following sections, both univariate tests and multivariate models are 
discussed.  
 
1.3.3.1 Univariate analysis  
The logrank test is the most common statistical test applied to test the significance 
of differences in survival between two or more groups. It tests the null hypothesis 
that there is no difference in survival between the two groups. The test is based on 
the same assumptions as the KM estimator, i.e. the censoring is uninformative, the 
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events happened at the specified times and the probability of the event occurring 
for an individual is independent of when the individual was recruited for the study. 
An advantage of this test is that it makes no assumptions regarding the survival 
distributions or the shape of the survival curves (Bland and Altman). The null 
hypothesis here is that there is no difference in the survival between the groups 
under consideration. The exact method of assessment has been described in detail 
in Methods section 2.6.2. 
 
The logrank test is considered to be a robust test for estimating differences in 
survival, when compared to other tests (Clark et al.), however, it cannot provide the 
effect size of the variable which is a definite limitation. A univariate Cox model 
(Cox) can be used here to compliment the logrank analysis and calculate the effect 
size or hazard due to the test variable. The Cox model is explained in greater detail 
in the section 2.6.5.  
 
The competing risk (CR) analysis is another popular method of choice when 
estimating survival especially when competing events might be taking place. For 
example if ‘death due to disease’ is the event of interest, death due to other causes 
is a competing risk event, as either of these will prevent the other from happening 
(Satagopan et al., Putter et al.).  In contrast to logrank test, which estimates the 
survival function of the variable under consideration, the CR analysis estimates the 
cumulative incidence function of a variable. This function calculates the proportion 
of patients at time t, which have had the event k, taking into account that patients 
can have other competing events.  
 
1.3.3.2 Multivariate analysis 
The Cox proportional hazards model (Cox) is the most commonly used multivariate 
model for analysing survival data. Here too the assumptions for censoring being 
right and is uninformative holds. It is a regression model, which defines the 
association between the occurrence of the event using the hazard function and a 
set of covariates. The Cox model estimates the hazard function based on a set of 
covariates, mathematically written as (Equation 1.2): 
Chapter 1 Introduction 
46 
 
 
 1.2 
 
Where β1, β2, β3 represent the coefficients of regression for each variable under 
consideration. The term h0 represents the baseline hazard and an important 
feature of the Cox model is that it estimates the baseline hazard non-parametrically 
giving the advantage of not assuming any underlying statistical distribution for the 
survival data (Bradburn et al.).  
 
1.4 Computational approaches to understand cancer biology 
1.4.1 Integrated genotype-phenotype analysis 
The previous sections have discussed the technological advances that have 
occurred over recent years and that have led to the accumulation of large 
heterogenous cancer datasets within public repositories and the identification of a 
growing number of cancer associated genes. Of particular interest for the 
advancement of the field is the integration of genetic alteration data with the 
corresponding gene expression data, which holds merit by virtue of the fact that, if 
deregulation of expression levels of genes relative to the genetic altered genes can 
be observed, then this serves to provide a stronger signal for the interpretation of 
the genotype to phenotype relationships in the dataset.  
  
At the most straightforward and simplistic level - combining gene expression data 
with somatic mutations has been shown to provide answers for elucidating the 
relationships between genotype and phenotype. Ragazzon et al. (Ragazzon et al.), 
performed a transcriptome analysis for Adrenocortical Cancers (ACC). They first 
identified two subgroups of patients by gene expression profiling, and showed that 
these subgroups had different survival outcomes. Subsequent integration of 
somatic mutation data with this classification of patients revealed that mutations in 
TP53 and CTNNB1 genes, which are the two most frequent mutations in ACC, 
seem to be mutually exclusive and occur only in the poor prognosis cases of ACC. 
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However, as pointed out previously, genome wide ‘omics’ analyses have revealed 
a staggering number of genetic alterations, and correlative approaches such as 
discussed in the previous paragraph, are no longer feasible. Thus, extending on 
the basic premise of genotype–phenotype relationships, newer methods need to be 
developed. The DriverNet algorithm (Bashashati et al.) was developed to identify 
driver mutations that affect and control the mRNA expression signatures of the 
disease of interest. This method creates a bipartite graph, where on one side are 
the genetic alterations and on the other is the gene expression network of the 
genes showing significant deregulation. An edge is drawn from one side to the 
other, if gene gi is mutated in the left partition; gene gj is deregulated in the right 
partition and there are known interactions between gi and gj. Then a greedy 
algorithm is applied so as to explain as many changes on the right using as few 
genes possible from the left partition, nominating these genes as driver alterations. 
Stochastic sampling for null distributions and statistical tests are then applied to 
filter the driver lists. 
 
Another method, Conexic (Akavia et al.), combines copy number alterations and 
gene expression data to identify SCNA drivers of cancer progression using 
Bayesian modelling approaches. It uses a score guided approach to devise a 
combination of drivers that may best explain the observed gene expression 
signature across all tumour samples, and then searches for the maximum scoring 
drivers in the amplified and deleted regions of the samples, to determine the driver 
SCNAs.  
 
1.4.2 Network analysis 
While the above work is commendable, such correlative analyses have still to 
reach their potential. The presence of high number of non-synonymous somatic 
mutations in individual tumours proves to be a major hurdle for correlative analyses 
between expression signatures and individual somatic mutations. A traditional gene 
or pathway centric approach, which individually evaluates the contribution of each 
gene or pathway alteration towards the overall cancer phenotype, is highly limited 
in large-scale ‘omics’ datasets for two reasons: the datasets are huge, consisting of 
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thousands of individual measurements and simple correlative analyses are often 
limited because of multiple testing errors. Secondly, gene- or pathway centric 
approaches are usually limited when applied to poorly characterized genes. 
Although they may reveal associations, they usually don’t allow identification of the 
functional relevance of alterations in poorly characterised genes. Nevertheless, 
connections between different genes and pathways can potentially be identified 
through integrative analysis of genome wide datasets, which requires the 
investigation of multimodal “omics” datasets such as DNA sequencing and mRNA 
expression data with computational and statistical modelling approaches.  
 
Coupled to this is our increased ability to generate detailed interactome maps that 
help to enrich our knowledge of the biological implications of cancer mutations. As 
a result, network analysis approaches have become an invaluable tool to predict 
and interpret mutations that are associated with tumour survival and progression. A 
detailed review has also been reported on the applicability of using protein 
networks information for disease analysis studies (Ideker and Sharan).  The 
authors discuss the applications of mapping human disease associated genes to 
protein interaction networks, and the subsequent boost in our understanding of 
human disease mechanisms.   
 
Interaction networks may be generated with information from multiple levels; 
networks can be created based on genetic alterations in the disease of interest 
representative of the genotype of the disease. Alternatively, networks can be 
generated based on gene expression data, which are representative of the 
phenotype of the disease. Examples of both these approaches are discussed 
below. 
 
Genetic networks are generally based on a background of protein-protein 
interaction networks, with an aim to understand cancer biology as well as predict 
novel cancer driver genes. These studies also aim to use such networks to explain 
inter-patient heterogeneity and the pathways that the specific cancer may be 
targeting. Such networks usually exploit two features in genetic alterations; firstly 
that major ‘driver’ events will have higher recurrence and secondly alterations in the 
same pathway would probably be mutually exclusive.  
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Protein-protein interaction networks are generated using physical interactions 
between proteins. Based on the premise of what you sow, so shall you reap; 
various sources of PPI data have been advocated in different studies. Physical 
PPIs are inferred through high throughput methods such as yeast two hybrid 
(Fields and Song), and tandem affinity purification-mass spectrometry (TAP-MS) 
(Rigaut et al.) (see review by Shoemaker and Panchenko (Shoemaker and 
Panchenko) for more methods). Multiple databases such as IntAct (Orchard et al.), 
HPRD (Keshava Prasad et al.), MINT (Licata et al.), dip (Ding et al.) and BioGrid 
(Chatr-Aryamontri et al.) collect and store information of such interactions from the 
published literature. Other databases may use text mining approaches to generate 
putative PPI data, for example the STRING database, which is a meta database 
which collects data from other primary databases and also predicts putative 
interactions by text mining (Szklarczyk et al.). Other approaches include the 
prediction of PPIs based on interactions in homologous proteins (Jonsson and 
Bates). Further, there are curated pathway databases that give directionality to 
interactions but also annotate them as belonging to specific functional pathways. 
Major examples include KEGG (Kanehisa et al., Kotera et al., Tanabe and 
Kanehisa), Biocarta (http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways) and 
Reactome (Croft et al., Haw and Stein).  
 
Prototypical studies which set the stage for integrating cancer genes were more 
focused on studying the global topological features of cancer genes; including 
centrality, inbetweenness of nodes, characteristic path length and shortest path 
length (Jonsson and Bates, Goh et al., Xia et al.) (Figure 1.7).  
 
Studies have also been successful in characterizing disease states by combining 
gene expression, sequence predictions and literature-based analysis. To identify 
links between transcription factors (TFs), Tuck et al. (Tuck et al.), constructed a 
human transcriptional regulatory network, by combining co-expression data with 
transcription factor-gene regulatory relationships based on sequence predictions 
and a careful examination of the literature. This approach can potentially identify 
key TF-gene pairs that show differential activity between diseased and healthy 
states. Once a list of potential TFs has been obtained, it is possible to build links 
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and generate networks from variations at the DNA level, then simulate by 
computational means, how these TFs are controlled and regulated in a cell.  
 
However, the view that that most biological networks are composed of strongly 
connected functional modules (Barabasi and Oltvai) (Figure 1.7), and 
developments in graph clustering algorithms to identify cancer genes (Bader and 
Hogue, Reimand et al.), has led to a shift in the trends to study cancer related 
networks.  
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Figure 1.7: Network analysis based workflows to study disease biology 
(A) Basic terminology and prototypical analysis as used in PPINs. (B) Methodology 
as applied by Gu et al. where the authors used a GBM specific PPIN to detect co-
altered modules. The right most panel shows an example of such co-altered 
modules. (C) Methodology as used by Chuang et al. to classify breast cancer 
metastasis. Gene expression data was mapped onto the human interactome and a 
greedy search algorithm was applied to identify subnetworks showing maximum 
differentiating behaviour between the two phenotypes (metastatic and non-
metastatic). (D) The left panel shows the main steps in the methodology as used in 
(Lefebvre et al.). First, the ARACNe algorithm to reverse engineer and generate a 
B cell specific interactome was applied, followed by the MARINa algorithm to infer 
master regulators (TFs) for this interactome. This figure is as presented in (Gulati et 
al.). 
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One of the most common approaches used to study cancer datasets has been to 
study characterised pathways/networks – such as signalling and metabolic 
networks as defined in databases such as KEGG (Kanehisa et al., Kotera et al.) 
and Reactome (Croft et al., Haw and Stein). Studies have indeed successfully used 
these databases to identify which curated pathways may be deregulated in specific 
cancers (Cancer Genome Atlas Research, Guichard et al.). However, it has been 
pointed out that concentrating only on pre-defined pathways is not sufficient, as 
many of the known human proteins have still not been assigned to any of the 
characterised pathways (Wu et al.). In this study, the authors generated a 
comprehensive PPIN by combining curated pathways with data from protein–
protein interactions, gene expression, protein–domain interactions, gene ontology 
(GO) annotations and text-mined protein interactions. They employed this network 
and applied graph-clustering algorithms to identify network modules enriched for 
genes altered in glioblastoma multiforme (GBM). They found two network modules, 
one formed of genes whose products are localised in the cytoplasm and plasma 
membrane, and the other with gene products in the nucleus. The authors also 
found similar network patterns when they analysed data for breast, colorectal and 
pancreatic cancers. 
 
Ciriello et al. (Ciriello et al.) have advocated that three major characteristics can be 
attributed to gene modules that may drive cancer progression. Firstly, these 
modules should be altered with high frequency, secondly genes in these modules 
belong to the same pathway or biological process and finally the genes exhibit 
patterns of mutual exclusivity across multiple patients. The authors designed an 
algorithm named ‘MEMo’ to detect such “candidate driver networks”. They have 
shown its applicability using the TCGA GBM and ovarian cancer datasets and 
claim, the affectivity of MEMo in suggesting genetic alterations, which have 
particularly strong selective effects when applied to any cancer dataset, and also 
are able to aid the design of drug combinations based on the rationale of ‘synthetic 
lethality’.  
 
In contrast, another study has developed an algorithm named Dendrix (Vandin et 
al.), where they find driver modules within genetic alteration data using mutation 
patterns in patients only. The algorithm uses a Monte Carlo search with two guiding 
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rules to search for driver networks. 1) The genetic alterations (genes) should have 
high coverage i.e. they should be occurring in a large number of patients and 2) the 
genes within the driver network should be mutually exclusive. 
 
Another study has developed an algorithm called RME modules (recurrent and 
mutually exclusive modules), based on the principles of recurrence and mutual 
exclusivity (Miller et al.). A mutation matrix is generated for the cancer of interest 
from which a gene exclusivity network was created using the WINNOW tool, which 
is an online-learning linear threshold method that can effectively detect patterns of 
exclusivity in a noisy dataset. Using a greedy search algorithm, starting with each 
gene in the network as seed gene, RME modules were detected.  
 
While the work discussed above has concentrated on detecting individual pathways 
and modules altered in cancer, a recent paper by Gu et al. (Gu et al.) has 
presented an approach to search for pairs of co-altered modules in glioblastoma 
(GBM) patients. They defined co-altered modules by two properties: firstly, each 
module is a group of genes that are strongly connected with each other with a 
frequency higher than random; secondly, alterations between module genes show 
a higher level of co-occurrence than random. They generated a GBM specific 
network, using genetic alteration profiles for GBM (both somatic mutations and 
genes altered due to copy number variations), and detected seven co-altered 
modules within this network. They found that genes occurring within these seven 
module pairs were significantly enriched with genes from both the F-census 
database and the Cancer Gene Census database. They also calculated that the 
average frequency of alteration of module genes was higher than the non-module 
genes (Figure 1.7). 
 
In a similar fashion, an extension of the Dendrix algorithm, Multi-Dendrix (Leiserson 
et al.) has been reported. The aim here was again to simultaneously identify driver 
pathways de novo in somatic mutation data. Again, Multi-Dendrix, does not take 
physical PPIs into account and only relies on mutation patterns.  
 
Another approach, based on tissue-specific expression data, has shown to provide 
useful indicators of breast cancer outcome (Taylor et al.). In this work, Taylor et al. 
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annotated a protein with greater than five interactions as a hub, and then divided 
them into two categories: intermodular and intramodular hubs, the former display a 
low correlation of co-expression with their interacting partners whereas the latter 
have high correlation of co-expression with their interaction partners. When they 
further preformed functional enrichment analysis on these hubs, they found that 
intramodular hubs have higher similarities with their partners than the intermodular. 
In addition, intermodular hubs were more associated with global network 
connectivity.  
 
In recent years, the application of reverse engineering algorithms to generate 
tissue specific PPINs have gained increasing popularity. For example, an analysis 
of brain tumours identified two master regulators (transcription factors), namely 
C/EBP and STAT3, of the mesenchymal transformation pathway for these tumours; 
inactivation of these genes in mouse xenografts blocked tumour growth and 
development (Carro et al.). In a second study by the same group (Lefebvre et al.), 
an analysis of a B-cell interactome identified two genes, MYB and FOXM1, to be 
master regulators of proliferation in the germinal centre. These studies provided a 
paradigm for the applicability of interactome analysis for studying normal and 
pathogenic tissues (Figure 1.7). 
 
Whether we study modules altered on their own or in a co-altered manner, a 
foremost objective in the field of cancer therapeutics is to extend their applicability 
as prognostic signatures. Two recent studies have used network analysis 
approaches to identify such prognostic signatures. The idea behind both studies 
being that it is not a single gene, but a network of genes that regulates cellular 
phenotypes, and hence using network analysis to study patient survival should 
provide better signatures for predicting prognosis. In the first study, Wu and Stein 
(Wu and Stein) developed a semi-supervised algorithm, which first identifies gene 
modules involved in disease independent of clinical status, and then applied the 
supervised principal component method (developed by Bair and Tibshirani (Bair 
and Tibshirani)) to identify clinically significant modules. When applied to breast 
cancer data, they found a signature consisting of 31-genes, which could be 
validated across five independent studies, and when applied to ovarian cancer, the 
algorithm identified a signature of 75-genes linked to patient survival. 
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In another study (Zhang et al.), networks were used to complement Cox regression 
analysis for studying patient survival in ovarian cancer. Their results show that by 
adding network information the accuracy of predicting survival outcome over using 
Cox regression on its own is improved. These results were shown to validate over 
three independent datasets. 
 
Another important application of network analyses methods has been as effective 
tools to classify patients into meaningful subtypes. Combining gene expression 
profiles with PPINs (Chuang et al.), a successful framework was developed to 
differentiate between metastatic and non-metastatic breast cancers (Figure 1.7).  
According to the authors, using a network-based method has several advantages 
over differential expression analyses. This is because the resulting subnetworks 
not only provide models for molecular mechanisms underlying cancer, but also are 
more reproducible between different cohorts of patients. In addition, typical cancer 
mutations may or may not be detected through analysis of differential expression 
but they play a central role in PPINs by interconnecting many crucial genes. 
 
Extending on the argument that network based signatures are much more 
reproducible than using single gene based signatures, in another study (Hofree et 
al.), somatic mutation profiles were used to stratify patients into subtypes by 
clustering patients with mutations in similar pathways/networks together. This 
method called network based stratification (NBS) was applied to cancer in different 
tissues, and in each case it was able to identify subtypes that were associated with 
clinical outcome. 
 
In a different approach, Teschendorff and Severini (Teschendorff and Severini) 
have studied cancer metastasis by assessing network flux. They argue that 
integrating PPINs and gene expression data can not only overcome some of the 
inherent problems associated with microarrays, such as background noise, but also 
allows distinguishing between direct and indirect protein–protein interactions. They 
integrated PPI data with gene expression measurements, and by using local 
entropy measures, showed that the cancer metastasis phenotype displays an 
increased randomness of local information flux patterns. They conclude that using 
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gene entropy measures on an integrated PPI and gene expression data set can be 
useful for identifying genes and pathways disrupted in one phenotype with respect 
to another. 
 
All work discussed here, has been on static PPI networks, however there have 
been studies showing the application of dynamic networks such as Boolean 
networks and ordinary differential equations in cancer studies; these networks have 
been reviewed elsewhere (Cheng et al.), and were not covered as part of the work 
of this thesis.  
 
1.5 Computational analysis in this thesis 
There are two parallel tracks in this thesis and a computational framework has 
been developed to understand the molecular mechanisms and the prognostic 
biomarkers underpinning ccRCC. To understand ccRCC mechanisms (Chapter 3), 
key ccRCC genes were first validated in the TCGA cohort using integrated ‘omics’ 
datasets. A comprehensive human protein-protein interaction network (PPIN) was 
generated by collecting and combining protein-protein interaction (PPI) data from 
five primary databases namely, IntAct, BioGrid, HPRD, MINT and DIP. A ccRCC 
specific PPIN was obtained by combining the two datasets. Network properties of 
ccRCC were assessed and strongly connected subnetworks were detected using 
the MCODE (Bader and Hogue) algorithm. The Dendrix (Vandin et al.) algorithm 
was applied to detect de novo modules of genes altered in a mutually exclusive 
manner and the results were compared with the modules detected via the MCODE 
algorithm on the ccRCC specific PPIN. Co-altered modules were obtained by 
adapting a probabilistic model previously developed by Gu et al. (Gu et al.). 
Expression based drivers were assessed using the ARACNE (Margolin et al.) and 
MARINa algorithms (Lefebvre et al.). Lastly, genotype-phenotype relationships 
were explored using the DriverNet algorithm (Bashashati et al.). 
 
To assess and validate prognostic markers, a statistical survival analyses 
framework was developed; where logrank and competing risk analyses were 
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performed for univariate analyses and Cox regression was applied to identify 
independent prognostic markers for ccRCC (Chapter 5).   
  
1.6 Thesis objectives and outline 
As discussed in this chapter, recent large scale ‘omics’ studies have led to the 
identification of key alterations in ccRCC, shown extensive inter-tumour and 
intratumour heterogeneity, and the possible utility of molecular biomarkers as 
clinical prognosis tools. However, multiple questions too have arisen from these 
studies; which somatic mutations/SCNAs drive ccRCC progression, which 
pathways are driving the aggressive subtype, how is resistance to therapy 
developing, can molecular markers help to improve patient prognosis and last but 
not the least, how may ITH affects all of the above. In this thesis, I present two 
parallel tracks, where a comprehensive integrated analysis of the available ccRCC 
‘omics’ datasets is performed, with the aim to better understand the biological 
mechanisms underpinning this cancer as well as evaluate prognostic biomarkers to 
improve prediction of patient prognosis.  The remaining chapters of this thesis are 
organised as follows: 
 
Chapter 2: Methods, presents the main methods and software applied in this work. 
This chapter introduces the two main datasets that were used to study ccRCC. The 
preliminary data processing before analyses is explained and all the methods and 
pipelines used in this thesis are detailed.  
 
Chapter 3: The molecular landscape of ccRCC. In order to explore the biological 
landscape of the cancer, this first results chapter details the analyses of the TCGA 
dataset – somatic mutations, CNVs and gene expression analysis. Data from Sato 
et al. (Sato et al.) and Scelo et al. (Scelo et al.) is discussed and compared with the 
TCGA dataset (The Cancer Genome Atlas Research Network). All datasets are 
carefully explained using some preliminary analyses. First, each individual ‘omics’ 
dataset is analysed on its own, following which integrated data analyses are 
presented. Individual somatic aberrations are investigated, discussing putative 
drivers and the gene expression signatures potentially controlled by these 
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aberrations. However, as cancer cells target pathways to mutate and not individual 
genes, this chapter details computational network analyses performed to explore: 
1) network properties of ccRCC genes. 2) Patterns of co-occurrence or mutual 
exclusivity of genetic aberrations. 3) Patterns of co-alterations of 
networks/pathways.  
 
Chapter 4: The quest for prognostic biomarkers. The above chapter 
investigates the biological factors contributing to variations in ccRCC. This chapter 
discusses the clinical impact of molecular signatures, including both genetic and 
transcriptomic makers for ccRCC, and further questions how ITH impacts the 
accuracy of these biomarkers. Here each identified molecular marker (n=28), is first 
assessed individually at the univariate level by 2 tests – logrank and competing risk 
analyses for association with Cancer Specific Survival (CSS). The validated 
biomarkers are then assessed in comparison to each other along with tumour stage 
and grade in a multivariate regression model. This model helped identify a 
molecular test, which adds further prognostic information to tumour stage. The 
effect of ITH of the identified biomarker is assessed in a multiregion biopsy cohort. 
 
Chapter 5:  Molecular drivers of the ccA/ccB signature. Having identified a 
molecular signature, which adds further prognostic information to tumour stage, 
and also shows reliable result despite ITH, this chapter explores this signature and 
the molecular drivers underlying these expression subtypes. The ultimate idea is to 
identify targets for adjuvant or immunotherapy for patients, which is as yet are 
lacking. Having observed clear differences between the ccA and ccB subgroups 
both at the genetic and transcriptomics levels individually, a more imperative 
objective is then to find the connections between these two levels and to identify 
putative drivers for both signatures, thereby identifying targets for therapy. 
 
Chapter 6: Discussion. An evaluation of the work performed in this thesis and 
conclusions drawn. The level of, importance and implications of ITH for ccRCC are 
discussed further along with future avenues still to be explored in the ccRCC field.  
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Chapter 2. Methods 
In this chapter, all methods used in the thesis are described in detail. Section 1 
details the datasets analysed whilst section 2 covers the preliminary data 
processing. Sections 3-4 describe the algorithms used to query these datasets in 
order to understand ccRCC biology. At each stage of the analysis, various methods 
were considered and evaluated. The method fitting best to the needs of each 
analysis was applied with typically the method providing the greater functionality 
being chosen. Sections 5-7 cover the statistical tests used for the prognostic 
analyses. Section 8 details the tests used to identify and analyse differentially 
regulated genes. Finally, section 9 describes the statistical tests used at various 
places throughout the thesis.  
 
2.1 Datasets 
There are two main datasets used for the analyses presented in this thesis; the 
data published by The Cancer Genome Atlas (TCGA) and a multiregion profiling 
dataset published by our collaborators.  
2.1.1 TCGA dataset 
The TCGA consortium has molecularly profiled over 400 ccRCC cases for somatic 
mutations, SCNA, RNA-Seq and clinical data (The Cancer Genome Atlas Research 
Network). Samples were collected from patients newly diagnosed with ccRCC, 
undergoing partial or complete nephrectomy and received no prior treatment 
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including chemo- or radiotherapy. There was no bias for sample collection against 
any surgical stage or histologic grade and staging was performed according to the 
American Joint Committee on Cancer (AJCC) staging system. According to this 
system, a tumour tissue can be classified as Stage I-IV, based on the size and 
extent of the primary tumour, the spread to neighbouring lymph nodes and the 
presence of distant metastasis (Figure 2.1). Stage I cancers are the least advanced 
while Stage IV are the most advanced with potential metastatic spread.  
 
 
Figure 2.1: The AJCC Staging system 
Figure explains the assignment of tumour stage I-IV based on the AJCC Staging 
system, taking into account the size of the primary tumour (T), the extent of 
necrosis (N) and the existence of metastasis (M). 
 
 
Histologic grade describes the microscopic appearance of the cancer cells. For 
kidney cancer, the Fuhrman grading system is used. There are four grades under 
this system; the higher the grade, the more abnormal the cancer cells look. Similar 
to the tumour stage, Grade 1 tumours are the most ‘normal’ in appearance and 
least likely to have spread whereas Grade 4 tumours would be most likely to have 
spread to metastatic sites.  
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Normal tissue specimens, where available, comprised either of blood components, 
adjacent normal tissue from > 2cm away from tumour or previously extracted 
germline DNA from blood or non-malignant tissue. The contributing tissue source 
sites were Catholic Health Initiative - Penrose St. Francis Health Services, Catholic 
Health Initiative - St. Joseph’s Medical Centre Cancer Institute, Christiana Care 
Health Services, Inc., Cureline, Inc., Fox Chase Cancer Centre, Harvard University, 
International Genomics Consortium, Mayo Clinic, MD Anderson, MSKCC, National 
Cancer Institute Urologic Oncology Branch, University of North Carolina and 
University of Pittsburgh. 
 
Data from TCGA has further been divided and referred into multiple datasets; the 
‘original’ dataset comprises data for somatic mutations (n=417), SCNAs (n=450), 
RNA-Seq (n=469) and clinical data (n=446); the downloaded time stamps were up 
to and including June 2013. A ‘core’ dataset of 350 cases was derived from this 
original dataset, which comprises cases for whom all of the above four information 
components is available. A further extension of some of these dataset components 
has been collated for use in certain places; time stamp for downloaded data 
corresponds to dates since January 2014, and this is referred to as the ‘extended’ 
dataset. 
 
2.1.2 Multiregion biopsy dataset  
Our collaborators in Prof. Swanton’s laboratory have profiled multiple regions from 
each tumour biopsy for ten ccRCC patients (Gerlinger et al., Gerlinger et al.), 
comprising of stage T2 (n=2), T3 (n = 7) and T4 (n = 1) cases. Eight out of the ten 
cases had metastatic disease (stage IV tumours) whilst two (RMH008 and RK26) 
were stage II patients. Three cases had no treatment prior to nephrectomy, while 
six (EV001, EV002, EV003, EV005, EV006 and EV007) received everolimus 
treatment, which is a mTOR inhibitor and one case (RMH002) received sunitib 
treatment, which is an anti-angiogenic drug. Biopsies from perinephric metastasis 
(M1) and from a chest wall metastasis (M2a and M2b) were available for EV001. 
For EV002, a biopsy from a metastasis obtained at the time of disease progression 
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on everolimus treatment was available (M2) (Gerlinger et al.). For EV006, lymph 
node metastasis (LN1a and LN1b) and a tumour thrombus from the renal vein of 
RMH004 (VT) were also available (Gerlinger et al.). 
 
Microarray data was generated with Affymetrix Gene 1.0 arrays. For the analyses 
performed in this thesis both microarray and DNA Sequencing dataset are 
available for a cohort of 63 regions from the ten patients (GSE31610 and 
GSE53000) with a minimum of at least four regions per patient. 
 
2.2 Data processing  
2.2.1 Somatic mutations 
Somatic mutation data was collected from the supplementary material of the TCGA 
ccRCC publication (The Cancer Genome Atlas Research Network). A mutation was 
considered to be non-synonymous (non-syn) depending on the value in the ‘Variant 
classification’ column (examples include ‘indels’, ‘missense’ and ‘nonsense’ for 
non-syn mutations and ‘silent’, ‘intron’ and ‘3’UTR’ for silent mutations), and was 
assigned to the mutant patient subgroup for each gene. Mutation frequencies for all 
genes were calculated based on non-syn mutations only unless otherwise specified.  
 
2.2.2 Copy number data and SCNA profiles 
The raw copy number profiles (original dataset) were downloaded and processed 
by Pierre Martinez in our collaborating laboratory for the original dataset. The 
aroma R package (CRMA v2, CalMaTe “v1” algorithm & TumorBoost) (Bengtsson 
et al., Bengtsson et al., Ortiz-Estevez et al.) was used to obtain logR and BAF 
values from SNP array data that was generated on Affymetrix Genome-Wide SNP 
Array 6.0 platform by the TCGA, using normal samples as references. Sex 
chromosomes were excluded from the analysis. The Allele-specific copy number 
analysis of tumours (ASCAT) algorithm was applied to all 450 samples to obtain 
copy number profiles (Van Loo et al.) as described in (Martinez et al.). The SCNA 
data was converted to cytoband level data using the cytoband coordinates 
retrieved from the UCSC Genome Browser database (http://genome.ucsc.edu/) 
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(Meyer et al., 2013). For each cytoband a weighted average copy number was 
obtained, and deletions and amplifications were defined as copy numbers deviating 
from the ploidy, as estimated by ASCAT, by more than 0.6, similar to the original 
ASCAT publication (Van Loo et al.). 
 
2.2.3 RNA-Sequencing data 
For each gene, raw RSEM (RNA-Seq by Expectation-Maximization) RNA-Seq 
counts as well as normalised counts, which had been normalised to the upper 
quartile counts by TCGA consortium, were downloaded from the TCGA data portal 
(https://tcga-data.nci.nih.gov/tcga/) on 18th September 2012. RSEM is a software 
package for estimating gene and isoform expression levels from RNA-Seq data.  
The files downloaded from TCGA included raw counts per gene per patient and a 
separate file contained normalised count per gene per patient.  
 
Raw counts were used where differential regulation analysis was performed 
(Sections 3.3.3.1 and 5.3.1.1). Normalised counts were used, after log2 
transformation, for performing clustering analysis (Sections 3.3.3.4 and 5.3). Only 
genes for which normalized RSEM counts were above 30 in at least 80% of the 
samples were included in further analyses. 
 
2.2.4 Microarray data 
Samples for mRNA expression profiling were collected in Prof. Swanton’s 
laboratory. RNA was extracted from all tumour specimens and corresponding 
normal kidney specimens where available and quantified on an Agilent Bioanlalyser. 
Expression profiling was done using the Affymetrix HuGene-1_0-st-v1 platform by 
an external service provider, for 63 tumour regions and for 6 samples from normal 
kidney from which sufficient high-quality RNA was available, and data was 
deposited in the in the GEO repository (GSE31232 and GSE53000). Samples were 
normalized using the oligo R package and the RMA algorithm in R.   
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2.2.5 Ploidy 
Ploidy is a measure of the number of chromosomes in a cell. Normal cells are 
diploid - that is they have two sets of each of the 23 chromosomes. Cancer cells 
can be diploid too but generally tend to have higher ploidy. Aneuploid cells are 
those that have either too many or too few chromosomes. Aneuploidy cancer cells 
may be more aggressive than diploid cancer cells. Ploidy estimates for each 
sample are obtained from ASCAT (Van Loo et al.). The algorithm calculates ploidy 
as the average total copy number for each sample.  
 
2.2.6 Weighted Genomic Instability Index (wGII) 
The wGII (Burrell et al.) score gives a numerical score between 0 and 1 and is the 
measure of the genomic instability of an individual’s genome. It is computed by first 
calculating for each chromosome of the sample, the proportion of bases whose 
copy number deviates from the ploidy value of the sample as given by ASCAT by 
more than 0.6. The sample wGII score is then calculated as sum of the 
chromosomal scores divided by the number of analysed chromosomes (n=22). This 
data was obtained from our collaborating laboratory. 
 
2.3 Significantly mutated genes and SCNAs 
2.3.1 MutsigCV 
To determine significantly mutated genes i.e. which are mutated more often than by 
chance, the MutSig (Mutational significance) algorithm (Lawrence et al., 2013) was 
used.  
 
This algorithm was implemented using the standalone package provided by the 
Broad Institute. A list of mutations identified through DNA sequencing is provided 
as input to the MutSig algorithm, along with information regarding the coverage of 
sequencing. The algorithm then models the background mutation processes that 
may be in play during tumour progression. It then assesses the mutations in each 
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of the input gene and identifies genes, which are mutated more often than random, 
given the background mutation model. 
 
Several versions of MutSig have been developed since its inception, differing in the 
manner in which they determine the background mutation rate (BMR); MutSigCV 
being the most recent and the most sophisticated to date. While MutSig1.0 
assumed a constant BMR to be applicable throughout the genome, MutSig1.5, 
estimated the BMR from assessing the silent mutations in each gene as well as the 
estimated expression levels of the gene. The TCGA consortium used Mutsig1.5 in 
their publication. MutSig2.0 added two new measures, namely clustering of 
mutations in hotspots in a gene and the functional impact of each mutation.  
 
After testing a number of prototype versions, MutSigCV was developed. The "CV" 
stands for "covariates". Here the BMR is estimated by taking into account 
information on ‘neighbouring’ genes in the covariate space. Genes selected to be in 
the neighbouring space are chosen on the basis of similar genomic properties to 
the gene under consideration. MutSigCV was applied to the original (n=417) as well 
as the extended (n=549) datasets and results were compared to those published in 
the TCGA publication (The Cancer Genome Atlas Research Network). 
 
2.3.2 GISTIC 
The results from a SNP array analysis, subsequently fed into the ASCAT algorithm 
provide a numerical copy number for each analysed cytoband. While this data can 
be used to assess which cytobands are amplified or deleted (as described in 
Section 2.2.2), identifying which of these regions maybe associated with the 
disease of interest presents a non-trivial problem. The GISTIC algorithm (Mermel et 
al.) was designed to identify regions of the genome, which are significantly 
amplified or deleted across a set of samples in a given phenotype (disease state). 
The algorithm works by assigning a so-called G-score to each sample that takes 
into account the amplitude of its aberration (amplification/deletion) as well as the 
frequency of aberration across all samples. Using this G-score, False Discovery 
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Rate (FDR) q-values are calculated for each aberrant region; regions with q-values 
below a user-defined threshold are considered significant.  
 
GISTIC 2.0 package (Mermel et al.) available on the Broad Institute’ GenePattern 
portal (Reich et al.) was run on SCNA data from TCGA to determine amplifications 
and deletions of interest in our cohort. The required inputs to the package include a 
segmentation data file, which provided copy number details for all cytobands for all 
samples (n=555). It has six columns, namely sample id, chromosome, start position, 
end position, number of markers for this region and a segmented copy number 
(CN) which is the log2 ratio of the CN with respect to the sample ploidy were 
provided. A markers file was also provided which gives the cytoband (markers) 
names and positions of the cytobands in the original dataset before segmentation. 
The reference genome used was hg19, the threshold for defining amplifications 
and deletions was set at the default value of log2 ratio = 0.1; all other parameters 
were set to their default values. 
 
For the output, GISTIC provides an all lesions file, which gives details of all the 
significant regions, identified by the algorithm. For each significant region, a “peak 
region” is identified, which represents the part of the aberrant region, which has the 
highest amplitude, and frequency of alteration. Additionally, a “wide peak” region is 
also determined in a leave-one-out manner to allow for errors in the identification of 
the boundaries in a single sample. These wide peaks are considered to be more 
robust for identifying the more likely gene targets in the region.  
 
2.4 Network analyses algorithms  
As discussed in section 1.4.2 of the Introduction, network analyses methods 
provide a great medium to study cancer biology. Various state-of-the-art algorithms 
were either directly applied or adapted for the work presented in this thesis. This 
section describes these algorithms. In brief, for detection of strongly connected 
subnetworks in an undirected PPIN, the MCODE algorithm was applied. This 
method was chosen due to its availability as a computationally inexpensive 
package in Cytoscape. To compare the results obtained from analysis of the PPINs, 
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the Dendrix algorithm was chosen as it provides a good contrast in terms of 
obtaining clusters of genes without using background knowledge of its interaction 
partners. To detect co-altered modules, an adaptation of a probabilistic algorithm 
by Gu et al. (Gu) was developed. At the time this study was performed, it was one 
of the few algorithms developed in this area and provided a good foundation for the 
analysis presented.  
 
At the gene expression level, to detect master regulators, ARACNE and MARINa 
algorithms were applied. These are well-established algorithms that are widely 
used in the field. Lastly, to assess if algorithms extending the paradigm of co-
relative analyses to test genotype-phenotype relationships could provide additional 
information, the DriverNet algorithm was applied.  
 
2.4.1 Constructing a Protein-Protein Interaction Network (PPIN) 
A protein-protein interactions (PPIs) database was created by downloading and 
combining data from five databases, namely IntAct (Orchard et al.), MINT (Licata et 
al.), DIP (Xenarios et al.), HPRD (Keshava Prasad et al.) and BioGRID (Chatr-
Aryamontri et al.) (all downloaded before September 2013). These primary 
databases collect potential PPIs from the scientific literature; these PPIs have been 
experimentally verified using methodologies such as yeast two-hybrid, mass 
spectrometry and co-immunoprecipitation. MySQL was used to generate the 
combined database of interactions. Each row of the database corresponded to one 
protein-protein interaction and along with the protein-id information was extracted 
on the method of detection, the source of interaction (given as PubMed id), and the 
database from which it was extracted. Interactions were extracted from this 
database for ccRCC altered genes to generate a ccRCC specific PPIN. 
 
2.4.2 Detecting strongly connected subnetworks 
Module or subnetwork detection was performed using the Molecular Complex 
Detection (MCODE) (Bader and Hogue, 2003) algorithm. The algorithm uses vertex 
weighting by local neighbourhood density and traverses outwards from a locally 
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dense seed protein to isolate the dense regions according to given parameters. 
There are several advantages of this algorithm; first it has a directed mode that 
allows fine-tuning clusters of interest without considering the rest of the network, 
secondly it allows examination of cluster interconnectivity, which is relevant for 
protein networks. Lastly, it is claimed not to be affected by a known high rate of 
false positives in data from high-throughput interaction techniques, which are 
generally applied to generate protein-protein interaction data.  
 
2.4.3 Dendrix 
To examine mutual exclusivity patterns of mutations independent of protein-protein 
interaction information the Dendrix algorithm was applied. Dendrix (De novo Driver 
Exclusivity) (Vandin et al., 2012) is an algorithm for discovery of mutated driver 
pathways in cancer using only mutation data. The algorithm applies a Monte Carlo 
search to find sets of genes mutations in which exhibit both high coverage and 
mutual exclusivity in the analysed samples. 
 
2.4.4 Co-altered modules 
To explore co-alteration of pathways, a probabilistic model (Gu et al., 2013) was 
applied. The algorithm was coded in the programming language Python. It takes 
into account the likelihood of co-occurrence of genetic alterations in patients and 
combines it with a network search algorithm to identify co-altered modules in a 
background gene interaction network. The ccRCC specific PPIN generated above 
was used as the background. The probability of co-occurrence of genes was 
calculated using Equation 2.1: 
 
 2.1 
  
 
Where G1, G2 are the modules, n is the number of all samples, a is number of 
samples with alterations in both modules, b is the number of samples with 
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alterations only in G1, c is the number of samples with alterations only in G2 and d 
is the number of samples with alterations in none of the modules.  
 
The score for each module pair is then calculated as the negative logarithm of the 
probability (Equation 2.2): 
 
 2.2 
                                                                   
 
2.4.5 Detecting master regulators at the Gene expression levels: MARINa 
algorithm 
The MARINa (Master Regulator Inference Algorithm) (Lefebvre et al., 2010) 
algorithm was applied to find gene expression based regulators. First, a gene 
expression network needed to be generated for which the ARACNE (Algorithm for 
the Reconstruction of Accurate Cellular Networks) algorithm (Margolin et al., 2006) 
was used. ARACNE reverse engineers a network from gene expression data using 
an information theoretic approach, to calculate mutual information between gene 
pairs. This approach has been described as effective to eliminate majority 
of indirect interactions, which are typically inferred by pairwise analysis. The 
ARACNE standalone implementation was downloaded and used to generate the 
network. The input to the tool is a gene expression matrix with each row 
representing a gene and columns correspond to patients. An adjacency matrix is 
retrieved as output with a probability of interaction between gene pairs in each cell. 
 
The R package ‘viper’ was used to implement the MARINa algorithm. The 
adjacency matrix obtained from the ARACNE algorithm along with the original gene 
expression matrix is provided as input. The algorithm is designed to infer 
transcription factors (TFs) controlling the transition between the two phenotypes – 
‘normal’ and ‘tumour’ in this work, as well as the maintenance of the latter 
phenotype.  
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2.4.6 DriverNet 
Extending on the genotype-phenotype relationship detection, the DriverNet 
algorithm was also applied (Bashashati et al.). This algorithm integrates genetic 
alterations (mutation and copy number variation data) and transcriptome data 
(gene expression data) to predict functional important driver genes in cancer. This 
algorithm makes a bipartite graph with the genetic alterations on one side of the 
graph and the corresponding gene expression data on the other side (as discussed 
in Introduction section 1.4.1). It then uses an influence graph, which is a gene-gene 
interaction network derived from pathway data. A greedy algorithm is then applied 
to find the possible driver genes (based on frequency of alteration), which may be 
pushing the gene expression values of the connected genes to some extreme 
values. 
 
2.5 Classification of patients into prognostic groups  
In Chapter 4, a number of variables were assessed for association with ccRCC 
prognosis. This section describes how patients were classified into subgroups for 
each variable under consideration.  
 
2.5.1 Somatic mutations 
Somatic mutations in five genes, namely VHL, PBRM1, SETD2, BAP1 and TP53 
were analysed. CSS was assessed for patients with tumours harbouring a non-
synonymous mutation in the gene vs. patients with tumours without the mutation. 
For VHL, association with survival was also tested under the specific constrains of 
only being in stage I-III tumours and for those with loss of function mutations only 
(defined as frameshift and nonsense mutations), as compared to all other patients. 
 
2.5.2 SCNAs 
A total of 14 candidate SCNAs were assessed for association with CSS. CSS was 
compared between patients with tumours harbouring a specific SCNA vs. those 
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with tumours without these SCNAs. Amplification or deletion of ≥50% of a 
chromosome arm or of both arms of a chromosome was considered to be 
equivalent to an arm level alteration as described (The Cancer Genome Atlas 
Research Network) or to a whole chromosome aberration respectively. For 
Chrom22 deletion (identified as a candidate prognostic biomarker), the SNP array 
data did not include any probes for the Chrom22 p-arm, thus deletion of Chrom22q 
was used as a substitute measure.  
 
2.5.3 Gene expression RNA-Seq data  
Log2 transformed expression data was used to divide the cohort into 2 groups at 
median values for CD31 and EDNRB expression levels and at 33rd percentile 
value for TSPAN7 expression levels (Wuttig et al.).  
 
For all cluster-based analyses performed in this thesis, the Non-negative matrix 
factorisation (NMF) clustering (Brunet et al.) method has been used. Consensus 
NMF clustering uses the principle of dimensionality reduction, using non-negative 
matrix factorisation, to find a set of metagenes from the given gene list; it then uses 
these metagenes to perform the clustering of samples. The metagenes are defined 
as a positive linear combination of the genes for which expression has been 
provided in the dataset submitted as input. It repeatedly runs the algorithm against 
variations of the gene expression data and creates a consensus matrix to assess 
the stability of the resulting clusters. 
 
The Consensus NMF clustering package provided on the Broad Institute’ 
GenePattern portal (Reich et al.) was used to implement this method. The input to 
the algorithm is the gene expression matrix, where rows are genes and columns 
represent patients and thereby each cell represents the expression for the gene for 
the respective patient. Log2 normalised RSEM counts were provided as input for 
this analysis. The cluster number (k) range was set between 2 ≤ k ≤ 10.  The 
number of clustering’s to be tested was set to 50 and 1000 iterations per clustering 
were performed for each k value.  
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Expression data for genes in each identified gene expression signatures (Kosari et 
al., Zhao et al., Lane et al., Brannon et al., Beleut et al.) was submitted for 
consensus NMF clustering analysis. Gene expression was available for 26 out of 
35 genes (74%) from (Kosari et al.), 220 out of 259 genes (85%) from (Zhao et al.), 
36 out of 44 (82%) genes from (Lane et al.), 103 out of 110 (94%) genes from 
(Brannon et al.) and 37 out of 48 (77%, Cluster B vs. A/C) and 21 out of 23 (91%, 
Cluster A vs. C) genes from the two gene panels from (Beleut et al.) respectively. 
The cluster number range was predefined from two to ten. Each clustering run 
returned a cophenetic correlation coefficient, which measures the stability of cluster 
assignments, as well as consensus clustering maps. Based on both these results, 
the optimal numbers of clusters for each gene expression panel were identified. For 
each signature, the same number of clusters was considered to be optimal as had 
been identified in the original publications. 
 
For the TGFβ pathway signature (Bostrom et al.), a TGFβ activity score for each 
sample was defined as follows. RNA-Seq counts were available for 145/157 TGFβ 
regulated genes, the log2 normalised RSEM expression counts for these genes 
were multiplied by either 1 or -1, depending on their expected regulation by TGFβ. 
These values were then averaged to give a relative TGFβ score for each sample. 
Using the median score of all samples as the cut-off, patients were divided into 
TGFβ low activity and TGFβ high activity cohorts as previously described (Bostrom 
et al.). 
2.5.4 Analysis of multi-region biopsy data: classification of tumour regions 
into ccA and ccB prognostic groups 
Expression data was available for 107 out of 110 genes from the ccA/ccB signature 
(Brannon et al.). This data was used to classify the 63 tumour regions into either 
ccA/ccB expression subgroups by applying consensus NMF clustering analysis for 
a predefined number of clusters from two to ten. The cophenetic coefficient was 
highest for two clusters. Clustering was also performed using the Clearcode34 
panel (Brooks et al.) and the same cluster assignments were obtained for 61 out of 
63 (97%) regions. 
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2.6 Clinical statistics for biomarker assessment  
One of the main questions asked in this thesis and presented in Chapter 4, is 
querying suitable biomarkers for predicting patient prognosis. To this end, the 
analyses query the effect of a biomarker on the patient cohort. A number of 
statistical measures in clinical studies were used, which are described here. All 
tests were implemented in R v 3.0.1 (R Development Core Team) using the 
packages ‘survival’ (Therneau and Grambsch, Therneau), ‘cmprsk’ (https://cran.r-
project.org/web/packages/cmprsk/index.html) and randomforestSRC (Ishwaran and 
Kogalur, Ishwaran et al.).  
 
2.6.1 The Kaplan-Meier estimate  
The Kaplan-Meier (KM) estimate (Kaplan and Meier) is the most prominent test 
used to estimate the effect of a variable on the survival of patients. It measures the 
length of time patients lived after a predefined point in time. For example, it may be 
used to estimate the length of life of patients after receiving a particular treatment. 
For cancer studies, the end point of interest is either relapse of disease or death 
due to disease. Mathematically, the KM estimate measures the probability of 
surviving a given length of time while considering time in many small intervals 
(Equation 2.3).  
 
 2.3 
                                                                              
 
Where S(t) is the probability of survival at time t, and F(t) represents the cumulative 
frequency distribution of the random variable T. 
 
However, certain points need to be considered here; apart from the cases which 
may or may not reach endpoint (death), there will be cases for which follow-up will 
be lost due to known or unknown reasons, such as death due to other unrecorded 
causes, loss of contact or unwillingness to maintain contact. In such cases, the 
patients are ‘censored’ at the point of last contact. Three main assumptions form 
the basis of the KM estimate; first, that at any point in time, survival probability is 
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similar between cases that are censored and those that continue to be followed up. 
Secondly, the chances of survival of any patient are independent of the time of 
recruitment of the patient into the study cohort. Finally, the event happens at the 
time recorded in the study.   
 
2.6.2 Logrank test 
The logrank test (Clark et al.) is one of the most routinely used measures to assess 
the effect of either a drug or a prognostic biomarker in clinical studies. While the 
KM estimate discussed above is the best measure to estimate survival probability, 
it is not capable of comparing multiple survival curves and assess if they are 
significantly different.  
 
Figure 2.2 clearly shows two survival curves to be different; however, the objective 
here is to assess the statistical significance of such differences. The logrank test is 
a widely used statistic to achieve this objective. It tests the null hypothesis that 
there is no difference between the KM curves for the different populations under 
consideration i.e. the probability of an event (here a ‘death’ event) is not different 
between the populations at any given point of time (Bland and Altman).  
 
 
 
Figure 2.2: Kaplan-Meier survival curves 
Figure depicts example survival curves to be compared and the need for a 
statistical test to distinguish between them  
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A definitive advantage of using the logrank test in this setting is the fact that it is 
based on the same assumptions as the KM estimate; i.e. censoring is unrelated to 
prognosis, the probability of survival is independent of the time of recruitment of the 
subjects and the events took place at the recorded time points (Bland and Altman).   
 
Logrank test was performed using the survdiff() function from the package ‘survival’ 
in R to estimate the p-value of significance for differences between the KM curves.  
 
2.6.3 Hazard ratio 
In a survival analysis, the hazard ratio (HR) refers to the rate of risk (death) due to 
the explanatory variable with respect to a reference state. It is often used in clinical 
trials to measure the survival at any point of time for patients in a particular group 
(e.g. treatment) with respect to the placebo group. A HR = 1 means that there is no 
difference in the survival of the two groups being compared. HR > 1 means the risk 
of death is higher in the considered group, while HR < 0 means the patients in the 
reference group are at a greater risk of death.  
 
Since the logrank test is a test of significance only, the effect of a variable using 
this test cannot be measured. For this purpose, a Cox proportional hazard model is 
applied. This model assumes that the hazard or risk of a factor is constant 
throughout the study period and calculates the hazard for a variable using the 
formula shown in equation 2.4; mathematically, if Oa and Ob are the observed 
number of events in the two groups a and b under consideration, and Ea and Eb are 
the expected number of events, the HR can be then calculated as: 
 
 2.4 
  
The null hypothesis here will be that there is no difference between the HRs of the 
two groups. The coxph() function from the package ‘survival’ in R (R Development 
Core Team) was used to estimate the HRs and 95% C.I. for each variable. 
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2.6.4 Competing risk analysis  
While the logrank is a widely used test, a limitation of the test is that the censoring 
is uninformative i.e. it cannot take into consideration the reasons for censoring. For 
example, for the work presented in this thesis, death due to cancer is the event of 
interest; thus for the purposes of the logrank test, all other patients, whether alive 
or dead due to other causes, were treated as censored at the time point where the 
information about them was last recorded. This may lead to overestimation of the 
effect of a biomarker. To avoid such overestimation, competing risk (CR) analysis 
was performed for all variables that were observed to be significant in the logrank 
analysis.  
 
A CR analysis evaluates the cumulative incidence of the variable under 
consideration (Equation 2.5). It also takes into account the death of patients due to 
causes other than cancer. The cumulative incidence of the variable k represents 
the proportion of patients at a time t who have died from cause k, while accounting 
for the fact that patients can die from other causes. 
 
 2.5 
                                                                                                          
Where hk represents the cause-specific hazard, X is the vector of covariates and S 
is the overall survival function. The CR test was implemented using the cuminc() 
function from the ‘cmprsk’ package in R and used to estimate the p-value of 
significance.  
 
2.6.5 Multivariate Cox regression analysis 
To assess the independence of the variables that were validated in the univariate 
analyses (logrank and CR analyses), and to question whether any of these 
variables added further information to the clinical variables in use, a multivariate 
Cox regression analysis was performed. A Cox model (Cox) calculates the hazard 
at any time point t as a function of the baseline hazard and the coefficient of 
regression β of each variable X in the model: 
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 2.6 
  
The backwards-stepwise selection model was used. All variables, which had a p-
value ≤ 0.05 in the univariate analyses, were added to the model along with the 
clinical variables Tumour stage and Fuhrman grade. An initial p-value was 
generated for all variables in the model, following which the variable with the worst 
(highest) p-value was iteratively removed from the model, until all variables in the 
model had a p-value ≤ 0.05.  The hazard ratio, 95% confidence interval (C.I.) and 
p-value was noted for all the significant variables, whilst for all non-significant 
variables, the hazard ratio, 95% confidence interval (C.I.) and the p-value was 
generated at the step it was removed. The coxph() function from the package 
‘survival’ in R was used to implement the backwards-stepwise regression model. 
 
2.7 Supervised learning algorithms 
2.7.1 Recursive partitioning – classification trees 
Decision tree based algorithms provide a useful extension to survival analysis 
methods. These algorithms can be applied to build stratification models where 
patients are classified using the statistical tests described above to guide the 
splitting process, into distinguishable groups. Recursive partitioning for single 
decision trees and Random Forests for cross-validated stratification modelling are 
two of the most commonly applied and robust methods for classification and 
regression problems and were therefore used in this study. 
 
Recursive Partitioning (RP) (Banerjee et al.) was used to build a stratified patient 
prognosis model. This is a tree-based analysis, which can be used to classify 
patients into different cohorts based on given input parameters. The response 
variable in this work was a survival object i.e. time to death and a R implementation 
of RP using the function ‘ctree()’ in the package ‘party’ (Hothorn et al.) was used. 
Briefly, the algorithm tests the null hypothesis for independence between the 
explanatory variables and the response. It stops if the hypothesis cannot be 
rejected; otherwise, it selects the input variable with strongest association to 
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response. It then implements a binary split based on this variable. This step is 
recursively repeated. For survival response, the split is based on maximising the 
likelihood ratio of survival. The input to this function was a matrix where each row 
represented a patient and columns represented the input parameters along with the 
days to death/last follow up of patients and dead/alive status of the patients. Unlike 
Cox analysis, RP is adept in uncovering variables that may be largely operative 
within a specific patient subgroup but may have minimal effect or none in other 
patient subgroups.  
 
2.7.2 Random forest  
The random forest (RF) (Breiman) method consists of a supervised learning 
algorithm that is commonly used for both classification and regression problems. It 
was used in this thesis to implement a classification model and to test the 
significance of the variables most important to distinguish between the two 
classifications. It uses an ensemble of trees to decide the classifications where 
each tree is generated on the principle of recursive partitioning. For classification 
problems, the final prediction is a majority vote of all the trained decision trees. The 
‘Random’ aspect of the RF algorithm is related to the way it builds each decision 
tree. For a training set of N samples, sampling with replacement is performed and 
two thirds of this sample is used as the training set for a given decision tree in the 
forest. The other one third (termed as the oob (out-of-bag) data), is used to get an 
unbiased estimate of the test error and for variable importance measures. The 
second randomization involved in the RF’s decision trees is that at each node, not 
all features are available for making a split. Rather random samples of ‘mtry’ 
features are chosen at each node and the best split is chosen amongst them. An 
important aspect of the RF is that the test error is reduced with more accurate and 
less correlated decision trees. Part of the randomization procedures employed in 
the tree building are in fact aimed at introducing variability in the hope of achieving 
low correlation between decision trees. The mtry parameter is therefore central to 
the RF method. Given a powerful descriptor in the set of features, for high mtry 
values, it is more likely that this descriptor would be chosen in the random sample 
and subsequently used at the node split. Therefore this descriptor would dominate 
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most of the trees, resulting in highly accurate trees but with low correlation. If the 
mtry parameter is set too low, then the powerful descriptor might be missed out 
from most of the trees. The RF would then consist of low correlation trees but with 
low accuracy. Though this parameter is the one to which the RF is most sensitive, it 
has a broad range of optimal values (Breiman).  
 
RF Variable Importance Measure: Once the random forest has been built and the 
oob error estimate for each tree recorded, the importance of each feature to the 
prediction is measured as follows. For each feature m, all of its values are 
randomly permuted and the oob examples are fed through the trees with m 
randomly permuted. The importance score of feature m is the different between the 
original oob error estimates, and the new ones with m permuted. The importance 
score is then normalized by the standard deviation of these differences across all 
trees. Large values imply more important features.  
 
Random forest was implemented using the R package ‘randomforestSRC’. The 
function rfsrc() was used to build trees with all default parameters and selecting a 
1000 trees to build the random forest. The Variable importance was then 
determined using the function vimp(), on the results obtained from the random 
forest prediction. 
 
2.8 Differential expression analyses 
Testing for differential expression between phenotypes (tumour vs. normal) 
enables the identification of the genes or pathways that may help define the 
phenotype. Differential expression analyses were performed at two levels; first to 
identify top deregulated genes (either up- or down-regulated) in ccRCC patients 
when compared to normal kidney samples. These genes were then assessed using 
overrepresentation analyses. In the second pipeline, Gene Set Enrichment analysis 
was performed using the complete set of genes for which RNA-Seq data was 
available. The details and differences between the two methods are discussed 
below. 
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2.8.1 Differentially regulated genes 
To identify genes most significantly deregulated in ccRCC, differential expression 
(DE) analysis was performed for tumour samples over normal samples (Chapter 3) 
and between ccRCC subgroups (Chapter 5) using the edgeR (Robinson et al.) 
package in R.  
 
The input to the package included two files; the first was a data matrix where the 
columns represented patients (j) and the genes represented rows (i) and thus every 
cell (ij) gave the raw RNA-Seq RSEM count for that gene for the respective patient. 
The second file was a phenotype file, which defined the patient’s subgroup (tumour, 
normal or ccRCC subgroup). This file was then used in the package to specify 
which subgroups should be used to make the comparisons.  
 
The edge R package is based on negative binomial distribution for count data. The 
algorithm estimates gene-wise dispersions and uses an empirical Bayes process to 
shrink this dispersion towards a consensus value. The differential expression is 
then assessed by an adaptation of Fisher’s exact test for over-dispersed count data.  
 
The output from the final DE estimation function gives three values for each gene 
that was assessed; the log fold change (FC), the log counts per million (CPM) and 
the p-value. These p-values were corrected using the False discovery rate (FDR) 
correction using the p.adjust() function in R. Using a fold change cut-off of |log FC| 
≥ 2.5 and a FDR q ≤ 0.05, the final list of differentially regulated genes was 
obtained. 
 
2.8.2 Overrepresentation analyses 
A Gene ontology (GO) or pathway overrepresentation (ORA) or enrichment 
analysis refers to an analysis which tests how significantly overrepresented are 
certain GO terms or pathways in a list of genes than if a similar list was chosen at 
random. Essentially each gene in the list is assigned to a term (GO term or 
pathway), and all genes belonging to the same term are then collected together; 
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this collection is compared with a random gene list of the same size to assign a p-
value of significance to the enrichment of this term. 
 
For this purpose, both a hit list (from the given gene list) and a population list 
(random list from all genes available) are compiled, and then the aim is to assess 
the significance of the difference between these two lists. The most common 
approach to test this statistically is by using the hypergeometric test (or its variants 
such as Fisher's exact test) to calculate the probability of seeing at least a 
particular number of genes containing the biological term of interest in the gene list. 
ORA analysis has been implemented in this thesis using tools available from 
MSigDB (Liberzon, Liberzon et al.) and genego portal (Thomson Reuters, 
https://portal.genego.com/).  
 
For MSIGDB, for the pathway ORA, KEGG (Kanehisa et al., Kotera et al., Tanabe 
and Kanehisa), Biocarta (http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways) 
and Reactome (Croft et al., Haw and Stein) databases were used to compile the 
background population lists. In the case of GO enrichment, only the biological 
processes (BPs) terms were used to compile the background. The top 100 
pathways overrepresented in the input list (as compiled by DE analysis) were 
returned. 
 
For the genego portal, for GO ORA, only the BP category as above was used. For 
the pathway ORA, pathway annotations from KEGG, Biocarta, Reactome were 
used. All pathways or GO processes which passed the FDR q ≤ 0.05 were returned. 
 
It was thought prudent to consider two sources, firstly for the sake of validation, and 
secondly since a longer/more extensive list was required and MSigDB only returns 
the top 100 hits; therefore, the genego portal was also used.       
                                                                                      
2.8.3 Gene set enrichment analysis 
Gene Set Enrichment Analysis (GSEA) (Subramanian et al., Mootha et al.) is a 
computational method that was developed to determine whether an a priori defined 
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set of genes shows statistically significant, concordant differences between two 
biological states, for example tumour samples and normal kidney samples in the 
work presented here. It is different from the ORA described above in the manner 
that a GSEA uses the complete list of genes assessed, irrespective of FCs and p-
values, to find significance of overlap between deregulated genes and the 
population gene sets. 
 
The stand-alone version of GSEA tool provided by the Broad Institute was used to 
run the analysis. For the purposes of this thesis, pre-ranked GSEA was performed. 
This means that edgeR was run, and using the log FC from the output, the 
complete list of genes was subsequently ranked. This ranked list was provided as 
input for GSEA.  
 
The GSEA output has two lists; one is a list of pathways which are up-regulated i.e. 
show more positive FCs than seen by chance and the other is the list of down-
regulated pathways. Using FDR q ≤ 0.05, a list of significant pathways for each 
comparison was compiled.  
 
2.9 Statistical measures 
2.9.1 Multidimensional Scaling 
Multidimensional Scaling (MDS) is a method to visualise the similarities and 
differences between individual samples in a dataset. The R implementation of 
MDS, cmdscale() was used to visualise the differences between tumour and 
normal samples in the RNA-Seq original dataset (n=469). A distance matrix was 
provided as input, which was calculated as the Euclidean distances between the 
cases based on the gene expression values.  
2.9.2 Wilcoxon test 
The Wilcoxon (Wilcox) test is a non-parametric test, which can be used when 
comparing the distribution of repeated measurements of a numerical variable 
between two groups such as disease vs. normal. It tests the difference between the 
median observations between the two groups where the null hypothesis is defined 
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as being no difference between the medians. It is used as an alternative to the 
paired Student's t-test when the population cannot be assumed to be normally 
distributed. It has been used at various points in this thesis to assess the 
differences between patient subgroups for various numerical variables. The 
wilcox.test() function in R was used to implement this test and to estimate a p-value 
of significance.  
 
2.9.3 Fisher’s test 
The Fisher's exact test is used to test the independence of two nominal variables. It 
estimates whether the proportions of one variable are significantly different 
depending on the values of the other variable. It has the definitive advantage over 
other tests, such as chi-square, since it can be used for smaller sample sizes as 
well. It has been used in this thesis to test the relationships of occurrence between 
mutations, SCNAs, patient subgroups and genetic alterations. The fisher.test() 
function in R was used to perform the Fisher’s exact test.  
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Chapter 3. The molecular landscape of ccRCC 
3.1 Introduction 
As discussed in the Introduction section 1.2, despite recent advances in the 
detection of recurrent mutations and somatic copy number alterations (SCNAs) in 
ccRCC, our understanding of the pathogenesis of the disease is still limited. While 
nephrectomy has shown to be curative for localised disease, relapse is not 
infrequent. ccRCC is highly resistant to chemotherapy and radiotherapy and 
therapeutic success is limited. To develop suitable therapies, understanding the 
disease mechanisms is imperative. Recent large-scale sequencing and expression 
profiling efforts provide the opportunity to comprehensively investigate genotype-
phenotype correlations. This should improve our understanding of ccRCC biology 
and potentially shed lights on what drives ITH. Researchers at The Cancer genome 
atlas (TCGA) have comprehensively measured and provided genomic, epigenetic, 
expression as well as clinical data for over 400 ccRCC patients. This dataset is 
based on single biopsies, and thus they overlook ITH; however, they have large 
numbers of patients, allowing for correlative analysis.  
 
In this chapter, with the aim to better understand ccRCC biology, somatic mutation, 
SCNA and RNA-Sequencing (RNA-Seq) data sets, molecularly profiled by the 
TCGA (The Cancer Genome Atlas Research Network) are investigated and a 
series of integrated analyses performed upon them. Wherever possible, 
comparisons were also made with other datasets identified in the literature (Sato et 
al., Scelo et al.), enabling some key insights into ccRCC mechanisms to be drawn. 
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In the TCGA publication on ccRCC (The Cancer Genome Atlas Research Network), 
a number of key disease associated factors were highlighted including mutations in 
oxygen sensing (VHL) and chromatin modifying genes (for example PBRM1), 
down-regulation of metabolism related pathways and recurrent mutations in the 
PIK3CA/MTOR pathway. Here these findings are expanded upon by making use of 
the availability of multiple “omics” datasets thereby providing the opportunity to 
perform integrated analyses of genetic and transcriptomic data to understand some 
of the functional consequences of the genetic mutations observed.  
 
Heterogeneity in cancer, both inter-patient and intratumour, were discussed in 
sections 1.2.5 and 1.4 of the Introduction. This presents a hurdle for quantitative 
correlative analyses between expression signatures and individual somatic 
mutations. The big question now, is how can this high volume of primary 
information, collected at both the genetic and phenotypic levels, be integrated to 
help cancer patients? Computational network algorithms have become increasingly 
popular as useful tools for the integration and interpretation of these complex 
datasets to study cancer mechanisms. In this work, advantage is taken of key 
concepts and state-of-the-art algorithms, which are then applied to both genetic 
and transcriptomic ccRCC datasets. 
 
3.2 Methods 
All the methods and algorithms applied in this chapter are briefly explained in the 
following sections; references to more detailed descriptions, Chapter 2, are 
provided in each section. 
 
3.2.1 Data processing 
Somatic mutations 
Somatic mutation data for the original dataset was obtained from the 
supplementary material of the TCGA publication for ccRCC (The Cancer Genome 
Atlas Research Network). A gene was considered to be mutated based on the 
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classification in the ‘VARIANT TYPE’ column. Mutation frequencies were calculated 
based on non-synonymous mutations only.  
 
Gene expression data 
For both the core and extended datasets RNA Sequencing (RNA-Seq) data was 
downloaded from the TCGA data portal. Both raw counts generated by the RSEM 
method and normalised RSEM counts, normalised to the upper quartile by TCGA, 
were downloaded from the data portal (https://tcga-data.nci.nih.gov/tcga/) on 18 
September 2012. Raw and normalised datasets have been used for different 
analysis in this chapter as described in the relevant sections. Normalised counts 
were log2 transformed before further analyses. In either case, only genes, for 
which the counts (raw and normalised resp.) were above 30 in at least 80% of the 
samples, were included in all analyses. 
 
3.2.2 Significantly mutated genes 
MutsigCV (Lawrence et al.) was run to assess significant mutations from the TCGA 
mutation matrix. The input data to MutSigCV is the list of mutations in all the 
samples for which DNA sequencing is available. It builds a model of the 
background mutation processes, and analyses the mutations of each gene to 
identify genes that were mutated more often than expected by chance, given the 
background model. (Methods section 2.3.1) 
 
3.2.3 SCNAs significantly associated with ccRCC 
To determine which SCNAs are associated with ccRCC biology, GISTIC (Mermel 
et al.) was run on the copy number calls from ASCAT (as described in Methods 
section 2.2.2). For this analysis an extended cohort of 555 cases for which SCNA 
data was available was used. This analysis was done in collaboration with Dr Peter 
Van Loo. GISTIC requires a segmented copy number profiles file, where each line 
represents the copy number of a particular chromosomal region (represented in 
coordinates) for each patient. Another file mapping these coordinates to specific 
regions is also provided (Methods section 2.3.2).  
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3.2.4 Multidimensional scaling 
Multidimensional scaling (MDS) was applied on the gene expression RNA-Seq 
data to determine and visualise the differences in expression between normal and 
tumour samples. The R implementation of MDS, the function cmdscale() was used 
and a distance matrix was provided as input to estimate similarities and differences. 
(Methods section 2.9.1) 
 
3.2.5 Differential regulation analysis 
The edgeR (Robinson et al.) package in R (R Development Core Team) was used 
to find differentially regulated genes. The edgeR output provides three different 
values for each gene in the input, namely log FC, log CPM, and the p-value for the 
significance of deregulation. All p-values can then be corrected for multiple testing 
using the function p.adjust() in R (R Development Core Team). A list of significantly 
differentially regulated genes can then be generated using p-value and/or fold 
change cut-offs. (Methods section 2.8.1)  
 
3.2.6 NMF clustering 
The top 1500 genes showing the maximum variation (high standard deviation) 
across all tumour samples were used to perform NMF clustering to find the optimal 
number of subgroups for ccRCC (Methods section 2.5.3). 
 
3.2.7 Overrepresentation analyses 
Using MSigDB (Liberzon et al., Liberzon) and the genego portal (Thomson Reuters, 
https://portal.genego.com/), GO and pathway overrepresentation analyses were 
performed for the genes showing high levels of deregulation between tumour vs. 
normal kidney samples. For the pathway overrepresentation analyses, only 
pathways defined in KEGG, Reactome and Biocarta were used (Methods section 
2.8.2).   
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3.2.8 Gene set enrichment analysis 
The Gene Set Enrichment Analysis (GSEA) (Subramanian et al.) algorithm was 
applied to gene expression data to determine pathways/gene sets deregulated in 
ccRCC. This method tries to determine whether an a priori defined set of genes 
shows statistically significant concordant differences between two biological states; 
here ccRCC samples vs. normal kidney (Methods section 2.8.3).   
 
3.2.9 Statistical analyses 
Fisher’s exact test was used to estimate co-occurrence or mutual exclusivity of 
genetic alterations relative to each other. All analyses were performed in R (R 
Development Core Team) version 3.0.1. 
 
3.2.10 Generating a ccRCC specific protein-protein interaction network 
A protein-protein interaction database was created by downloading and combining 
data from five databases, namely IntAct (Orchard et al.), MINT (Licata et al.), DIP 
(Xenarios et al.), HPRD (Keshava Prasad et al.) and BioGRID (Chatr-Aryamontri et 
al.). These primary databases collect potential PPIs from the scientific literature, 
which have been experimentally verified using methodologies such as yeast two-
hybrid, mass spectrometry and co-immunoprecipitation. Interactions for genes 
altered in ccRCC were extracted from this database to create a ccRCC protein-
protein interaction network (PPIN) (Methods section 2.4.1). 
 
3.2.11 Detecting sub-networks  
Module or subnetwork detection was performed using the Molecular Complex 
Detection (MCODE). This algorithm gives a weight to each node and uses 
neighbourhood density to grow a subnetwork from each tested seed node 
(Methods section 2.4.2). 
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3.2.12 Dendrix 
Dendrix (De novo Driver Exclusivity) (Vandin et al.) is an algorithm for discovery of 
mutated driver pathways in cancer using only mutation data. It finds sets of genes, 
domains, or nucleotides whose mutations exhibit both high coverage and high 
exclusivity in the analysed samples (Methods section 2.4.3). 
 
3.2.13 Co-altered modules 
To identify co-altered modules likely to drive the growth of ccRCC, a probabilistic 
model (Gu et al.) was implemented, which takes into account the likelihood of co-
occurrence of genetic alterations in patients, and combines it with a network search 
algorithm to identify co-altered modules in a given gene interaction network 
(Methods section 2.4.4). 
 
3.2.14 ARACNE and MARINa 
To generate a gene expression based network and find its regulators, the ARACNE 
(Margolin et al., Basso et al.) algorithm was applied. This algorithm reverse 
engineers a network by calculating mutual information between associated genes. 
Log2 normalised RSEM counts for RNA-Seq data were provided as input. The 
output network from ARACNE, provided as an adjacency matrix, was used as input 
to the MARINa (Lefebvre et al.) algorithm, which estimates the master regulators of 
a gene expression network. The MARINa algorithm was implemented in R using 
the ‘viper’ package (Methods section 2.4.5). 
 
3.2.15 DriverNet 
The DriverNet algorithm was used to assess genotype-phenotype relationships. 
This algorithm uses bipartite graphs and a background gene-gene interaction 
network to find cancer drivers at the genetic level that may explain the 
corresponding gene expression level changes (Methods section 2.4.6). 
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3.3 Results 
3.3.1 Somatic mutations 
In the original dataset, somatic mutation data was available for 417 patients, 
spanning mutations in a total of 10401 genes. These included 2,389 
insertions/deletions, 16,821 missense mutations, 1149 nonsense mutations and 
6,383 silent mutations. 
 
Figure 3.1 shows the frequency of mutations of all genes in this dataset. 
Characteristic of cancer, a long tail of mutation frequency is observed. VHL, 
PBRM1, SETD2, BAP1 and JARID1C/KDM5C were observed to be the top five 
most recurrently mutated genes. However, taking only the frequency of mutation 
events is no longer considered to be the most appropriate method when assessing 
the most important cancer drivers (Lawrence et al.). It is imperative to take into 
account other factors, such as the background mutation frequency rate and gene 
size.  
 
 
Figure 3.1: Somatic mutations in ccRCC 
A Frequency bar chart for the top 100 genes with somatic mutations in ccRCC in 
the TCGA dataset. The most frequently mutated genes were VHL (53%), PBRM1 
(33%), MUC4 (20%) SETD2 (12%), and BAP1 (10%). Beyond this Frequency of 
mutations was ≤ 10% for all genes.  
 
 
MutSigCV (Lawrence et al.) was used to assess the most significantly mutated 
genes in this cohort. The TCGA ccRCC publication had used an older version of 
this same algorithm (see Methods section 2.3.1 for a comparison of the two 
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versions). Comparing both these results as well as published literature, 11 genes 
namely VHL, PBRM1, SETD2, KDM5C, BAP1, MTOR, TP53, PTEN, PIK3CA, 
ARID1A and HMCN1 formed the top targets for further investigation. Other studies 
published at the same time (Sato et al.) and recently (Scelo et al.) observed 28 
(Sato et al.) and 17 (Scelo et al.) genes to be significantly mutated in their study 
cohorts. Table 3.1 shows the genes assessed as significant in this analysis (FDR ≤ 
0.05), and in the other studies (The Cancer Genome Atlas Research Network, Sato 
et al., Scelo et al.).  
 
Table 3.1:  Significantly mutated genes in major ccRCC studies 
This table shows the top significantly mutated genes obtained in this analysis in 
comparison to the 3 other major studies. As seen major genes such as VHL, 
PBRM1, SETD2 were observed in all analyses; however, each analyses showed 
additional genes such as STAG3L2, NEFH (this analysis) and MLL3 and CSMD3 
(Scelo et al.)  
 
 
 
 
Interestingly VHL had a much higher frequency of mutations in the Scelo (Scelo et 
al.) cohort when compared to the TCGA (The Cancer Genome Atlas Research 
Network) and Sato (Sato et al.) datasets. The Scelo study was performed on a 
European cohort including patients from Czech Republic, Romania, Russia and the 
United Kingdom, whereas the TCGA cohort is a USA based dataset and the Sato 
study had patients from Asia. Differences in frequency were also observed for other 
genes; KDM5C showed lower frequencies of mutation in the Sato cohort, while 
MTOR showed higher frequency of recurrence in the Sato dataset.  Furthermore, 
certain genes seen to be mutated with moderate to high frequencies in one study 
were not seen in the other (Figure 3.2). These data may indicate the role of race in 
ccRCC pathogenesis. 
 
Study Top significantly mutated genes
Our analysis VHL, PBRM1, SETD2, KDM5C, BAP1, C16orf3, KCNMB4, PTEN, STAG3L2, NEFH, ZNF717, KANK3
The Cancer Genome Consortium VHL, PBRM1, SETD2, KDM5C, PTEN, BAP1, MTOR, TP53, PIK3CA
Sato et al. VHL, PBRM1, BAP1, TCEB1, SETD2, TP53, FPGT, MUDENG, KEAP1, TET2, MUC4, MLLT10, MSGN1
Scelo et al. VHL, PBRM1, SETD2, BAP1, ZFHX4, CSMD3, MTOR, KDM5C, ZNF469, MLL3
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Figure 3.2: Comparison of frequency of mutations in the three data cohorts 
Figure shows a bar chart depicting a comparison of the frequency of mutation for a 
few example genes in the three data cohorts (The Cancer Genome Atlas Research 
Network, Sato et al., Scelo et al.). As shown, mutations in the VHL gene were 
observed at much higher frequency in the Scelo cohort. Likewise, SETD2 gene 
was also mutated at higher frequency in the Scelo cohort. MUC4 and PIK3CA 
genes while observed to be mutated in both TCGA and Sato cohorts were not seen 
to be mutated in the Scelo cohort. 
 
 
As discussed in section 1.2.4 of the Introduction, the PIK3CA/MTOR pathway has 
been shown to be an important pathway for ccRCC pathogenesis. Mutations in this 
pathway lead to an up-regulation in HIF1A levels, thereby giving a VHL 
independent route to HIF regulation (Zhong et al., Brugarolas et al., Thomas et al.). 
The MTOR gene was observed to be mutated in all three datasets at varying 
frequency; 6% (The Cancer Genome Atlas Research Network, Sato et al.), and 
8.5% (Scelo et al.). When other genes in this pathway were assessed, the overall 
mutation frequency of the MTOR pathway associated genes was observed to be 
17% in the TCGA dataset (Figure 3.3). Convergent evolution on the MTOR 
pathway by mutations in different genes of the pathway within the same patient has 
also been observed (Fisher et al.). These results highlight the fact, that assessing 
mutations in individual genes by themselves does not elucidate the complete 
picture mechanistically and pathways/networks should be assessed together. This 
idea is further explored from section 3.3.4 onwards. 
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Figure 3.3: Somatic mutations in the MTOR/PIK3CA pathway 
Figure shows a bar chart depicting somatic mutations occurring in the 
MTOR/PIK3CA pathway per sample in ccRCC. The MTOR gene is the most 
frequently mutated in this cohort, however, taken together, mutations in this 
pathway cover ~17% of cases. The figure was generated using the cbio portal tool 
(http://www.cbioportal.org/) and has been zoomed in and cropped to remove 
unaltered cases. 
 
 
Next, to examine relationships between key mutations (n=11), co-occurrence and 
mutual exclusivity patterns were explored using Fisher’s exact tests. Mutations in 
the VHL gene were observed to be co-occurring with mutations in the PBRM1 gene. 
PBRM1 mutations showed a tendency of co-occurrence with SETD2 mutations as 
well, while showing a tendency of mutual exclusivity with BAP1 mutations, which 
agrees with previous published data (Kapur et al.). Other genes were not seen to 
show any statistically significant associations. 
 
Lastly, to assess the impact of intratumour heterogeneity (ITH), mutation 
frequencies were compared in the TCGA cohort (T2-T4, VHL mutated cases only) 
and the multiregion biopsy cohort (Gerlinger et al.). Apart from VHL and PBRM1, all 
other genes were observed to be subclonal events in the multiregion biopsy cohort. 
Most striking differences were observed for mutations in the TP53 gene, which was 
observed to be mutated in only 5% of the cases in TCGA as compared to 40% of 
the samples in the multiregion biopsy cohort (Table 3.2). 
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Table 3.2: Comparison of frequency of mutations in key genes for ccRCC 
between the TCGA and multiregion biopsy cohorts 
The table compares the frequencies of mutations of key genes in ccRCC between 
the TCGA (n=102) and the multiregion biopsy cohorts. As can be seen while similar 
frequencies are observed when considering each multiregion biopsy as an 
individual sample (Columns 1 and 2 of the table). However, if all multiregion 
biopsies from each patient are considered as 1 sample (Column 3), much higher 
frequencies are observed for most genes, the most prominent example being TP53 
and BAP1 genes.  
 
 
 
 
3.3.2 Somatic copy number alterations 
After processing the raw copy number data into copy number calls using ASCAT, 
amplifications and deletions were determined as copy numbers deviating from the 
ploidy (estimated by ASCAT), by more than 0.6, similar to the original ASCAT 
publication (Van Loo et al.). Gistic (Mermel et al.) was applied to these copy 
number profiles to assess which of these cytobands may be significantly 
associated with ccRCC. Amplifications in 20 cytobands and deletions of 27 
cytobands were observed to be significant in this cohort of 555 cases (Figure 3.4). 
These results were in concordance with those observed by the TCGA and 
previously published by others (Beroukhim et al.), though the exact focal positions 
differed from one dataset to the other (In the TCGA publication GISTIC was run on 
~450 cases, whereas the data presented here is for the extended cohort of 550 
case).   
 
Gene Prevalence in TCGA samples (n=102) Prevalence in all M-Seq regions (n=79 regions) Prevalence in total M-Seq based cases (n=10)
PBRM1 42% 39% 60%
SETD2 18% 27% 30%
BAP1 21% 23% 40%
KDM5C 7% 11% 10%
TP53 5% 6% 40%
ATM 3% 4% 10%
ARID1A 6% 1% 10%
PTEN 5% 10% 20%
MTOR 9% 8% 10%
PIK3CA 3% 4% 20%
TSC2 2% 6% 10%
Chapter 3 molecular landscape of ccRCC 
 
95 
 
 
Figure 3.4: GISTIC analysis of copy-number changes in ccRCC tumours.  
The left panel of the figure depicts the significant amplifications (red) and the right 
panel depict the significant deletions (blue). The G-score represents the frequency 
average amplitude of the aberrations identified in the SNP arrays. False discovery 
rate q values, representing the statistical significance associated with these scores 
with correction for multiple testing, are displayed on the bottom axis of the figure. 
Regions with q values < 0.25 (green lines) were considered to be significantly 
altered. Chromosome positions are indicated along the vertical axis with 
centromere positions indicated by dotted lines. The locations of the peak regions of 
maximal copy-number change are annotated on the right. 
 
 
To identify the cis-effects of these SCNAs, gene expression data was evaluated; to 
determine the genes showing the corresponding expression changes (up-
regulation for amplifications and down-regulation for deletions). Table 3.3 details 
the frequency of these SCNAs and gives the examples of putative targets on these 
bands. Prominent kidney cancer genes such as ARID1A and SMARCA5 
(chromatin regulators), and other cancer genes such as BRCA1, RET and BRAF 
were observed to be altered. This analysis requires further follow up with published 
literature as well as experimental validation to find evidence for the role of these 
putative target genes in ccRCC.  
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Table 3.3: Summary of SCNA drivers 
This table shows the significant peaks (SCNAs) as observed in the GISTIC 
analysis. Column 3 gives the frequency of alteration of each peak. Column 4 and 5 
give the number of putative target genes on each peak and some example genes 
respectively. Putative targets were assessed by considering the corresponding 
gene expression data. 
  
 
Status Peak Frequency(%) Number	of	putative	targets Examples
Amplification	Peak		1 1p31.1		 3 3 AK5,	PTGFR,	TTLL7
Amplification	Peak		2 1q21.1		 13 15 CHD1L,	FAM72D
Amplification	Peak		3 2q31.3		 14 3 CERKL,	CWC22
Amplification	Peak		4 3q26.32	 13 4 KCNMB2,	KCNMB3
Amplification	Peak		5 4p16.3		 4 0
Amplification	Peak		6 4p16.3_1 6 16 FAM53A,	POLN
Amplification	Peak		7 4q31.21	 5 5 SMARCA5,	RNF150
Amplification	Peak		8 5q21.3		 43 3 PJA2,	EFNA5
Amplification	Peak		9 5q34				 57 6 CCNG1,	GABRB2
Amplification	Peak	10 7p12.1		 30 3 COBL,	DDC
Amplification	Peak	11 7q34				 30 0
Amplification	Peak	12 7q34_1 31 23 BRAF,	CASP2
Amplification	Peak	13 8q24.12	 13 4 MTBP,	TAF2
Amplification	Peak	14 10q11.21 6 2 RET,	TMEM72
Amplification	Peak	15 11p11.12 8 0
Amplification	Peak	16 11q13.4	 7 4 P2RY2,	P2RY6
Amplification	Peak	17 12p13.31 20 41 CLEC2B,	MLF2
Amplification	Peak	18 12q24.13 20 11 TRAFD1,	RPL6
Amplification	Peak	19 14q11.2	 9 0
Amplification	Peak	20 16p13.12 18 5 PARN,	ERCC4
Deletion	Peak		1 1p36.33	 25 26 FAM132A,	C1orf159
Deletion	Peak		2 1p36.11	 20 31 FCN3,	ARID1A
Deletion	Peak		3 1p31.1		 14 14 SLC44A5,	ACADM
Deletion	Peak		4 1q21.1		 10 8 NBPF15,	FCGR1C
Deletion	Peak		5 2q37.3		 12 29 C2orf54,	HDAC4
Deletion	Peak		6 3p26.1		 84 5 SUMF1
Deletion	Peak		7 3p21.31	 85 93 SETD2,	AMT
Deletion	Peak		8 4p16.3		 14 27 CTBP1
Deletion	Peak		9 4q35.2		 16 3 KLKB1
Deletion	Peak	10 6q24.1		 27 8 TXLNB
Deletion	Peak	11 7p22.3		 6 1 LFNG
Deletion	Peak	12 8p21.3		 27 26 CHMP7,	C8orf58
Deletion	Peak	13 8q24.3		 12 60 C8orf31
Deletion	Peak	14 9p23				 23 3 NFIB
Deletion	Peak	15 9p21.3		 24 5 KLHL9,	MLLT3
Deletion	Peak	16 9q12				 27 0
Deletion	Peak	17 9q34.3		 33 33 NOTCH1
Deletion	Peak	18 10q26.3	 23 11 PPP2R2D,	BNIP3
Deletion	Peak	19 11p15.5	 9 1 IGF2
Deletion	Peak	20 15q11.2	 14 5 SNURF
Deletion	Peak	21 16p13.3	 10 9 CLDN9
Deletion	Peak	22 16p11.1	 7 0
Deletion	Peak	23 16q22.2	 7 2 HYDIN
Deletion	Peak	24 17q21.31 7 17 BRCA1,	ADAM11
Deletion	Peak	25 17q25.3	 10 6 TSPAN10,	AATK
Deletion	Peak	26 19p13.3	 15 9 PLIN4,	PLIN5
Deletion	Peak	27 19p12			 6 1 ZNF208
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3.3.3 Gene expression analyses 
In the original dataset, RNA-Seq data was available for 469 tumour samples and 
68 normal samples. Of these, 65 were matched normal and tumour samples, 3 
were unmatched normal samples and 404 were unmatched tumour samples. 
Matched samples had sequencing data from both normal kidney and kidney cancer 
tissues in the same ccRCC patients, whereas unmatched samples only have 
sequencing data from either disease or no disease tissues.  
 
To decide if it was suitable to compare all tumour samples to all normal samples, 
multidimensional scaling (MDS) was performed (Figure 3.5). As all tumour samples 
were sufficiently clustered together, and were clearly distinguishable from the 
normal samples, it was deemed acceptable to groups all tumour samples vs. all 
normal samples for all further analyses. 
 
 
Figure 3.5: MDS plot for RNA-seq gene expression data for ccRCC 
MDS plot comparing ccRCC tumour and normal tissue samples. 469 ccRCC 
tumour samples were available (red) along with 68 normal kidney tissue samples 
(black). 
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3.3.3.1 Differentially regulated genes 
To obtain genes differentially regulated between the normal and tumour samples, 
the edgeR (Robinson et al.) package in R (R Development Core Team) was used. 
Using FDR q ≤ 0.05 and fold changes (FCs) of |log FC| ≥ 2.5 (equivalent to |FC| 
=5.6) as selection criteria, a list of 867 genes was obtained as significantly 
deregulated in ccRCC when compared to normal kidney samples.  
 
Genes showing the highest FCs included DOC2A, LPPR5, BIRC7, HP and MYEOV 
showing high up-regulation and UMOD, SCL12A1, DUSP9, KCNJ1 and KNG1 
showing high down-regulation. The biological roles of these genes are discussed in 
the following sections.  
 
3.3.3.2 GO and pathway enrichment for significantly deregulated genes 
GO overrepresentation analyses showed enrichment for genes involved in signal 
transduction, immune system processes, developmental processes and cell 
surface receptor linked signal transduction, and apoptosis related genes as top 
terms (Appendix A). Pathway enrichment analyses showed similar results; 
specifically cytokine receptor interaction genes, transmembrane transport, immune 
system genes and metabolism related genes represented the top pathways 
(Appendix 0).  
 
3.3.3.3 Gene Set Enrichment Analysis (GSEA) 
While an overrepresentation analyses as performed above enabled highlighting the 
major processes under play in ccRCC patients, a gene set enrichment analysis 
(GSEA) was performed to get a deeper understanding of the deregulation of these 
processes. All genes for which RNA-Seq data was assessed were included. A pre-
ranked GSEA was performed whereby a list of genes ranked according to FC was 
provided as input. The top pathways up-regulated in the ccRCC cohort included 
pathways belonging to immune cell regulation processes such as cytokine-cytokine 
receptor interaction and allograft rejection. The down-regulated pathways included 
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genes belonging to metabolic pathways, namely valine, leucine, isoleucine 
degradation, propanoate and fatty acid metabolism.  
 
3.3.3.4 NMF Clustering reveals the existence of at least two subgroups for 
ccRCC 
NMF clustering using the top 1500 most variable genes revealed two major 
subgroups of ccRCC. The cophenetic coefficient was highest for k=2 and k=3, but 
then dropped rapidly. The consensus clustering matrices also supplemented this 
result. The two subtypes contained 301 (Group 1) and 168 (Group 2) samples 
(Figure 3.6). 
 
This result is in concordance with recent work (Brannon et al.), which showed two 
subgroups for ccRCC, namely ccA and ccB subgroups. These two subgroups were 
shown to have a different prognosis, with ccA patients having a better survival than 
ccB. Using the classifier panel devised in the publication, 305 cases were classified 
as the ccA and 164 were classified as the ccB subgroup. 88% of the samples 
overlapped between Group 1 above with ccA classification and Group 2 with ccB, 
the mismatch for the rest can be explained with the possible existence of a third 
subgroup which has been discussed above. Since the ccA/ccB classification 
scheme has been shown to have prognostic significance, it has been used as the 
classification of choice for the purpose of this thesis. This work has been discussed 
in greater details in the results chapters, Chapter 4 and Chapter 5. 
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Figure 3.6: NMF clustering plot using the top 1500 most variable genes in the 
ccRCC cohort 
Consensus NMF clustering heatmaps depicts the stability of consensus clustering 
assignment into clusters using the top 1500 most variable genes for ccRCC based 
on RNA-Seq data. A. Ordered Consensus map for k=2. B. Ordered Consensus 
map for k=3. C. Cophenetic coefficient plot for k=2 to k=10. The coefficient was 
highest for k=2 and k=3. Both the coefficient and the clustering maps suggested 
the existence of two ccRCC subgroups and potentially a small third subgroup of 
ccRCC tumours (top red square in panel C). 
 
 
3.3.4 Network properties of ccRCC genes 
To study the network properties of ccRCC genes, all genes with somatic mutations 
were considered. These genes were then mapped to the PPIN to study network 
properties.  
 
Closely connected sub-networks (clusters) were determined for the ccRCC specific 
network using MCODE (Bader and Hogue). A total of 11 clusters were obtained 
with a degree cut-off of 4. Out of the 11 high confidence drivers, only five genes 
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namely VHL, PBRM1, ARID1A, BAP1 and TP53 were observed to cluster. The 
VHL gene was part of a 29-gene cluster (Figure 3.7A). A total of 11 genes in this 
cluster are ribosomal protein encoding genes or are involved in RNA metabolism. A 
few others were implicated in immune system related pathways while 11 genes 
could not be assigned to any particular pathway.  
 
PBRM1 and ARID1A are part of SWI/SNF complex. They were observed to be 
interacting with other genes in a larger complex of 147 genes (Figure 3.7B). A set 
of ~17 genes were implicated to be involved in the spliceosome and another large 
cluster of genes were identified to be immune system regulated genes. Multiple 
other chromatin modifiers were also observed to be part of this cluster. Both BAP1 
and TP53 genes were observed as part of a large cluster of 352 genes. The genes 
from this cluster are involved in transcription, cell cycle and immune system related 
pathways.  
 
Another cluster of 27 genes, which did not contain any apparent drivers (high or 
low confidence), was seen to be variably mutated in ~10% of the patient samples 
(Figure 3.8). These genes are ribosomal proteins involved in metabolism and 
translational processes. This observation might indicate that alternate pathways 
control multiple ccRCC mechanisms. Another smaller set of genes annotated as 
passengers, which were observed to be mutated in all together 5% of cases, 
seems to be part of a cluster (separate from the previous one) interacting with 
genes involved in ribosomal processes (the 42 gene cluster). While it is hard to 
comment on the relative significance of these modules, these data may indicate yet 
unthought-of pathways that may be playing a part in ccRCC biology. All 11 clusters 
are provided in appendix C. 
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Figure 3.7: Strongly connected subnetworks within the ccRCC PPIN 
Two example clusters (subnetworks) detected as part of the ccRCC specific PPIN. 
A. Depicts the 29-gene cluster which consisted of the VHL gene (red). B. Depicts 
the 147-gene cluster, which consisted of other chromatin modifiers such as ABL1 
and CREBBP. 
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Figure 3.8: Mutations in a cluster consisting of ribosomal proteins 
Figure depicts a bar chart showing somatic mutations occurring in genes encoding 
ribosomal proteins per sample in ccRCC. Taken together, mutations in this cluster 
have a total coverage of 10% of cases. The figure was generated using the cbio 
portal tool (http://www.cbioportal.org/) and has been zoomed in and cropped to 
remove unaltered cases. 
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3.3.5 Determining ccRCC driver modules using mutual exclusivity patterns 
The Dendrix (Vandin et al.) algorithm was applied to the mutation matrix of TCGA 
patient samples. Parameters were set similar to the original Dendrix publication. 
The algorithm was run for a range of set sizes k, for 2 ≤k ≤10. For each k, the 
algorithm was run 10000 times, starting with random seeds. Similar to the original 
publication, only sets that were sampled at frequency ≥ 1% were considered to be 
significant for each k. In the first instance, all genes mutated in at least three cases 
(total n=417) were considered as part of the analyses. Statistical significance was 
not observed for any sets with k ≥ 3. For k=2, five sets were sampled with a 
frequency ≥ 1%, (VHL and MUC4), (VHL and SETD2), (VHL and PBRM1), (VHL 
and PABPC1) and (VHL and KDM5C). Similar to the Dendrix publication, the 
mutual exclusivity of these gene pairs is not significant when tested using standard 
statistical tests. However, it may be postulated that these gene pairs might be 
biased due to the high coverage of the VHL gene. Therefore, the Dendrix algorithm 
was run again after removing the VHL gene; two sets, namely (MUC4 and PBRM1) 
and (BAP1 and PBRM1) were observed to be sampled with average frequencies of 
~8% and ~2%  respectively. While no direct interactions are known between either 
of PBRM1 with BAP1 or MUC4 genes, the role of mutations in the SWI/SNF 
(PBRM1 complex) and its impact on other pathways has been highlighted by the 
TCGA (The Cancer Genome Atlas Research Network). Furthermore, as discussed 
in sections 1.2.1 and 1.2.7, BAP1 and PBRM1 genes have been previously shown 
to be mutated in a mutually exclusive manner (Kapur et al.). The authors also 
showed differences in patient outcome for BAP1 and PBRM1 mutated cases. 
Moreover, a recent pan-cancer analysis also showed the mutual exclusivity 
between the SWI/SNF (PBRM1 complex) and the BAP1 complex in ccRCC in the 
TCGA cohort using the HotNet2 algorithm (Leiserson et al.).  
 
Biologically, MUC4 (Mucin 4) gene is known to be associated with intestinal 
epithelial cell differentiation. It has been implicated in tumour progression by 
repression of apoptosis. Expression levels of MUC4 have been associated with 
various cancers (up-regulated in pancreatic (Ansari et al., Singh et al.) and down-
regulated in breast (Cho et al.)). There are no known interactions between MUC4 
and PBRM1 genes. However, for set size k=3 (after removing VHL), two sets 
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namely, (MLL3, MUC4 and PBRM1) and (BAP1, MUC4 and PBRM1) were 
reported with an average frequency ~2.6% and 1.4% respectively. MLL3/KMT2C 
(Lysine (K)-Specific Methyltransferase) is a histone methyltransferase gene, a 
central component of MLL2/MML3 complex and is a coactivator complex of nuclear 
receptors, involved in transcriptional co-activation. It was also reported to be 
significantly mutated in Scelo et al. (Scelo et al.). While all these genes (MLL3, 
MUC4 and PBRM1) have different mechanisms of action, they all could potentially 
be modulating their functions by affecting the transcription machinery of the cancer 
cells. No sets were reported with frequency ≥ 1% above k=3. 
 
3.3.6 Co-alteration patterns reveals chromatin modifiers as key players in 
ccRCC 
Until now this analysis has focused on either driver genes or driver modules in 
isolation. Next, gene modules are explored that may be altered in a co-altered 
fashion. A probabilistic algorithm was adapted from the literature (Gu et al.) to test 
this hypothesis. The algorithm assigns each pair of co-altered modules a score, 
where a higher score indicates a higher likelihood for the module to be a putative 
signal for ccRCC (Methods section 2.4.4 and Figure 3.9). When the distribution of 
frequency of scores was assessed, a peak of coaltered modules with scores ≥ 30 
(max score = 36) was observed. Co-altered modules were analysed in this peak 
area, which contained ~19000 module pairs. This analysis is ongoing work being 
pursued in collaboration with Dr Tammy MK Cheng and data presented here form 
part of the preliminary analysis. 
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Figure 3.9: Schematic for detection of co-altered modules in ccRCC 
Figure depicts the workflow used to determine modules of genes that maybe 
mutated in co-altered manner. In each iteration of the algorithm, the search is 
begun with a pair of random seed genes (mutations in ccRCC), and iteratively the 
closest interaction partner of each seed gene is added to the module. At each step 
the score is calculated as shown at the bottom of the figure. Genes whose addition 
to the module does not increase the score are removed. Apart from the seed 
genes, all other genes in the module are removed iteratively to get the maximum 
score possible. The search stops when the score stops increasing.  
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The module pairs with the most frequent gene occurrences, or sets of genes, were 
interpreted. Chromatin modifier genes especially PBRM1 and ARID1A were the 
most frequent gene set. Modules containing these genes were observed to be 
coaltered along with genes associated with a range of functions and pathways, for 
example, ubiquitin proteolysis, the TGFβ pathway, the cell cycle and the EGFR1 
pathway. Further assessment showed that this gene set was most commonly 
altered with gene sets consisting of the VHL and SETD2 genes. While this is in line 
with the data presented here (section 3.3.1), it does contradict the results obtained 
from Dendrix when VHL was included in the analysis; however, as previously 
postulated, those results may have been biased due to high recurrence of VHL 
mutations. Nevertheless, further validation of these findings in independent cohorts 
will be required.  
 
Other genes that were observed to be part of multiple module pairs were TP53, 
VHL, SETD2 and the MTOR pathway related genes (MTOR, PIK3CA and PTEN). 
While unsurprisingly modules containing the TP53 gene were co-altered with a 
whole range of other genes with various cellular functions, VHL showed a tendency 
of co-alteration with genes belonging to immune system related functions or 
signalling genes such as those belonging to WNT, NOTCH and MAPK pathways. 
Intriguingly, most other top hits were seen to be occurring in conjunction with one 
or more chromatin modifying genes (for example, KDM5C). As part of this first pass 
analyses, chromatin regulators were observed to be the key players in ccRCC 
biology; however, at the time of writing of this thesis, certain analysis were still 
missing. These include assessing the differences between genes, which were 
observed to be part of module pairs vs. those not part of the module pairs, 
accounting for bias if any introduced due to the background PPIN and lastly, 
correlating mutational patterns of module pairs with ccRCC aggressiveness still 
remains to be elucidated.  
  
3.3.7 Detecting master regulators at the gene expression level 
To assess regulators at the gene expression stage, the MARINa algorithm was 
used. First a ccRCC specific gene expression network was generated using the 
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ARACNE algorithm (section 2.4.5 and 3.2.14). ARACNE uses minimal information 
between nodes to reverse engineer a network from gene expression data. MARINa 
was then applied to this network to get the master regulators (MRs) of gene 
expression for ccRCC. A total of 8442 regulators were obtained, out of which 692 
were significant at the FDR cut-off q ≤ 0.05 after bootstrapping. Following this list 
with a shadow analysis, to remove false positive regulators, gave a list of 76 
putative MRs. One of the top MRs in this was the epidermal growth factor (EGF) 
gene. EGF is implicated to be upstream of the PIK3CA/MTOR pathway and thus is 
involved in its regulation. Furthermore, not surprisingly, pathway enrichment on this 
list showed some genes belonging to metabolic pathways. However, while now a 
list of putative MRs at the gene expression level has been obtained much work is 
still required. This list needs to be comprehensively followed up with a literature 
search to gather data on these genes and their potential roles and how they may 
be enabling ccRCC mechanisms. Ultimately, experimental validation of the final list 
of MRs will be required.  
 
3.3.8 Genotype-Phenotype relationships 
Finally, a preliminary analysis to explore genotype-phenotype relations by 
integrating the genetic alterations to the gene expression data was performed. To 
find which genetic alterations may explain the gene expression changes observed, 
the DriverNet algorithm was applied. As explained in the Methods sections 2.4.6 
and 3.2.15, DriverNet, generates a bipartite graph and an edge is drawn from the 
left (genetic alterations) to the right (gene expression matrix), if an alteration could 
explain the corresponding gene expression changes. Intriguingly, while DriverNet, 
came up with a list of 100 putative drivers, this list was composed of primarily rare 
mutations. While it consisted of key transcription factors such as TP53 (mutated in 
2% of cases) and MYC (~0.5%), which do regulated numerous other genes, their 
coverage is low, which fails to explain what would be controlling the genes in the 
majority of the patient cohort. This avenue of investigation will require further 
exploration. 
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3.4 Summary 
The analyses performed in this chapter revealed the key genes involved in ccRCC 
pathogenesis. At the genetic level, these analyses, along with others reported in 
the literature, confirmed the importance of somatic mutations in VHL, PBRM1, 
SETD2, BAP1, KDM5C and TP53. Analyses of SCNA data, confirmed previously 
results (amplification of 5q and deletion of 9p), and also indicated deletion of 
chromosomes 1p (ARID1A) and 6q as putative target events. Comparison of these 
events with multiregion biopsy data, revealed that apart from VHL mutations and 
loss of chromosome 3p, almost all other events are subclonal, and single biopsy 
approaches are not effective in detecting such alterations due to under-sampling 
(Gerlinger et al.). Gene expression analysis established the existence of two 
subgroups of ccRCC, which map to the published prognostic signature ccA/ccB 
(Brannon et al.).  
 
Multiple network algorithms were employed to understand the pathways that 
genetic alterations are targeting as well as tackle inter-patient heterogeneity and in 
turn shed light on ITH. Using the MCODE algorithm, subnetworks/clusters of genes 
consisting of VHL, PBRM1 and ARID1A could be detected. In comparison, using 
the Dendrix algorithm to de novo identify new pathways, showed that in this dataset 
of ccRCC cases, adding PPI data is imperative to understand the mechanisms and 
that using mutational patterns alone are underpowered to do so.  
 
Further, assessing co-altered pathways at the genetic level revealed the 
importance of chromatin modifier genes both in terms of coverage and also as 
important genes that are altered along with multiple other pathways. Moreover,  
VHL, PBRM1 and SETD2, which are the three most recurrently altered genes in 
ccRCC, appears to be co-altered within pathways; co-alteration within key 
pathways was observed for other gene sets. These results shed insight into ccRCC 
mechanisms. Further exploration of such analysis for larger cohorts, with higher 
frequency of events, may enable answering questions such as which combinations 
of co-alteration patterns may lead to the more aggressive disease phenotype, or 
which combination of protein functions within key pathways should be 
simultaneously targeted to gain maximum therapeutic benefit. 
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Importantly, most analysis pointed out the significance of PBRM1 and other 
members of the SWI/SNF machinery, including ARID1A, to be key players in 
ccRCC biology. The complex was observed to be part of a larger module consisting 
of 142 genes (MCODE). PBRM1 was observed to be significant along with BAP1 
and MUC4 genes (Dendrix). Even in the co-altered module analysis, a high 
likelihood is assigned for multiple pathways to be co-altered with PBRM1, ARID1A 
and other chromatin modifying genes. Therefore, these analyses strongly 
emphasize the importance of chromatin regulators in ccRCC biology. While the 
utility of PBRM1 as a prognostic marker is still disputable (further discussed in 
Chapter 4 and see (Kapur et al., Gulati et al.)), these results are indicative of the 
importance of the SWI/SNF complex in ccRCC biology.   
 
While an attempt was made to elucidate genotype-phenotype relationships using 
the DriverNet algorithm, significant results were not obtained. There could be 
multiple reasons for this. The analyses may have been underpowered due to low 
frequency of events at the genetic level. Furthermore, the gene list obtained from 
DriverNet was enriched for genes that were hub genes i.e. had high numbers of 
PPIs. It can be speculated that the results may be biased towards such genes and 
thus producing false positives. Lastly, the algorithm was developed for microarray 
data and no significant changes have been made to the underlying calculations for 
RNA-Seq data. There is a step within the algorithm where expression outliers are 
calculated from the gene expression matrix, it may be that the algorithm is under 
detecting deregulated genes due to inherent differences in the microarray and 
RNA-Seq read outs.  
 
Finally, it should be noted that due to time limitations, for all network-based 
analyses only somatic mutation data was considered. Adding genes altered via 
SCNAs could potentially add more definitive information to the analyses performed. 
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Chapter 4. The quest for prognostic biomarkers 
4.1 Introduction 
So far it can be seen that, fitting to the overall picture of a typical cancer, ccRCC 
has a heterogeneous landscape with a few highly recurrent and numerous low 
frequency, somatic mutations as well as somatic copy number alterations (SCNAs). 
Moreover, in a number of studies, multiple gene expression based subtypes have 
been observed for ccRCC (Brannon et al., Zhao et al., Beleut et al.). As discussed 
in section 1.2.7 of the Introduction, outcome prediction for ccRCC greatly relies on 
clinical factors, such as tumour stage and tumour grade. Prognostic models have 
been formulated using these and other factors identified through routine clinical 
practice; such as the Mayo clinic, stage, size, grade and necrosis (SSIGN) score 
for predicting cancer specific survival (CSS) and the University of California 
Integrated Staging System (UISS), which includes TNM category, Fuhrman grade, 
and performance status to predict overall survival (OS). It is fit to presume that 
combining the existing clinical models to molecular biomarkers may help improve 
the accuracy of prognostic models. Through the years various research groups 
have found recurrent somatic mutations, SCNAs as well as gene expression 
signatures to be clinically associated with ccRCC. While a few of these events such 
as mutations in the BAP1 gene and deletion of chromosome 9p have been 
observed to be associated with patient prognosis in multiple studies (Kapur et al., 
Hakimi et al., Sanjmyatav et al., Klatte et al., La Rochelle et al.), most of these 
signatures have not been independently validated on different patient cohorts. 
Furthermore, the presence of a substantial amount of genetic intra-tumour 
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heterogeneity in ccRCC, detected through exome sequencing (Gerlinger et al., 
Gerlinger et al.), as well as SNP array analysis (Martinez et al.), of several regions 
from the same tumour, has raised questions regarding the applicability of such 
signatures in clinical practice. Taken together, these caveats suggest that further 
research is required to validate all available signatures in larger and independent 
cohorts. 
 
Availability of somatic mutation, SCNA, gene expression (RNA sequencing) and 
follow up data for over 400 ccRCC cases, published by The Cancer Genome Atlas 
consortium (TCGA, https://tcga-data.nci.nih.gov/tcga/), has enabled the direct 
comparison of the known ccRCC genomic predictors and provide the opportunity to 
systematically validate previously identified genetic and transcriptomic prognostic 
biomarkers in a large independent patient cohort.  
 
Thus, the analyses explained in this chapter were devised with an aim to answer 
two particular questions; first, to validate and compare published ccRCC prognostic 
biomarkers in an independent patient cohort and secondly, to assess intratumour 
heterogeneity (ITH) of the most promising markers to guide biomarker optimisation.  
 
4.2 Methods 
The framework for the analysis in this chapter has been described in detail here. All 
statistics applied in this chapter are briefly outlined with references to more detailed 
descriptions in Chapter 2 provided in relevant places. 
 
4.2.1 Literature Search 
While putative driver events were identified in Chapter 3 (such as mutations in the 
VHL gene, BAP1 gene and SCNAs in Chrom 3p), due to the lack of availability of a 
second independent validation cohort, candidate prognostic markers to be 
assessed in this chapter were selected using an exhaustive literature search. 
Biomarkers were selected that had been previously shown to have distinctive 
prognostic association as apposed to just simply being identified with driver events. 
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The aim here was to validate these prognostic biomarkers using an independent 
cohort from the TCGA data set.  
 
To compile an exhaustive list of possible biomarkers for validation, a systematic 
search of the PubMed and Google Scholar databases for publications describing 
genetic or transcriptomic prognostic biomarkers for RCC, was performed.  The 
terms, renal cell carcinoma, biomarker, prognosis and survival were used as 
keywords, and the search restricted to combinations of these terms. Articles 
published before and until December 2013, and in the English language, were 
considered for further analyses. Studies had to be based on either exclusively clear 
cell histology or could be mixed cohorts with other histologies; studies exclusively 
based on non-clear cell histology were excluded. Additional literature cited in 
identified prognostic marker publications or recent review articles (Brannon and 
Rathmell, Jonasch et al., Tang et al., Eichelberg et al., Junker et al., Arsanious et 
al., Oosterwijk et al.) was also assessed.  
 
As a final filter, the inclusion of follow-up data to show association with prognosis 
was deemed essential; studies that only showed an association with other poor 
prognosis clinical factors, such as tumour stage and grade were removed. Several 
publications investigating gene expression levels as potential prognostic 
biomarkers lacked information about how the identified genes can be applied to 
clinical samples in order to identify prognostically distinct subgroups. These were 
also excluded from further analysis. Using all these filters, 30 publications 
describing in all 32 RCC genetic or gene expression based prognostic biomarkers 
were identified in the literature search. However, four biomarkers were excluded 
from further analysis due to technical reasons. One biomarker (Yao et al.) was 
based on regression coefficients devised using microarray gene expression data. 
This could not to be applied to RNA-Seq data and was therefore excluded. The 
other three studies included multi-gene expression signatures, for which fewer than 
70% of gene probes mapped to genes annotated in the TCGA RNA-Seq dataset, 
which was chosen as an arbitrarily justified cut-off to be able to reproduce the 
respective signature (Takahashi et al., Sultmann et al., Vasselli et al.).   
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4.2.2 Patient cohort 
To study the above outlined objects, two cohorts were used. For the first part of the 
analysis, where an attempt to identify prognostic biomarkers was made, data 
published by TCGA was used. As described in Methods, sections 2.1.1, somatic 
mutation (n=417) and clinical data (n=446) were obtained for the same cohort from 
the supplementary material of the TCGA ccRCC publication (The Cancer Genome 
Atlas Research Network), SNP array (n=450) and RNA sequencing (RNA-Seq) 
data (n=469), and were downloaded (https://tcga-data.nci.nih.gov/tcga/) on 14th 
March 2012 and 18th September 2012, respectively. All of somatic mutations, 
SCNA, RNA-Seq and clinical data were available for a common cohort of 354 
patients. However, follow-up data or tumour grade were missing for four patients, 
leaving 350 patients, which formed our study cohort (core dataset). 
 
For the second part of the analysis, to assess ITH of the identified biomarkers, data 
published by our collaborating laboratory was used (Gerlinger et al., Gerlinger et 
al.). The multi-region gene expression datasets GSE31610 and GSE53000 were 
downloaded from the gene expression omnibus for the assessment of ITH. The 
dataset and preliminary processing of the microarray data is detailed in sections 
2.1.2 and 2.2.4; clustering of regions was performed using NMF clustering, as 
explained in section 0. 
 
4.2.3 Classification of patients into prognostic groups 
For somatic mutations, patients were classified into prognostic groups as those 
having non-syn mutations in the gene versus those not having these mutations. For 
VHL two additional cases were considered; 1) Non-syn mutations for Stage I/II/III 
cases only and 2) Loss-of-function mutations only. For SCNAs, patients were 
compared as those with the specific SCNA versus those without. For gene 
expression based signatures, for the three individual genes, CD31, EDNRB and 
TSPAN7; the cut-offs as given in the reference publication were used. For gene 
panel based classifiers, NMF clustering was performed to classify patients into 
cohorts. Lastly, for the TGFβ signature, pathway activity score was calculated and 
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patients were divided into two cohorts using median score value (Methods section 
2.5). 
 
4.2.4 Statistical Methods 
Assessment of association with prognosis was done at both i) univariate, using the 
logrank test (Methods Section 2.6.2) and the competing risk analysis (Methods 
Section 2.6.4), and at the ii) multivariate level using the Cox regression analysis 
(Methods Section 2.6.5). Death due to ccRCC was the chosen endpoint of interest. 
For all analyses, patients with the field “Composite Vital Status” = “DECEASED” 
and “Composite Tumour Status” = “WITH TUMOR” were considered to be dead 
with clear cell renal cancer related causes, while those with “Composite Vital Status” 
= “DECEASED” and “Composite Tumour Status” = “TUMOR FREE” were 
considered to be dead due to other causes. Follow-up time was defined using the 
“Composite Days to Death” field in case of patient death, and “Composite Days to 
Last Contact” for patients alive at the end of study period. For the multivariate Cox 
regression analysis, a backwards-stepwise selection process was implemented. 
The selection step was repeated till all the variables left in the model had p≤0.05. 
Although it is hard to define a formal way to determine the number of parameters, 
which can be tested in multivariate analysis based on the death event rate, to the 
best of our knowledge, we should not have more than ‘n’ number of variables in the 
final model where n = total number of deaths from disease/10, which for our study 
would equal 8 variables (Zwiener et al.). Our final multivariate model after stepwise 
selection has only two variables, which is in accordance with this criterion.  
 
Recursive partitioning (Methods section 2.7.1) was performed using the ctree() 
function in the ‘party’ package in R to generate a prognostication model. The 
logrank method was used to generate the p-values, and each node was split based 
on the logrank statistic and p ≤ 0.05. 
 
All statistical analyses were performed in R (v3.0.1) (R Development Core Team), 
using the packages ‘survival’ ‘gplots’, ‘cmprsk’ and ‘party’. Survival graphs were 
generated with GraphPad Prism (v6.03).  
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4.3 Results 
The median follow-up for the analysed patient cohort was 51 months. Clinical and 
pathological characteristics for the cohort are described in 
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Table 4.1 and were similar to the RCC cohorts from which the candidate 
biomarkers had been identified. All patients had undergone nephrectomy, which is 
the current line of treatment for kidney cancers and from which the samples for 
molecular analysis had been taken. After passing through the filters described in 
section 4.2.1, the literature search resulted in a total of 26 studies describing in all 
28 prognostic biomarkers (Table 4.2).  
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Table 4.1: Patient and tumour characteristics for the data cohort 
Table gives key clinical patient and tumour characteristics for the core dataset of 
350 cases. 
 
 
 
 
 
 
 
  
Variable TCGA Cohort (n=350)
Age
Median (IQR)   61 (52-70)
Gender
Male 222 (63%)
Female 128 (37%)
Fuhrman Grade
G1     4 (1%)
G2 145 (41%)
G3 146 (42%)
G4   55 (16%)
Clinical Stage
Stage I 162 (46%)
Stage II   34 (10%)
Stage III   96 (27%)
Stage IV   58 (17%)
Primary Tumour Spread
T1 166 (48%)
T2   40 (11%)
T3 139 (40%)
T4     5 (1%)
Metastatic Spread
M0 293 (84%)
M1   57 (16%)
Lymphnode Spread
N0 168 (48%)
N1     8 (2%)
NX (Undetermined) 174 (50%)
Median Follow-up   51 months
Total number of deaths 121
Number of deaths from ccRCC 80
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Table 4.2: Literature Search Results  
This table gives a summary of all the studies, biomarkers from which were 
considered part of this analysis, along with a reference of each study.  
 
Details on the cohort size of the original 
study, along with the method of detection 
of the biomarker as well as the endpoint 
of interest (CSS or overall survival) are 
shown.  
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Table 4.2 continued 
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4.3.1 Univariate analyses 
In order to validate the identified prognostic biomarkers, univariate analyses were 
performed using two different tests. All identified biomarkers were first tested using 
the logrank test, and all biomarkers assessed to be significant in logrank test, were 
then re-validated using the competing risk analysis. 
  
4.3.1.1  logrank test 
The logrank test assesses the significance of the difference in the survival 
distribution of samples under two or more conditions. The working of the logrank 
test is explained in more detail in section 2.6.2. This test was used to validate all 
identified prognostic signatures along with tumour stage and Fuhrman grade. The 
analysis started with assessing clinical factors, which have established association 
with prognosis. As expected, higher tumour stage and grade were significantly 
associated with poor CSS (Figure 4.1 and Table 4.3). Other established clinical 
prognostic variables such as blood test results, performance status or necrosis 
were not available for all patients and hence were not evaluated at this point. 
 
 
 
Figure 4.1: Kaplan Meier survival estimates for cancer specific survival 
determined for key clinical variables 
A. Depicts the Kaplan Meier (KM) survival curves based on tumour stage. Tumour 
Stage I has the best survival while stage IV has the worst survival. B. Depicts the 
KM curves based on Fuhrman grade. Due to the low number of G1 cases (n=2), 
they have been included along with G2 cases, with these cases having the best 
prognosis and G4 the worst. 
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Somatic mutations 
Somatic mutations in five tumour suppressor genes have been described to have 
prognostic associations (Kim et al., Schraml et al., Yao et al., Kapur et al., Hakimi 
et al., Sato et al., Kandoth et al.). While for genes, PBRM1, BAP1, SETD2 and 
TP53, association has been observed for non-synonymous mutations with CSS; for 
the VHL gene, association has been shown for non-synonymous mutations in one 
case for stage I-III grade tumours only (Yao et al.), while in two other studies, loss-
of-function mutations (frameshift and nonsense mutations) were shown to be 
associated with prognosis (Kim et al., Schraml et al.). Significance was assessed in 
accordance with each study, however only non-synonymous mutations in the BAP1 
(HR 1.94, p=0.022) and TP53 (HR 5.09, p<0.001) tumour suppressor genes 
validated as predictors of poor CSS (Figure 4.2 and Table 4.3). 
 
Chapter 4 prognostic biomarkers 
 
124 
 
 
Figure 4.2: Kaplan Meier survival estimates for cancer specific survival 
determined for somatic mutations 
A. VHL non-synonymous (non-syn) mutations (all cases), B. VHL loss-of-function 
mutations, C. VHL non-syn mutations (Stage I-III), D. PBRM1 non-syn mutations, 
E. BAP1 non-syn mutation status, F. SETD2 non-syn mutations, G. TP53 non-syn 
mutation status 
WT = wild type 
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Somatic copy number alterations 
A total of 14 copy number alteration events were identified as candidate biomarkers, 
including four focal SCNAs (Gunawan et al., Sanjmyatav et al.), six arm level 
alterations (Klatte et al., Monzon et al., Klatte et al., Kroeger et al., Elfving et al., La 
Rochelle et al., Moch et al., Brunelli et al.) and four whole chromosome alterations 
(Elfving et al., Antonelli et al.). Several of these SCNAs have been identified by 
cytogenetic and other low-resolution analyses. To facilitate comparison, copy 
number profiles generated from high resolution SNP array data, obtained from 
TCGA, were converted into lower resolution cytoband level data. Amplification or 
deletion of ≥50% of a chromosome arm, or of both arms of a chromosome, was 
considered to be equivalent to an arm level alteration, or to a whole chromosome 
aberration, respectively (The Cancer Genome Atlas Research Network). 
 
Nine out of the 14 SCNAs validated to be associated with prognosis and 
interestingly all showed association with poor prognosis. Chromosome 8q 
(Chrom8q) amplification (HR 2.70, p<0.001), Chrom12 amplification (HR 1.74, 
p=0.034), Chrom20 focal amplification (HR 2.44, p<0.001), Chrom20 amplification 
(HR 2.37, p<0.001), Chrom4p deletion (HR 1.97, p=0.019), Chrom9p focal deletion 
(HR 2.33, p<0.001), Chrom9p deletion (HR 2.56, p<0.001), Chrom19 deletion (HR 
3.25, p=0.034) and Chrom22q deletion (HR 2.23, p=0.012) were significantly 
associated with poor CSS. The remaining five SCNA markers failed validation 
(Figure 4.3 and Table 4.3).  
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Figure 4.3: Kaplan Meier survival estimates for cancer specific survival for 
somatic copy number alterations 
A. Chrom5q focal amplification (amp) status, B. Chrom 7q focal amp status, C. 
Chrom8q amp status, D. Chrom12 amp status, E. Chrom20q focal amp status, F. 
Chrom20 amp status, G. Chrom3p deletion (del) status, H. Chrom4p del status, I. 
Chrom8p del status, J. Chrom9p focal del status, K. Chrom9p del status, L. 
Chrom14q del status, M. Chrom19 del status, N. Chrom22q del status. 
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Gene expression analysis 
Nine gene expression biomarkers were identified, which included gene expression 
levels of three individual genes namely EDNRB, CD21 and TSPAN7, five gene 
expression panel based classifiers, and one signature based on TGFβ pathway 
activity. Eight out of the nine signatures validated. EDNRB and TSPAN7 gene-
expression above defined cut-offs (Wuttig et al.) correlated with improved CSS (HR 
0.29, p <0.001 and HR 0.37, p<0.001 respectively); however, CD31 overexpression 
was not significant. NMF clustering was applied for each multi-gene expression 
signature (Brannon et al., Kosari et al., Lane et al., Zhao et al., Beleut et al.) in 
order to identify samples with distinct expression profiles (consensus clustering 
maps can be found in Appendix D). All prognostic gene expression signatures 
validated: the aggressive subgroup defined by Kosari (Kosari et al.) had worse 
CSS than the non-aggressive subgroup (HR 2.85, p<0.001);  the Zhao (Zhao et al.) 
poor prognosis Cluster 2 had worse CSS than Cluster 1 (HR 5.26, p<0.001); the 
aggressive subgroup defined by Lane (Lane et al.) showed worse CSS than the 
indolent subgroup (HR 4.21, p<0.001); the Brannon (Brannon et al.) poor prognosis 
ccB subgroup (HR 4.90, p<0.001) had worse CSS than the ccA subgroup. Based 
on Beleut (Beleut et al.), CSS was significantly worse for patients in the poor 
prognosis Clusters C (HR 2.21, p=0.034) and B (HR 2.46, p=0.002) than for those 
in Cluster A; although CSS of Clusters B and C showed no significant difference. 
Bostrom’s (Bostrom et al.) poor risk subgroup with high TGFβ score had worse 
CSS than the subgroup with a low score (HR 1.98, p=0.003) (Figure 4.4 and Table 
4.3). 
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Figure 4.4: Kaplan Meier survival estimates for cancer specific survival for 
clinical gene expression based signatures  
A. EDNRB expression levels, B. TSPAN7 expression levels, C. Gene expression 
subgroup of patients – Kosari signature, D. Gene expression subgroup of patients 
– Zhao signature, E. Gene expression subgroup of patients – Lane signature, F. 
Gene expression subgroup of patients – ccA/ccB, G. Gene expression subgroup of 
patients – Beleut signature, and H. Gene expression subgroup of patients 
according to TGFβ activity score.  
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Table 4.3: Results from logrank analysis 
Table gives the results as obtained by logrank analysis for each of the 28 assessed 
biomarkers. For each biomarker, the number of cases, the hazard ratio (HR) 
calculated by univariate Cox analysis and the p-value of significance calculated by 
logrank analysis is provided.  
 
 
Variable Number of cases (n=350)   HR (95% C.I.) p-value
Stage II vs. Stage I   34 (10%)   4.45 (1.55 – 12.77) 0.006
Stage III vs. Stage I   96 (27%)   7.34 (3.16 – 17.08) <0.001
Stage IV vs. Stage I   58 (17%) 25.24 (11.26 – 56.71) <0.001
G3 vs. G1/G2 146 (42%)   2.35 (1.30 – 4.26) 0.005
G4 vs. G1/G2   55 (16%)   7.43 (3.99 – 13.81) <0.001
VHL loss of function mutation   86 (24.5%)   0.59 (0.34 – 1.04) 0.064
VHL non-syn mutation (all cases) 178 (51%)   0.80 (0.51 – 1.25) 0.323
VHL non-syn mutations (stage I-III cases) 155/292 (53%)   0.95 (0.50 – 1.80) 0.873
PBRM1 non-syn mutation 117 (33%)   0.90 (0.56 – 1.43) 0.643
BAP1 non-syn mutation   37 (10.5%)   1.94 (1.08 – 3.45) 0.022
SETD2 non-syn mutation   39 (11%)   1.41 (0.76 – 2.60) 0.273
TP53 non-syn mutation     7 (2%)   5.09 (1.85 – 14.00) <0.001
5q focal Amplification 191 (54.5%)   0.72 (0.47 – 1.12) 0.143
7q focal Amplification   95 (27%)   1.29 (0.81 – 2.05) 0.283
8q  Amplification   33 (9%)   2.70 (1.52 – 4.81) <0.001
12 Amplification   56 (16%)   1.74 (1.04 – 2.91) 0.034
20q focal Amplification   51 (15%)   2.44 (1.49 – 3.99) <0.001
20 Amplification   47 (13%)   2.37 (1.41 – 3.97) <0.001
3p  Deletion 318 (91%)   0.86 (0.41 – 1.79) 0.687
4p  Deletion   42 (12%)   1.97 (1.10 – 3.52) 0.019
8p  Deletion 101 (29%)   1.58 (0.99 – 2.50) 0.051
9p focal Deletion   85 (24%)   2.33 (1.49 – 3.64) <0.001
9p Deletion   88 (25%)   2.56 (1.64 – 3.99) <0.001
14q Deletion 140 (40%)   1.51 (0.97 – 2.35) 0.064
19 Deletion     6 (1.7%)   3.25 (1.02 – 10.32) 0.034
22q Deletion   26 (7%)   2.23 (1.18 – 4.23) 0.012
Clinical and Pathological Characteristics
Copy Number Variations
Somatic Mutations
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Table 4.3 continued 
 
 
4.3.1.2  Competing risk analysis 
While a logrank test is commonly used when assessing the association of an event 
with patient prognosis, as discussed in section 2.6.4, a competing risk (CR) 
analysis assesses the cumulative incidence of an event and takes into account 
death due to other causes. Thus, a CR analysis is less likely to over fit the 
significance of an event. Keeping this in mind, all 19 of the 28 molecular 
biomarkers, which were observed to be significantly associated (p≤0.05) with CSS 
in the logrank test, were re-assessed using competing risk analysis. As shown in 
Table 4.4, 17 out of the 19 assessed biomarkers showed significant association 
Variable Number of cases (n=350)   HR (95% C.I.) p-value
< median 175 (50%)
≥ median 175 (50%)
< median 175 (50%)
≥ median 175 (50%)
< 33 percentile 105 (30%)
≥ 33 percentile 245 (70%)
Non - aggressive 242 (69%)
Aggressive 108 (31%)
Cluster 1 (good) 269 (77%)
Cluster 2 (poor) 81 (23%)
Indolent 219 (63%)
Aggressive 131 (37%)
ccA 240 (69%)
ccB 110 (31%)
Cluster A 127(36%)   1.00 (Ref)
Cluster B 175 (50%)   2.27 (1.31 – 3.96)
Cluster C 48 (14%)   2.30 (1.13 – 4.66)
Low expression score 175 (50%)
High expression score 175 (50%)
Expression Analysis
0.051  0.64 (0.41 – 1.01)
  0.37 (0.23 – 0.59) <0.001
CD31 expression
EDNRB expression
TSPAN7 expression
Kosari signature
Zhao signature
Lane signature
ccA/ccB status
0.009
  1.98 (1.23 – 3.16) 0.003
TGFβ signature
  0.29 (0.18 – 0.45) <0.001
  2.85 (1.84 – 4.43) <0.001
  5.26 (3.37 – 8.22) <0.001
  4.21 (2.62 – 6.77) <0.001
  4.90 (3.09 – 7.76)
Beulet signature
<0.001
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with poor prognosis and only non-synonymous mutations in the BAP1 gene and 
Chrom19 deletion failed to validate.  
 
Table 4.4: Competing risk analysis 
Table gives the p-value of significance for the 19 biomarkers which were re-
assessed in a competing risk analysis. 17 out of the 19 biomarkers validated in this 
analysis. 
 
 
 
4.3.2 Multivariate Cox regression analysis 
At this stage, 17 of the 28 identified candidate biomarkers, using two univariate 
analyses, could be validated. Of further interest, is how independent these 
biomarkers were in comparison to each other, and if any of them were able to 
added prognostic information to established clinical factors. To assess this, a 
multivariate analysis was performed, containing these validated biomarkers along 
with established clinical variables.  As there were overlapping SCNA events that 
passed validation in the univariate analysis, to avoid redundancy, Chrom9p focal 
deletion and Chrom20 whole arm amplification were excluded on the basis of their 
Variable p-value
BAP1 non-syn mutation 0.072
TP53 non-syn mutation 0.006
8q  Amplification <0.001
12 Amplification 0.047
20q focal Amplification <0.001
20 Amplification 0.001
4p  Deletion 0.028
9p focal Deletion <0.001
9p Deletion <0.001
19 Deletion 0.081
22q Deletion 0.016
EDNRB >= median <0.001
TSPAN7 >= 33% <0.001
Kosari signature : aggressive <0.001
Zhao signature: poor subgroup <0.001
Lane signature: aggressive <0.001
ccA/ccB subgroup status <0.001
Beulet signature 0.015
TGFβ signature: high expression 0.003
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lower hazard ratios as compared to the overlapping Chrom9p arm level deletions 
and Chrom20 focal amplifications. Two instances of Cox regression were 
performed; in the first instance, the 17 biomarkers remaining after removing the 
above two, which had been validated in the logrank analysis, were included 
together with tumour stage and grade into the multivariate analysis (MVA). Tumour 
stage, the ccA/ccB gene expression signature and Chrom19 deletions were the 
only independent predictors of CSS (Table 4.5). In the second instance of the 
analysis, the two markers (BAP1 mutations, Chrom19 deletions), which had not 
been significant in the competing risk analysis, were excluded and only tumour 
stage and the ccA/ccB signature remained significant in the MVA (Table 4.5). 
Taking both these results into consideration, along with the small number of six 
tumours showing Chrom19 deletions, the ccB signature was the lead candidate for 
further assessment. For all non-significant variables, the hazard ratio, 95% 
confidence interval (C.I.), and a p-value, was generated at the step it was removed 
(Appendix E). 
 
Table 4.5: Multivariate Cox Regression analysis 
Table shows the results as obtained in both the iterations of the backwards-
stepwise regression analysis. The left side of the table gives the HR and p-value for 
the three significant variables remaining at the end when all 19 variables were 
considered. The right side of the table shows the results when the analysis was 
performed considering only the 17 variables which validated both in the logrank 
and competing risk analysis.  
 
 
 
 
 
 
Variable
Hazard Ratio (C.I.) p-value Hazard Ratio (C.I.) p-value
Stage I   1.00 (Ref)   1.00 (Ref)
Stage II   3.48 (1.20 – 10.06) 0.022   3.40 (1.18 – 9.82) 0.024
Stage III   4.61 (1.93 – 11.00) <0.001   4.86 (2.05 – 11.55) <0.001
Stage IV 18.01 (7.89 – 41.12) <0.001 17.77 (7.79 – 40.53) <0.001
Chromosome 19 deletion   4.18 (1.27 – 13.69) 0.018 - -
ccA status   1.00 (Ref)   1.00 (Ref)
ccB status   2.99 (1.87 – 4.80)   2.95 (1.84 – 4.72)
Including BAP1 mutations and Chrom19 deletion Excluding BAP1 mutations and Chrom19 deletion
<0.001 <0.001
Tumour stage
ccA/ccB status
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The ccB signature was consistently associated with a worse prognosis in patients 
with stage I (HR >10, p<0.001), stage II/III (HR 3.03, p=0.003) and stage IV 
ccRCCs (HR 2.15, p=0.015) (Figure 4.5). A total of 135 patients with stage I 
tumours expressing the ccA signature, demonstrated particularly good outcomes 
with no cancer specific deaths for over 6 years.  
 
 
 
Figure 4.5: Kaplan Meier survival estimates for cancer specific survival for 
ccA/ccB split by tumour stage 
KM curves depicting that even if patient cohorts are divided according to stage, for 
each stage wise cohort, significant differences in survival (all logrank p <0.05) are 
observed based on the ccA/ccB subgroup of the patients.  
 
 
A further point to note here is that in section 3.2.6 of chapter 3, we had seen that 
results using the ccA/ccB gene panel of 110 genes correlate well with the results of 
using the much larger panel of 1500 genes when attempting to classify patients into 
subgroups.  
 
In February 2014, after completion of the literature search, a newer prognostic 
signature named ClearCode34, which is based on the ccA/ccB signature, was 
published (Brooks et al.). This signature is based on the expression of 34 genes to 
classify patients into the ccA and ccB subgroups. As the ccA/ccB signature proved 
to be a lead candidate throughout all the analyses, this signature was also tested 
for its applicability. ClearCode34 was significant in univariate analysis, and together 
with tumour stage in MVA, if the ccA/ccB signature was omitted (Appendix F).  
Although the HR for ClearCode34 in the MVA was lower (HR=2.23) than that of the 
ccA/ccB signature (HR=2.95), the implementation of this 34-gene signature may be 
easier in clinical practice than the 110-gene ccA/ccB signature. However, for the 
purposes of this work, the cluster assignments obtained using the full 110-gene 
panel were used for all further analyses.  
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4.3.3 Recursive partitioning reiterates the importance of ccA/ccB subgroup 
status 
The multivariate Cox regression model developed in this analysis enabled a 
consensus set of prognostic markers to be selected in an unbiased manner. A tree 
based recursive partitioning was applied, using these markers, namely, tumour 
stage and ccA/ccB subgroup status, to propose a risk stratification model. This 
analysis highlighted key points; firstly patients with tumour stage I and expressing 
the ccA expression signature represented the low risk groups, with no deaths for 
over 6 years within this subgroup. Secondly, while the ccA subgroup showed 
significantly different survival between stages I and stage II/III cases, this was not 
true for the ccB subgroup. Finally, even within the Stage IV cases, for cases 
expressing the ccA subgroup signature, the median survival was almost twice that 
of those in the ccB subgroup (Figure 4.6). This analysis reconfirmed the results 
observed by Cox regression analysis and the stage-wise logrank test for ccA/ccB 
subgroup status (Figure 4.5 and Table 4.5).  
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Figure 4.6: A prognostic model based on tumour stage and the ccA/ccB 
subgroup status of patients 
Risk stratification based on recursive partitioning using only tumour stage and the 
ccA/ccB subgroup status of patients. Each node is split based on logrank p ≤ 0.05. 
The bottom panel of the figure shows the Kaplan Meier curve for each risk 
subgroup. 
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4.3.4 Comparison of the ccA/ccB signature with other prognostic scoring 
schemes 
The SSIGN prognostic scoring system is a validated and a widely used scoring 
measure used to predict ccRCC prognosis and is based on stage, grade and 
tumour necrosis (Frank et al., Ficarra et al., Zigeuner et al.). As tumour necrosis 
data was missing for 16 of the 350 cases in our cohort, this measure was not 
included in our main analyses; however it was compared with the ccA/ccB 
signature in a separate analysis. In the multivariate setting, the ccA/ccB signature 
was significant when adjusted for the SSIGN score. CSS of patients whose 
tumours displayed the ccA or ccB signature were significantly different in three out 
of five validated SSIGN score categories as seen in logrank tests (Ficarra et al., 
Zigeuner et al.) (Table 4.6 and Figure 4.7).  
 
Table 4.6: Multivariate analysis with the SSIGN score and ccA/ccB subgroup 
status 
Table shows the results of Multivariate Cox analysis considering both the SSIGN 
score and the ccA/ccB subgroup of the patients. As shown, even when adjusted for 
the SSIGN score, the ccA/ccB subgroup status still remains significant predictor of 
CSS. 
 
 
 
 
The ccA/ccB signature could not be compared with other clinical nomograms, such 
as haemoglobin, LDH, ECOG performance and UISS score (Motzer et al., Heng et 
al., Zisman et al., Sorbellini et al.) as essential parameters were not available for 
the majority of patients in the TCGA cohort.  
 
Variable Hazard Ratio (C.I.) p-value
SSIGN Score
SSIGN 0-2   1.00 (Ref)
SSIGN 3-4   2.69 (0.64 – 11.29) 0.175
SSIGN 5-6   8.28 (2.28 – 30.06) 0.001
SSIGN 7-9 13.23 (3.92 – 44.61) <0.001
SSIGN ≥ 10 34.73 (10.29 – 117.20) <0.001
ccA subgroup
ccB subgroup
  2.24 (1.38 – 3.64) 0.001
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Figure 4.7: Kaplan-Meier cancer specific survival estimates for ccA/ccB 
subgroups split by SSIGN score classes (n=334) 
Cases were split by SSIGN score categories (Ficarra et al., Zigeuner et al.) and 
Kaplan-Meier estimates were reassessed based on ccA/ccB subgroup status for 
each category. The subgroup status showed significant association with CSS in 
three of the five assessed categories. 
 
4.3.5 ITH of the ccA/ccB signature 
In the Introduction, section 1.2.5, the evidence of extensive levels of Intratumour 
heterogeneity in ccRCC was discussed (Gerlinger et al., Gerlinger et al.). Also, in 
(Gerlinger et al.), it was shown that the ccA and the ccB signature were present 
simultaneously within an individual ccRCC. The results discussed so far in this 
chapter, were based on single-biopsy data, and at this stage of the analysis, it was 
important to evaluate whether ITH can lead to ccA and ccB signatures being 
displayed within a single tumour. To this end, previously analysed published gene 
expression data was reinvestigated (Gerlinger et al., Gerlinger et al.). 63 tumour 
regions from 10 stage II-IV ccRCCs were classified as ccA/ccB using the gene 
expression panel (Appendix G), and the results mapped onto the phylogenetic 
trees previously published for these tumours (Gerlinger et al.) (Figure 4.8). ccA and 
ccB signatures were observed to occur within the same tumour in eight out of the 
10 cases and only two tumours homogenously expressed the ccA signature. This 
signifies the need to sample multiple tumour regions in order to reliably detect poor 
prognostic clones. 
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Figure 4.8: Heterogeneity analysis of ccA/ccB expression profiles 
ccA and ccB profiles detected by consensus NMF clustering in a multi-region 
analysis dataset from 10 ccRCCs, which were mapped onto the phylogenetic trees 
of these tumours (adapted with permission from (Gerlinger et al.)). Regional gene 
expression signatures were assigned to the dominant clones detected within the 
region and the minority clones detected in some regions in the original publication 
have been omitted. This figure is as presented in (Gulati et al.). 
Chapter 4 prognostic biomarkers 
 
139 
 
4.4 Summary 
In this biomarker study, performed in an independent validation cohort, out of 28 
previously published genetic and transcriptomic prognostic ccRCC markers, 17 
validated in logrank and competing risk analyses as predictors of CSS. However, 
only the ccB gene expression signature, along with tumour stage, was significant in 
the MVA. Taken together, this analyses suggested that the ccA/ccB gene 
expression signature outperforms other transcriptomic and genetic biomarkers for 
the prediction of ccRCC CSS and that it adds prognostic information to tumour 
stage and to the SSIGN prognostic model. This signature could be particularly 
relevant for the profiling of stage I ccRCCs where the detection of the ccA signature 
was associated with an excellent prognosis. Stage I ccA tumours may only require 
minimal follow-up whereas ccB tumours may benefit from more stringent 
surveillance and may therefore be good candidates for adjuvant therapy trials.  
 
Evaluation of the ccA/ccB signature across multiple tumour regions from each of 10 
stage II-IV ccRCCs demonstrated heterogeneous expression patterns with ccA and 
ccB signatures co-existing in 8/10 cases. ITH within spatial separated subclones, 
that may harbour distinct transcriptomic profiles, demonstrates that single tumour 
biopsies are unlikely to reveal a complete picture of the landscape of even the best 
current binary classification ccRCC biomarkers. These observations highlighted the 
need for multi-region profiling of larger cohorts, which could help define how to 
integrate heterogeneity assessments into biomarker predictions and subsequently 
improve the accuracy of the ccA/ccB signature. 
 
This study had a few limitations. Firstly, several candidate markers, which failed 
validation in univariate or multivariate analysis, such as Chrom19 deletion, 
Chrom8q amplification and BAP1 and TP53 mutations have low prevalence 
(≤10%); therefore this study may be underpowered to definitively assess the role of 
these markers. Secondly, biomarkers based on immunohistochemistry could not be 
assessed due to the lack of protein expression data for the validation cohort. 
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Chapter 5. Molecular drivers of the ccA/ccB 
signature 
5.1 Introduction 
The analyses in the previous chapter have shown that the ccA/ccB gene 
expression signature was the only biomarker, which validated as an independent 
predictor of patient prognosis even when adjusted for clinical established variables. 
Furthermore, although ITH was observed for this signature; in a single biopsy per 
patient setting, this signature was observed to successfully classify poor prognosis 
patients. While, questions regarding the impact of ITH on the accuracy of these 
predictions still remain unanswered, an important question is to ascertain what 
drives the poor prognosis ccB subgroup and how is it different from the ccA 
subgroup. This is imperative, since due to a marked absence of effective adjuvant 
strategies, prognostic ccRCC markers are of limited clinical utility. Thus in this 
chapter, an attempt is made to deconvolve the molecular mechanisms behind 
these expression signatures.  
 
Previously, in the original publication for this signature, the authors revealed that 
genes overexpressed in samples with the ccA signature are enriched for genes 
implicated in angiogenesis, fatty acid-, organic acid- and pyruvate metabolism. 
Whereas genes overexpressed in samples displaying the ccB signature are 
enriched for cell differentiation, epithelial to mesenchymal transition, mitotic cell 
cycle control, response to wounding and TGFβ and Wnt signalling pathway 
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regulation (Brannon et al.).  In this chapter, these signatures were further explored. 
Three major objectives were set:  
 
1. To determine the pathways deregulated in both ccA and ccB subgroups. 
2. To elucidate drivers of ccA and ccB subgroups at the genetic level. 
3. Finding driver networks and regulators for the ccA/ccB signature by 
performing genotype-phenotype analysis. 
 
5.2 Methods 
The methods used for the analyses in this chapter are briefly outlined below; for 
further details, a reference to the appropriate section is provided at the end of each 
section.  
 
5.2.1 Patient cohort 
In the analyses performed in this chapter, the original dataset of 469 ccRCC 
patients for which RNA-Seq was available for each patient from TCGA was used. 
Depending upon the requirements of the analysis, either raw count generated by 
the RSEM method or normalised RSEM counts to the upper quartile normal counts 
of the TCGA, were used. This has been clarified in the relevant sections. 
Normalised counts were log2 transformed before further analyses. In either case, 
only genes, for which the counts (raw and normalised resp.) were above 30 in at 
least 80% of the samples, were included in the analyses. 
 
The ccA/ccB subgroups were determined for all 469 cases using supervised NMF 
clustering; however, when comparing with other variables the number of cases may 
be different depending upon data availability of the variable under consideration. 
Case counts (n) have been given in all such places.  
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5.2.2 NMF clustering 
Expression data was available for 103/110 genes in gene expression signature 
used to validate biomarkers for ccRCC (Brannon et al.), and was submitted for 
consensus NMF clustering analysis (Brunet et al.) to the Broad Institute’s 
GenePattern server (Reich et al.). The cluster number (k) range was predefined 
from two to 10. Each clustering run returned a cophenetic correlation coefficient 
that measures the stability of cluster assignments as well as a consensus 
clustering maps for the respective k value. Based on both these data, the optimal 
number of clusters could be identified. (Refer methods section 2.5.3) 
 
5.2.3 Statistical analysis 
Differential regulation analysis was performed using the edgeR (Robinson et al., 
2010) package in R (R Development Core Team, 2013). (Refer methods section 
2.8.1).Over representation analysis for gene ontology and pathways was performed 
using the MSigDB (Liberzon, Liberzon et al.) and genego portal (Thomson Reuters, 
https://portal.genego.com/). (Refer methods section 2.8.2). Gene Set Enrichment 
Analysis was performed using the standalone tool from the Broad Institute using 
the curated pathways dataset as background (Subramanian et al., 2005). (Refer 
methods section 2.8.3). To evaluate the differences in the occurrences of genetic 
alterations in the ccA/ccB subgroups, Fisher’s exact test was performed in R to 
calculate the odds ratio and the p-value of significance. 
 
5.2.4 Weighted Genomic Instability Index (wGII) 
The weighted genomic instability index (wGII) (Burrell et al.), is a measure of the 
overall copy number alterations within a tumour genome, and thus provides a score 
for the level of genomic perturbations within tumour samples; a numeric score 
between 0 and 1 is returned where a wGII ≥ 0.2 is considered to be genomically 
unstable (Lee et al.). The returned numbers are a weighted average of the 
deviation from the proportion of bases on each chromosome away from the sample 
ploidy. (Refer methods section 2.2.6) 
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5.2.5 Machine learning: random forest 
In order to find the more important features to classify the ccA (n=240) and ccB 
(n=110) subgroupings the Random Forest (RF) machine learning protocol, in R, 
was used; the package randomForestSRC (Ishwaran et al., Ishwaran and Kogalur). 
In this implementation, the number of trees was set to 1000 for each iteration; all 
other parameters were set to their default values. (Refer methods section 2.7.2). 
After training, the random forest feature importance values were invoked (Breiman). 
This gives a ranked list of the features, which were most important for 
accurate classification, and hence features which can discriminate best between 
ccA and ccB. 
 
5.3 Results 
The ccA/ccB subgroup status was ascertained for the 469 cases for which RNA-
Seq data were available. To meet the objectives set out in the introduction of this 
chapter, firstly a pathway enrichment analyses was performed using the gene 
expression data to find out major pathways controlling the ccA and ccB subgroups. 
Following this the putative genetic drivers of the ccA/ccB subgroups were 
ascertained through enrichment analyses using Fisher’s exact tests. Subsequently, 
genotype – phenotype relationships were elucidated for these subgroups.  
 
Consensus NMF clustering led to the classification of 305 cases belonging to the 
ccA subgroup and 164 cases belonging to the ccB subgroup (Figure 5.1). Clinically, 
the ccA subgroup tended to be more Stage I/II than Stage III/IV, while the ccB 
subgroup tended to consist of more from the higher stages (n=417, OR=3.43, 
p<0.001). There were no statistical differences in the age of patients in the two 
subgroups (n=417, p=0.348). In the full cohort of patients, for whom both SCNA 
and RNA-Seq data were available, chromosome 3p was observed to be more 
enriched in the ccA subgroup (n=422, OR=0.31, p<0.001). In contrast to the 
primary study (Brannon et al.), in this cohort of cases there were higher odds of 
ccA patients having a non-synonymous VHL mutations than the ccB patients 
(n=390, OR=0.48, p<0.001). Median survival for ccA was not yet reached at the 
Chapter 5. ccA/ccB signature 
 
144 
 
end of the study period where as for ccB subgroup this was 4.45 years (n=415, 
nccA=281, nccB=134).  
 
 
 
Figure 5.1: NMF clustering results for the ccA/ccB gene panel 
A. Cophenetic correlation coefficient. The cophenetic coefficient depicts the 
strength of clustering at different values of k. The coefficient was highest for k=2. B. 
Consensus clustering matrix for k=2. 
 
5.3.1 Differential regulation analysis 
Differential gene expression analysis was performed using the edgeR (Robinson et 
al.) package, for three separate comparisons. Genes deregulated in ccA cases 
when compared to normal kidney samples in the first instance, second comparison 
was between ccB and normal cases and the last analysis was performed by 
comparing ccA cases to ccB. The edgeR output provides three different values for 
each gene in the input namely log fold changes (log FC), log CPM, and the p-value. 
A list of significantly differentially regulated genes can then be generated using p-
value and/or fold change cut-offs. However, another approach is to rank the input 
list of genes using either the fold changes or p-values and then run a Gene set 
enrichment analysis (GSEA). Both analyses were performed for all pairwise 
comparisons.   
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5.3.1.1 Differentially regulated genes  
To generate a list of significantly differentially regulated genes, all p-values were 
first corrected for multiple testing. The final list of differentially expressed genes 
was compiled using a statistical FDR q-value ≤ 0.05 and a FC cut-off of |log FC| ≥ 
2.5 (equivalent to |FC| =5.6) as selection criteria, for each comparison. 
 
When comparing ccA and ccB gene expression levels to normal kidney cell 
expression levels, some genes were identified to be deregulated in both subgroups. 
This was not unexpected since both are ccRCC subtypes. After removing these 
genes, 235 genes were obtained to be uniquely deregulated in the ccA subgroup, 
and 539 genes were deregulated in the ccB subgroup, only.  
 
Gene ontology (GO) term enrichment and pathway over-representation analysis on 
these genes were performed using two sources, namely MSigDB (Broad Institute 
(Liberzon, Liberzon et al.)) and the genego portal (Thomson Reuters, 
https://portal.genego.com/). 
 
MSigDB was used to obtain the top 100 pathways and the top 100 GO Biological 
Processes (BPs), enriched respectively in the ccA vs. Normal samples (Appendix 
H) and ccB vs. Normal samples (Appendix I). In the pathway enrichment analysis 
only 13 pathways were considered to be enriched for the ccA subgroup using the 
FDR q-value ≤ 0.05 as cut off, whereas the ccB subgroup had 100 pathways 
enriched of out of which only five were also observed in the ccA subgroup. The five 
pathways which were present in both lists, included genes involved in 
developmental biology, PDGF signalling, homeostasis, axon guidance and peptide 
ligand-binding receptors. ccA samples were enriched for genes involved in glycine, 
serine and threonine metabolism, GPCR signalling and transmembrane transport. 
Whereas, genes involved in mitotic cell cycle and cell cycle checkpoints, immune 
signalling, immune response activation genes, regulation of the immune system 
were enriched specifically in the ccB subgroup. 
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For the GO enrichment analysis, 44 BPs were seen to be enriched for from the ccA 
list of differentially expressed genes, whereas a total of 100 BPs were obtained 
from the ccB list, 12 of which were shared with ccA. The ccA subgroup showed an 
enrichment for genes involved in genes involved in cellular transport, G protein 
coupled signalling while the ccB subgroup showed similar results to the pathway 
enrichment with significant enrichment of mitotic cell cycle, cell cycle regulation and 
checkpoint control genes, apoptosis control and immune regulation. The results 
from genego portal did not add any significant new pathways to the above results.  
 
As a final check, differential expression was also tested specifically between the 
ccB subgroup vs. the ccA subgroup. 144 genes were obtained to be deregulated 
with FDR q ≤ 0.05 and |log fc| ≥ 2.5. Enrichment analyses for this list showed 
differential regulation of genes involved in organ development, immune response, 
response to external and internal stimuli and apoptosis pathways. This comparison 
highlighted the differential regulation of these pathways within ccRCC subgroups, 
and may indicate their role in the pathogenesis of the poor prognosis ccB subgroup. 
 
5.3.1.2 Gene set enrichment analysis (GSEA) 
Furthermore, gene set enrichment analyses was also performed for all the three 
comparisons under consideration. When both of the ccA and ccB subgroups were 
compared to the Normal samples, using the FDR q-value ≤0.05 as cut off, 90 
significantly enriched pathways were obtained for the ccA subgroup and 150 
pathways were enriched for in the ccB subgroup. As previously observed (Brannon 
et al.) the metabolic pathways showed a down-regulation in both cohorts. In the 
ccA subgroup, up-regulation was seen for phagosome and myogenesis pathways 
while genes belonging to the oxidative phosphorylation pathway and signalling by 
ERBB4, and amino acid synthesis pathways, showed a down-regulation. In 
contrast, in the ccB subgroup, significant up-regulation was seen primarily for 
genes involved in extracellular matrix (ECM) reorganisation, ECM-receptor 
interaction, mitotic cell cycle and cell cycle check point genes, while genes 
belonging to histidine metabolism, pyruvate metabolism, glycolysis, glucose 
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transport and transmembrane transport pathways in general, were seen to be 
significantly down-regulated. 
 
These results suggest that the ccA subgroup is primarily controlled by metabolic 
pathways, which is representative of the metabolic nature of ccRCC. However, the 
ccB subgroup has additional deregulation of immune signalling pathways and cell 
cycle checkpoint genes, which may be contributing to the aggressive nature of this 
subgroup.   
 
5.3.2 Molecular drivers of the ccA and ccB subgroups 
To determine if the molecular drivers of the ccA/ccB expression subgroups could 
be associated with the genetic factors assessed in the prognostic analyses 
described in Chapter 4, the following analysis was performed. 
 
All the genetic prognostic factors that were found in the literature search (n=17*, 
duplicate entries of Chrom9p and Chrom20 were removed based on lower (HRs)), 
were categorised as those that validated in the log-rank tests (n=9) and those that 
failed to validate (n=8). The ccB expression signature was then investigated to see 
if it might reflect the transcriptomic impact of the poor risk genetic alterations, which 
were significant in logrank analysis but failed in the multivariate analysis. For this 
analysis, the cohort of all 350 cases, as devised in Chapter 4, was used. Seven out 
of the nine poor prognosis genetic alterations (BAP1 and TP53 mutations; 
Chrom8q, Chrom12 and Chrom20q focal amplifications; Chrom9p and Chrom22q 
deletions) were significantly enriched (p<0.05) in the ccB subgroup (Figure 5.2). In 
contrast, on repeating the analyses for the eight candidate genetic markers that 
had failed univariate validation, only two were found to be enriched in ccB samples 
(Figure 5.3). 
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Figure 5.2: Enrichment analysis for the poor prognosis genetic events in the 
ccA/ccB subgroups 
The top part of the figure depicts a heatmap, showing the gene expression of the 
103/110 gene panel (Brannon et al.). The ccA subgroup is represented on the left 
and the ccB subgroup on the right. The bars below the heatmap depict the 
occurrence of the genetic events in each patient. The odds ratio of the occurrence 
of these events in the ccB subgroup with respect to the ccA subgroup is given on 
the right side, along with a p-value of significance for the odds (Fisher’s exact test). 
The barchart at the bottom of the figure depicts the total number of these events 
per patient. The highest number of these events occurring in a single patient is 
seven, with both of these cases belonging to the ccB subgroup. This figure is as 
presented in (Gulati et al.). 
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Figure 5.3: Enrichment analysis for the genetic events, which failed validation 
in the ccA/ccB subgroups 
The top part of the figure depicts a heatmap, showing the gene expression of the 
103/110 gene panel (Brannon et al.). The ccA subgroup is represented on the left 
and the ccB subgroup on the right. The bars below the heatmap depict the 
occurrence of the genetic events in each patient. The odds ratio of the occurrence 
of these events in the ccB subgroup with respect to the ccA subgroup is given on 
the right side, along with a p-value of significance for the odds (Fisher’s exact test). 
The barchart at the bottom of the figure depicts the total number of these events 
per patient. The highest number of these events occurring in a single patient is 
seven, with both of these cases belonging to the ccB subgroup. This figure is as 
presented in (Gulati et al.). 
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Further assessment of these aberrations showed that about 72% of the ccB 
samples had at least one of the seven enriched aberrations in contrast to only 30% 
of ccA samples (Figure 5.4A). Both, the maximum and the median number of the 
poor prognosis aberrations per sample were higher in the ccB group than in the 
ccA group (Figure 5.4A and 5.4B). However, when the distribution of aberrations 
which failed validation in the prognostic analysis was compared, the median 
number of these aberrations between ccA and ccB samples was not statistically 
different (Figure 5.4C and 5.4D). 
 
Figure 5.4: Comparison of genetic markers in the ccA/ccB subgroups 
A. Comparison of the number of poor prognosis genetic aberrations per sample 
between ccA and ccB subgroups. Only aberrations, which are enriched in the ccB 
subgroup, were considered. B. Box and whisker plot comparing median number of 
poor prognosis genetic aberrations between samples assigned to the ccA and the 
ccB group. C. Comparison of the number of number of genetic aberrations, which 
did not pass univariate validation per sample between ccA and ccB subgroups. D. 
Boxplot and whisker plot showing the median number of genetic aberrations, which 
did not pass univariate validation between ccA and ccB subgroups.  
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Chromosomal instability is known to foster the acquisition of SCNAs and has been 
associated with poor prognosis in several cancers (McGranahan et al., 2012). To 
reveal whether enrichment of chromosomal aberrations in ccB was a result of 
increased chromosomal instability, the weighted Genomic Instability Index (wGII), a 
measure of overall copy number aberrations, was calculated for each sample (wGII 
≥ 0.2 is considered unstable (Lee et al.)). The ccB samples had significantly higher 
wGII scores when compared to ccA samples (p<0.001, Figure 5.5A). However, the 
mutation load was not significantly different between the two cohorts (p>0.05, 
Figure 5.5B and 5.5C). Based on these results, it appears possible that the 
aggressive ccB phenotype is partially driven by several poor prognosis genetic 
alterations, co-occurring within these samples, which may be permitted by a cancer 
genomic background of elevated chromosomal instability.  
 
 
 
Figure 5.5: Comparison of genomic measures in the ccA/ccB subgroups 
Box and whisker plots comparing genomic factors between the ccA/ccB subgroups. 
A. Comparison of wGII between the two cohorts where wGII ≥ 0.2 is deemed to be 
genomically unstable; ccB patients were observed to be more genomically 
unstable. B. and C. compare the total mutation load and the number of non-syn 
mutations between the two subgroups respectively. No statistical differences were 
seen between the two cohorts.  
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5.3.3 Random forests elucidate the most important determinants of the ccB 
subgroup   
At this point, it was decided to test the hypothesis, that while high genomic 
instability fosters the development of the aggressive ccB subgroup, it is not the 
absolute determinant of the aggressiveness of this subgroup. Since an important 
part of the random forest classification method is to report the weights of each 
factor contributing to the classification, this method was chosen to test the 
hypothesis.  Multiple iterations were performed with different sets of events as 
variables to first determine the most accurate set of variables, which could 
distinguish between the ccA and ccB subgroups (Table 5.1). Most accurate (least 
error rate) classification was achieved using all the variables under consideration in 
the classifier (Iteration 6, Table 5.1). The variables from this iteration were ranked 
to find the most important variables that were able to distinguish between the ccA 
and ccB subgroups (Figure 5.6). In decreasing order of importance, Chrom8q, 
Chrom20q and Chrom5q amplification status, the BAP1 non-synonymous 
mutations and deletion of Chrom9p were observed to be the most important 
variables for distinguishing between the ccA and ccB subgroups; followed by 
genomic instability. It should be noted here, none of the variable sets achieved high 
accuracy on cross validation, especially when predicting the ccB subgroup; 
however, since the aim of analysis was not to build a classifier but to determine the 
factors more likely to be important for distinguishing between the subgroup. It may 
be said with some confidence that while a genomically unstable background fosters 
the aggressive subtype, other unknown factors, along with the ones discussed in 
this chapter, are important for the establishment and progression of the cancer  
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subgroups.  
 
 
  
Table 5.1: Random Forest Iterations  
Table gives the results as obtained by multiple iterations of the random forest analysis.  
Each row represents 1 iteration of the analysis, and 
the details for the variables considered and error 
rates: overall error rate and error rate in specifically 
predicting the ccA and ccB subgroups. 
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Figure 5.6: Variable importance calculated from Random forest analysis 
The bar charts depict the importance of various factors when distinguishing 
between the ccA/ccB subgroups. The top bar chart depicts the importance of each 
variable when predicting the overall classification, while the remaining two depict 
the importance of each variable when specifically differentiating the ccA subgroup 
(1) and the ccB subgroup (2). Positive importance is shown as blue bars whereas 
negative is shown as red bars.  
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5.3.4 Genotype – phenotype relationships  
In the above analyses, both genetic and transcriptomic have ascertained that there 
are clear differences in the ccA and ccB subgroups.  This led to the question of 
finding what genetic alterations may be controlling the transcriptomic regulation of 
these two signatures, identifying drivers and thereby suggesting targets for therapy.  
 
Interestingly, results from employing the random forest method also indicated that 
taking into account only the above 17 genetic events, along with wGII, is not 
sufficient to accurately distinguish between the ccA and ccB phenotypes. However, 
investigating genotype - phenotype relationships in a very simplistic manner, simply 
by comparing the co-occurrence of events relative to the ccA/ccB subgroups, some 
putative driver events can be identified.    
 
Apart from BAP1, Chrom8q, Chrom20q and Chrom9p, all have genes involved in 
the ubiquitin mediated proteolysis pathway (UMPP), all of which have higher odds 
of alteration in the ccB subgroup; which may explain the higher deregulation of the 
UMPP in this subgroup of ccRCC cases. Further, Chrom8q and Chrom20q also 
have genes involved in the ECM receptor interaction pathway, which is deregulated 
in the ccB subtype.  
 
5.4 Summary 
In this chapter the ccA/ccB signature is explored in detail, with the objective of 
explaining the mechanisms that distinguish the aggressive ccB subgroup from ccA. 
The analyses confirmed previously known observations but also add further 
information and understanding. As discussed in the introduction of this chapter, 
previous work had revealed that genes overexpressed in samples with the ccA 
signature are enriched for genes implicated in angiogenesis, fatty acid-, organic 
acid- and pyruvate metabolism. Genes overexpressed in samples displaying the 
ccB signature are enriched for cell differentiation, epithelial to mesenchymal 
transition, mitotic cell cycle, response to wounding and TGFβ and Wnt signalling 
genes (Brannon et al.). In the differential gene expression analysis, while the ccA 
subgroups showed a deregulation of genes involved in metabolic pathways, in 
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concordance with previous results, the ccB group in addition showed significant 
deregulation in immune regulation and cell cycle checkpoint pathways.  
 
Seven out of nine specific genetic alterations, which were validated in univariate 
analysis, were shown to be enriched in ccB samples with 72% of samples 
harbouring at least one and up to six of these alterations per patient. These genetic 
changes were only found in 30% of the ccA samples with a maximum of four 
aberrations per sample. Thus, the ccB signature may reflect the transcriptomic 
impact of these poor prognosis alterations, but more than one alteration may be 
necessary to establish this phenotype and as yet unknown alterations are also 
likely to contribute. We had also pointed out that prognostic markers are of limited 
clinical utility in ccRCC due to the current absence of effective adjuvant strategies. 
Further study of the interplay of these genetic aberrations and the pathways 
deregulated in the ccB signature are clearly necessary in order to reveal the 
mechanisms and biological implications of the ccB phenotype. Such insights could 
eventually foster the development of specific therapeutic approaches for poor 
prognosis ccRCCs. 
 
Chromosomal instability indices (wGII) were higher in ccB than in ccA samples; 
however; the mutational load was not statistically different between these two 
cohorts. Random forest analysis also ranked individual alterations higher than wGII, 
when distinguishing between the two subgroups. These data suggest that 
chromosomal instability may catalyse the evolution of the ccB phenotype by 
providing the permissive heterogeneous genomic background, from which these 
genetic alterations can be selected, but it may not be the sole driver of the 
aggressive subtype. These results are hypothesis generating and will require 
further study. 
 
In a simple genotype-phenotype analysis, putative drivers of the ccB signature can 
be identified; however, a complete picture of specific drivers of the ccA/ccB 
subgroups could not be discerned. There are a number of confounding factors. 
Firstly, there may be other elements, such as epigenetic alterations and 
methylation patterns, contributing to the aggressive subtype, which have not been 
considered as part of this overall analysis. Secondly, intratumour heterogeneity is 
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not taken into consideration and this is likely to play an important role, not least 
because some tumours may actually consist of both a ccA and ccB cellular 
phenotype. Finally, as exemplified by the relatively high error rates associated with 
the ccA/ccB classification when employing the random forest methodology, it 
appears various factors such as cohort sizes and the accuracy of some of the 
calculated features, is not yet sufficient to attempt a full and definitive classification 
for the drivers and dynamic network attributes associated with each cancer 
subgroup.   
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Chapter 6. Epilogue 
In this thesis, I have reported on ccRCC in terms of its biology and prognosis using 
multi ‘omics’ datasets. Primary aims were to evaluate the catalogue of genetic 
alterations, understand the molecular mechanisms driving ccRCC evolution, come 
up with better molecular markers to improve prognostication and even to predict 
novel therapeutic avenues. Chapter 3 covered the biology led analyses. Chapter 4 
covered the prognostic analyses, with both these chapters culminating in a 
description of the molecular mechanisms of the lead prognostic marker, namely the 
ccA/ccB gene expression subgroup, described in Chapter 5.  
 
Today, NGS technologies permit analyses at nucleotide resolution for both protein 
coding regions (exomes) and whole genomes. Through deep coverage, it is 
possible to detect mutations that occur in even a small population of cells, allowing 
the subclonal architecture of tumours to be inferred (Nik-Zainal et al.). Over the 
past few years, this has led to the identification of multiple new ccRCC genes, 
increasing our knowledge of the disease. Our research (Chapter 3) as well as well 
as that of others (The Cancer Genome Atlas Research Network, Gerlinger et al.), 
have established loss of chromosome 3p and biallelic mutations in the VHL gene 
as the two key events in ccRCC. Moreover, mutations in major chromatin modifiers 
such as PBRM1, SETD2 and KDM5C were also verified as key recurrent events. In 
terms of SCNAs, amplification of chromosomes 5q, 8q, 12 and 20q as well as 
deletion of chromosomes 9p, 8p and 14q were observed to be potential driver 
events. At the gene expression level, we were able to confirm the existence of at 
least two subgroups for ccRCC (Brannon et al.). Further gene expression analysis 
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showed ccRCC to be primarily a metabolism driven cancer and that the more 
aggressive subgroup has higher deregulation of immune signalling pathways 
(Chapters 3 and 5).  
 
However, inter-patient as well as intratumour heterogeneity, especially taking into 
account the fact that most genetic events in ccRCC are rare, raises important 
questions as to the pathogenesis of the cancer. Inter-patient heterogeneity has 
been thought to be the most common reason for the diversity in patient outcomes 
even between tumours with the same histology, stage and grade (Gerlinger et al.). 
Nevertheless, computational network analysis algorithms have been successfully 
utilised to study cancer and disease genome previously and therefore provided the 
platform to explore these rare events in ccRCC. In Chapter 3, multiple state-of-the-
art algorithms were used, leading to the finding of multiple chromatin regulators as 
the major players in ccRCC biology. While this has been observed by others (The 
Cancer Genome Atlas Research Network), our analysis on co-altered modules 
further emphasised their role in ccRCC pathogenesis. 
 
Furthermore, in Chapter 3, using the ARACNE and MARINa algorithms, putative 
drivers at the gene expression level were identified. This provided an indication of 
some important genes controlling the gene expression of ccRCCs; however, further 
analysis of these genes is warranted. One important exercise could be to compare 
if any of these drivers are regulated in other cancer types. This may provide 
important clues as to the mechanism of actions of these genes and also validate 
the analysis presented in this thesis.  
 
Compounding this inter-patient heterogeneity further, is the intratumour 
heterogeneity, whereby molecular characteristics vary within individual tumour 
biopsies. ITH complicates the precise molecular profiling of tumours and thereby 
constitutes a major hurdle in identifying optimal patient therapy. Our capabilities to 
detect and characterise ITH have improved significantly as the sequencing 
technologies no longer present the biggest limitation (Gerlinger et al.). 
Nevertheless, the challenge now is to develop optimal sampling technologies that 
will enable the identification of somatic alterations across different regions from the 
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same tumour and associated metastasis, which would enable effective modelling of 
the dynamics of tumour evolution.  
 
Cancer evolution has always been depicted as a linear evolution over time, where 
successive accumulation of alterations provides corresponding increases in fitness 
(Gerlinger et al.). However, work by and with our colleagues has refuted this claim 
and shown branched evolution patterns for 10 ccRCCs that were analysed through 
multiregion biopsies (Gerlinger et al., Gerlinger et al.). Moreover, analyses 
presented in this thesis on assessment of the heterogeneity of the ccA/ccB gene 
expression signature, has shown heterogeneity for this signature within individual 
tumour regions (Gulati et al.).  
 
In terms of prognostic biomarkers, as shown in Chapter 5, 17 out of the 28 
published genetic and transcriptomic prognostic ccRCC markers could be validated 
in logrank and competing risk analysis as predictors of CSS for an independent 
validation cohort. Of those, only the ccB gene expression signature was significant 
in MVA. Tumour stage was the only other independent predictor of CSS in MVA. 
Importantly, the ccA signature identified patients with Stage I ccRCCs who had an 
excellent prognosis with no cancer specific deaths over more than 6 years of follow 
up. The ccA/ccB signature was also significant in MVA with the established SSIGN 
prediction model, demonstrating that this molecular marker can add additional 
information to one of the best currently available predictors based on clinical and 
pathological information. Thus, the ccA/ccB signature could refine personalized 
follow up strategies or stratification into adjuvant therapy trials. The novel 
ClearCode34 signature is based on the ccA/ccB signature but can be assessed 
from 34 instead of 110 genes. The performance of this new marker was slightly 
inferior but it may nevertheless be valuable as clinical adoption may be easier 
(Gulati et al.). 
 
Alternatively, as discussed in section 1.4.2 of the Introduction, methods combining 
network analysis with cox regression analysis (NetCox) can be employed to build 
more robust prognostic signatures. NetCox based strategies may prove to be an 
effective pipeline to overcome the problems associated with rare genetic alterations. 
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It also provides a method to combine different transcriptomic and epigenetic data 
types such as somatic mutations, SCNAs, methylation data, and RNA-Seq data. 
 
Therapeutically speaking, several actionable driver genetic markers were shown to 
be subclonal, for example mutations in the MTOR gene (Gerlinger et al.), thereby 
raises questions as to the suitability of these markers as therapeutic targets. It has 
been suggested that targeting the alterations on the trunk (ubiquitous alterations) 
may be an effective clinical strategy (Yap et al.); however, thus far identified 
definitive ubiquitous events in ccRCC are limited to mutations in VHL gene and loss 
of chromosome 3p. Targeted therapies against VEGF, which is downstream to VHL 
mutations, have been previously tested, but as discussed in the Introduction, these 
are no longer thought to be the most effective route for treatment.   
 
The work described here (Chapter 6), along with the work of others (Brannon et al.), 
has also shown that the aggressive ccB subtype is associated with genes involved 
in vascular, immune response, inflammation, cell cycle progression, and 
proliferation pathways. It has been suggested that this may explain the 
ineffectiveness of existing targeted treatment strategies as they mainly tackle 
angiogenesis pathways; hence these treatments might preferentially target 
vascularised tumours and are in turn ineffective in the treatment of the highly 
aggressive hypoxic renal cell carcinomas (Kroeger et al.). Likewise, targeting 
multiple alterations from different subclones might also provide more effective 
treatment strategies and help in improving outcomes. Furthermore, immune 
therapies which are independent of the heterogeneity of single target genes have 
been suggested to have potential as they may overcome ITH (McGranahan and 
Swanton). Indeed, before the emergence of antiangiogenic targeted therapies, 
immune based therapies were the method of choice for metastatic ccRCC care. 
Curative responses had been observed for IL-2 based therapies, whereas only 
delayed progression has been shown for targeted therapies (Fyfe et al., McDermott 
et al., Yang et al.). Recently, there has been a resurrection of immune therapies for 
ccRCC in the form of immune checkpoint inhibitors, which have shown good results 
for melanoma and are now in clinical trials and show promising early stage results 
(Naidoo et al., Topalian et al., Yang et al.). A recent review also comprehensively 
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assesses the progress of PD1/PDL1 inhibitors for Urologic cancers (Carosella et 
al.). 
 
Further extending on the topic of prognostication models, recently, Rini and 
colleagues (Rini et al.) investigated the association between outcome post-
nephrectomy for ccRCC patients and the expression levels of 732 genes in a 
cohort of 942 cases. They selected 11 best performing genes that represent key 
ccRCC pathways, combining them with 5 reference genes to develop a recurrence 
score. They then validated this score in a cohort of 626 cases. 
 
To address ITH, Rini et al. (Rini et al.) focused on 8 cases. They used two 
representative formalin-fixed paraffin-embedded (FFPE) blocks for each case and 
sampled 3 sections from each block. They concluded that little or no intratumour 
heterogeneity was associated with their score. However, in our analysis of more 
extensively sampled, albeit more advanced-stage tumours (Gerlinger et al.), we 
observe pervasive intratumour variability of expression of the 11 genes from the 
Rini score (Figure 6.1). Thus, our analysis does not support the authors’ conclusion 
that this transcriptomic signature is a truncal event that can be fully captured in a 
single biopsy approach (Gulati et al.). 
 
 
Chapter 6. Epilogue 
 
163 
 
 
Figure 6.1: Heatmap based on hierarchical clustering of multiple regions from 
10 tumours (Gerlinger et al.) based on the 11 cancer related genes from the 
Rini score (Rini et al.).  
Columns represent tumour regions (n=63) and rows correspond to the genes 
(n=11). Regions derived from the same tumour (coloured identically) do not cluster 
together, demonstrating intratumour heterogeneity with respect to the expression of 
the 11 genes. Specifically, based on EDNRB expression Region 1 (R1) from 
patient EV002 shows down-regulation while the remaining regions show varying 
degrees of up-regulation; based on IL6 expression Region 2 (R2) from patient 
RMH004 shows strong up-regulation while all other regions show down-regulation.  
 
Besides our work on the ccA/ccB gene expression signature validating as the only 
biomarker adding prognostic value over and above the clinical parameters 
available for the TCGA cohort (Gulati et al.), ClearCode34, as discussed above, 
which is based on the ccA/ccB signature, has been shown to be a significant 
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predictor of RFS (Brooks et al.). While the Rini score is based on the expression of 
16 genes, ClearCode34 is based on a 34-gene signature. Both the Rini score and 
the ClearCode34 model have been independently validated and add value to 
recurrence predictions. However, while the Rini score has been developed based 
on RT-PCR data, the ccA/ccB signature was developed based on microarray data, 
and validated using RNA-Sequencing data. There are inherent differences in these 
methodologies both in terms of the read-out and expression normalisation. 
Therefore, it would be worthwhile to compare both signatures in the same cohort, 
profiled by the same technique. This should enable an assessment of the most 
robust signature and its clinical applicability.  
 
The scoring scheme devised by Rini et al. is commendable. Whilst we have shown 
the existence of heterogeneity for both these signatures, it is yet to be established 
as to which of them would be more robust against the background of ITH. Caution 
is therefore recommended when commenting on the relative contribution of tumour 
heterogeneity to prognostication models. 
 
These data suggest some interesting avenues for research. Despite ITH, the ccB 
signature out performs every other candidate biomarker in this analysis. It is 
currently unknown whether a tumour with a small ccB component has a similarly 
poor prognosis to an identical size tumour, which is dominated by the ccB signature. 
If the absolute size of the poor risk clone, irrespective of the entire tumour 
population, is the most critical parameter, then ITH may be less problematic in 
small tumours as the chance of analytical techniques sampling the high risk cell 
population would be high. However, detection of a poor risk ccB clone in larger 
tumours may be more difficult unless the entire tumour is sampled or dominated by 
the ccB signature. These considerations demonstrate that insights into the impact 
of ITH on clinical outcomes are limited, raising important questions regarding the 
clinical interpretation of subclonal abundance and how heterogeneous tumours can 
be better profiled for biomarker discovery and precision medicine.  
 
All the analyses presented in this thesis underline that the challenges lying ahead 
of us are linked to sampling technologies and how they can improve both 
prognostic models as well as understanding how tumour clonal heterogeneity 
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impacts upon clinical outcome. How cancer subclones compete, adapt, and evolve 
through the disease course in relation to therapy, is an area of unmet clinical and 
scientific need.  Multiple samples from the same tumour are imperative for the 
determination of the most aggressive molecular signature or subclone within the 
tumour. A major effort has been launched in this direction known as the Lung 
TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx], 
ClinicalTrials.gov number, NCT01888601), which is a prospective study in primary 
non-small cell lung cancer (NSCLC). This study, aims to define the genomic 
landscape of NSCLC and to understand the impact of ITH on therapeutic and 
survival outcome through multiregion and longitudinal tumour sampling and 
sequencing (Jamal-Hanjani et al.). While this methodology was initially proposed 
for the TRACERx trial for Non-small cell lung cancer, our colleagues are now 
implementing this for ccRCC as well (Soultati et al.).  
 
While efforts such as TRACERx are commendable, longitudinal sampling for solid 
tumours presents greater problems both in terms of finances and discomfort for the 
patient. Non-invasive sampling methods such as circulating tumour cells (CTCs) 
and circulating tumour DNA (ctDNA) are increasingly becoming popular as proxy 
measures for tumour biopsies. While solid tumour biopsies remain the gold 
standard for tumour characterisation, the evolving demands of precision medicine 
require the development of more real time assays which can enable tumour 
evolution studies (Mateo et al.). CTCs shed from tumour cells into the blood stream 
are extremely rare (Allard et al.). Metastatic tumours are more likely to have higher 
counts of CTCs in the blood stream (Tanaka et al.), and primary tumours 
undergoing treatment have also shown the existence of CTCs, reflective of the 
probability of recurrence of disease (Hofman et al.). 
 
Studies have been successful in showing the correlation between the number of 
CTCs in the blood stream and patient prognosis for metastatic disease for prostrate, 
breast and colorectal cancer (Cristofanilli et al., de Bono et al., Cohen et al.); 
promising results are also being seen in other cancer studies, for example, lung 
(Krebs et al., Hiltermann et al.), melanoma (Rao et al.), head and neck (Nichols et 
al.) and pancreatic cancers (Han et al.).  Furthermore, CTCs have been shown to 
be promising biomarkers for early stage diseases in colorectal (Iinuma et al.) and 
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breast cancers (Rack et al.), establishing that enumeration of CTCs is a powerful 
prognostic tool.  
 
Moreover, profiling of DNA and RNA from CTCs can enable extensive longitudinal 
studies evaluating the molecular landscape of the cancer, intratumour 
heterogeneity and the response of the cancer top therapy. Indeed in multiple 
cancers, targeted approaches have revealed tumour specific SCNAs (Shaw et al.), 
mutations driving drug response (Diaz et al.).  Whole exome and genome 
sequencing has revealed the clonal structure of the primary tumour (Chan et al.), 
variant selection by therapy (Murtaza et al., Dawson et al.) and de-novo genomic 
rearrangements (Leary et al.).  
 
While questions regarding the extent to which ctDNA is representative of tumour 
DNA present some obvious caveats, the benefits in terms of sampling and ease of 
analysis and the obvious associations seen with prognosis warrant further studies 
to evaluate and develop the clinical applicability of CTCs and ctDNA. Both the 
above mentioned longitudinal trials are incorporating the serial collection of blood 
samples in their assessments and are working on evaluating the utility of ctDNA to 
study disease burden and progression. Such studies will provide unparalleled 
platforms to study cancer mechanisms and offer insights into further advancing 
cancer therapy and personalised treatment opportunities. 
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Appendix 
A. GO overrepresentation analysis: Tumour vs. Normal 
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C. MCODE Clusters 
 
C
lu
st
er
 
Genes 
C
lu
st
er
 1
 RPS24,RPL5,RPL22,RPS13,RPS21,RPS3A,RPS3,CUL1,RPL4,NOP56,RPL7,EIF2AK2,VC
AM1,RPS11,RPL19,RPL18,RPS5,RPS2,RPLP0,RPL31,RPL30,CAND1,RPS27A,RPL18A,R
PL10A,RPL11,RPS26 
C
lu
st
er
 2
 RPLP0P6,FN1,RPS19,RPL23A,RPSA,RPS23,ESR1,RPL23,RPS4X,RPS16,RPL14,RPS6,R
PL37A,SLC25A5,EEF1A1,ITGA4,RPL6,CSNK1A1,RPS8,ILF3,COPS5,RPL8,UBL4A,RPS7,
RPL10L,RPS15A,RPL24,CUL5,RPS14,CDK2,RPL3,RPL17,FBL,RPL15,PAN2,RPS20,RPL
21,RPL9,NHP2L1,RPL12,HNRNPM,RPL7A 
C
lu
st
er
 3
 
PSMB6,GNL3,PSMD14,PSMB2,ADRBK1,MED4,MED29,PSMD4,ANAPC5,MED13,MED10,
CDK8,PSMD12,STK25,PSMD8,DHX9,PSMC4,TRAF6,EIF6,RPS6KA1,RPS29,MAP1LC3A,
MYBBP1A,PSMA6,MAP3K14,ICAM1,RPS27,HNRNPK,RPS17,RPL32,FAU,PIK3R2,MED12
,UCHL5,PSMA7,RPS9,ANAPC7,RPL36,CDC23,RAD23A,PABPC1,SND1,PSMD2,RPS10,F
KBP8,ZC3H13,PSMD7,PSMB7,PSMC6,IGSF8,ESR2,PSMD11,PSMD13,PSMA5,PSMC5,M
KI67IP,PSMD1,PSMB3,PSMB1,CDK19,PSMC3,PSMA1,MED24,PSMB5,USP14,PSMA2,M
ED14,PSMD3,PSMC1,MED16,MED30,MED25,MED26,MED28,HNRNPD,NOS2,PRKAA1,P
SMC2,SIRT7,HSP90AB1,MED19,PHKG2,MED9,TUFM,MED18 
C
lu
st
er
 4
 
MRE11A,UBE2D1,DCAF11,IGF2BP3,MED17,TUBA4A,CCT8,RTCB,COPS7B,EEF2,DDB2,
ERBB3,RAD50,NFKB2,SYNCRIP,CDC27,HNRNPR,COPS2,RPL27A,EIF4A3,SF3B2,CBL,
NPM1,RPL29,DDX1,RPS18,ANAPC11,CD81,RPL35,RPS15,CDC26,ACTB,SOS1,TRIM33,
FBXO5,DCAF8,BUB1B,APC2,ADRM1,ANAPC16,MED21,RPLP2,RPL38,CDC16,DCUN1D1
,FZR1,KRT2,SRSF5,CAMK1,TRRAP,STAU1,ANAPC4,EEF2K,OXSR1,STK4,CRK,TADA2A
,TAF15,PRKACB,PTTG1,FBXW7,RAD21,GPS1,PLCG1,MED15,PRPF19,EPAS1,DDA1,RF
WD2,SRSF1,ARRB2,EIF3CL,MDC1,UBE2C,TSR1,HNRNPU,ANAPC2,GNB2L1,HNRNPL,E
RBB4,HNRNPH1,EFTUD2,COPS8,COPS7A,SH3KBP1,HNRNPA1,FTSJ3,COPS4,COPS3,
TP53BP1,NOP58,CDC20,CCNB1,MED27,RFC1,PSMD5,SNRPD3,U2AF2,ANAPC1,MOV1
0,MED8,SMURF1,ERCC8,CDC5L,MED1,DDB1,PRKACA,FLT1,SF3A1,n/a,RRS1,EBNA1B
P2,UBD,MED11,HNRNPA0,PSMB4,LYAR,EWSR1,KRT10 
C
lu
st
er
 5
 CUL4B,PSMA3,RPS28,RPS12,RPL13,PSMA4,TP53RK,RPS25,CSNK1E,CUL2,GABARAP
L1,RPL27,VHL,RPLP1,NEDD8,CSNK2A2,GABARAPL2,GABARAP,NOP2,ILK,RPS27L,UB
C,RPL10,RIOK2,ILF2,NCL,PSMD6,YWHAZ,CUL3 
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C
lu
st
er
 6
 
TAF10,WIBG,HNRNPF,ABCF1,STAT5A,PPP4C,PDGFRB,SNRPD1,TAF13,HNRNPUL1,C
CT2,DHX15,CCT4,SRSF2,CCT7,SNRNP70,DDX17,IRS2,SRSF4,TAF2,CD2AP,SF3B3,SR
PK1,RELA,STRN3,STRIP1,PHF10,TAF8,TCP1,ERBB2,TAF7,TCEB2,LRR1,TCEB1,IKBKB,
SMARCA2,INPP5D,ARID1B,YY1,MED6,ARID1A,MED23,HRAS,IGF1R,INSR,PTK2,ACTL6
A,YWHAG,SRRM2,ZAP70,HSPA1L,SFPQ,EZR,HCK,EPOR,TAF3,SNRPA1,HNRNPA2B1,
EIF2B3,PTK2B,PML,ARID2,PIK3R1,CHD7,SYK,PBRM1,STAT5B,TOP1,PTBP1,CRKL,MAP
3K7,MAP1LC3B,KIT,SREBF1,SNRNP200,EP300,LEF1,NCOR2,SF3B1,CBLB,FGFR1,RUN
X1,CTR9,SRSF9,HNRNPH3,TAB2,TAF4,PRPF40A,BCAR1,RPL28,EFS,FBXO25,CTTNBP
2NL,NMT1,TRA2A,NELFB,PAF1,HSP90B1,HNRNPH2,PNO1,BCR,SRA1,DLGAP2,RBMX,
HNRNPDL,CTDP1,ASAP1,RTF1,CREBBP,RBX1,EPHA2,LEO1,PPP2R2A,MLH1,CDC73,R
NPS1,CTTNBP2,MOB4,BLM,PA2G4,KAT2A,IRS1,BUB3,MET,BYSL,PPP2R1B,ABL1,CSF1
R,HNRNPA3,MAGEB2,RUNX2,DLGAP1,SNRPC,EIF2B2,RBM4,FEM1B,TAF11,DDX5,SMA
D7,HSPD1,RBM39,MAPK14,RALY,ZBTB16,INPPL1,LYN,MSH2 
C
lu
st
er
 7
 TRAPPC8,TRAPPC2,TRAPPC3L,TRAPPC10,TRAPPC11,TRAPPC9,TRAPPC3,TRAPPC4,
TRAPPC12 
C
lu
st
er
 8
 COG4,COG6,COG8,COG1,COG3,COG2 
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C
lu
st
er
 9
 
ERC1,ELL2,TMED9,TXN,GTF2H2,VAV2,CSF3R,CCT3,AP3M1,PPP2R5A,TRIM63,AP3S1,
STK11,PTPRE,KIAA1279,GHR,MLLT4,DOCK5,AP3S2,BIRC5,GAB1,STAT2,EZH2,ATXN2,
ANK1,ZNF259,COPG1,SPEN,KCNA2,SPC25,KCNA1,USP8,SOCS7,RTN4,ALB,PTPRS,ND
UFV1,ARPC5L,HOOK3,NFYA,CCNA2,TNRC6C,GRB7,KRT3,CREM,MDH1,SYN1,MAP2K5
,CASP8AP2,HECTD3,RYK,SUMO3,WHSC1,DSG1,COG5,SEC24D,PTPRA,AKTIP,HSPB1,
TBPL1,RBL1,GTF3C5,DNAJC7,SHMT1,ZC3H15,TAB1,IL4R,AGL,HIST1H4A,IL2RG,EIF3B,
TSEN34,MIS12,PDGFRA,PAWR,MIER1,KHDRBS1,ATF4,AARSD1,NKX2-
1,NSL1,CD247,TOR1AIP1,RNF8,GINS3,MORF4L1,ARAP1,NDUFS8,COMMD1,KIAA1598,
PIAS2,BCL11B,ITGB3,PTPN18,SERBP1,RASA1,TAF1B,LAT2,CCP110,SCNN1A,XRCC6,A
RNTL,KANK2,PAG1,EGF,UFC1,SLC25A3,USP9X,TRMT112,SSSCA1,NEURL4,RAB3GAP
1,MAP3K5,EIF3J,ARHGEF7,TAF1L,KRT73,AHR,DCD,HIST1H1C,MYCBP,EIF5,EIF4G2,TF
DP2,DAPK3,TARDBP,APPL1,PRKCE,CBX5,GTF2B,TEK,TRIM37,ZNF217,PRPF4,ACTR3
B,DCC,TPM3,SEC24A,ATP5B,CEP290,SH3GL1,CEP76,EEF1B2,SUV39H2,CHERP,CD22,
TERF2,EHMT2,CSTF3,CXCR4,LIG4,TTC8,CEP97,EGFR,CCNT1,THOC1,PTGES3,E2F1,B
BS5,GTF2E1,ICT1,GTF3C2,IRAK2,PDHX,BBIP1,SLC1A5,LRSAM1,USP5,HIST4H4,DOK2,
PPP2R5D,SET,CHEK1,TOPBP1,TOPORS,SART3,CALU,MRPS15,PDLIM5,GNE,NCKIPSD
,PRDX6,CBX1,PIAS3,SNX6,RPL34,ALDOB,USP22,PRMT5,SCNN1G,AP1M2,NDC80,RQC
D1,CNOT3,CNOT2,LAP3,CNOT1,NUF2,GSS,OGFR,BECN1,KDM4A,GTF2H3,EIF2S1,SRC
AP,TRAT1,STUB1,MLLT1,CBFA2T2,GTF2H4,PRMT3,GRB2,PAX3,CD2BP2,ARPC2,PNMA
1,BBS12,TUT1,GTF2H5,FES,TP53,TIAM1,LCP2,RBM7,ARPC3,PHC2,ERCC2,RAB3GAP2,
KDM5B,IQCB1,SRSF11,DNMT1,BRCA1,AFF1,HOOK2,VARS,BAP1,CBFA2T3,BRD8,SAE1
,SKAP2,EPM2AIP1,USP25,SLC7A11,NEDD4L,MYH10,PARD6A,KRT9,ITK,SUPT3H,BMPR
1B,TNFAIP3,NINL,SPC24,SPP1,TDG,HP1BP3,MCM10,IL1R1,COG7,NR4A1,TPI1,UBQLN
2,AURKA,IRAK4,LAGE3,COPB2,KDM5A,KHDRBS2,KCNA3,UBXN7,ADAM15,MYD88,TBC
B,PPARD,MECP2,SERTAD1,ARPC1A,CCND2,ARCN1,COPG2,TAF9B,ADRB2,CDK4,ATF
7IP,SPTAN1,ARHGAP32,PEBP1,TSC1,KAT5,PELI1,SOCS3,BBS4,MSX1,SLC9A2,ATRX,H
DAC3,CTBP1,EXOC7,WIZ,DDX39B,CDC34,MEPE,SKIL,KMT2A,SMARCA5,MERTK,AIFM
1,OGDH,USP10,EIF4G3,PPP5C,NCOA2,GRAP2,CLOCK,FLNC,TAF9,FLNB,AP2M1,SP10
0,ZMIZ1,UBASH3A,DNTTIP2,GTF3C4,SH3GLB2,POLR3C,TNK2,CDYL,RPS6KA5,BBS1,F
HOD1,BBS7,NUDCD3,PSMG1,PRKD1,RANBP3,APEX1,ERCC5,THOC3,PABPN1,FARSB,
ANKRD28,DFFA,MAPK8IP1,ERC2,MRPS27,TRAF5 
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C
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 1
0 
LUC7L3,EIF3E,EIF4A2,HSPBP1,DIS3,RANGAP1,PPME1,NXF1,SRSF3,OGT,LEPRE1,ALA
D,TNFRSF1A,OSGEP,AGFG1,BAZ1B,INO80E,EIF3L,G3BP2,FADD,TRADD,SRRM1,EPS1
5,RBM14,SMARCD2,ARPC4,ALYREF,NCOA3,EXOSC9,ORC3,RIPK1,RIPK2,SIRT2,TNFR
SF10B,PPP2R4,HIST2H2BE,AP2B1,HIST3H3,AR,VCP,CDC7,LPP,NAP1L4,SMARCB1,JA
K2,PRMT1,SAP30,RRN3,LARS,PINX1,RNF11,TONSL,TPD52L2,TAF1A,MCRS1,TAF1C,D
YRK2,TFPT,EPRS,VPRBP,NR3C1,ETS1,ORC6,PPP2CB,EIF1B,SRPK2,SIN3B,PPP2R2D,
EXOSC6,MMS22L,NFRKB,ACTR8,PANK4,DBNL,INO80B,TAF1D,H3F3A,U2AF1,PDIA6,IN
O80C,CCT6A,AARS,RBM25,EFTUD1,EXOSC5,ACTR5,AICDA,PDS5A,WAPAL,SKIV2L2,
WFDC5,HDAC9,CDCA5,STAG2,ORC5,EIF3A,PCBP1,EXOSC1,TAF12,NR2C1,KDM1A,EX
OSC7 
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C
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 1
1 
TNKS2,FAF1,CHM,GSTK1,XPO7,SEPHS1,SLC9A3R2,BFAR,RAB8B,MGA,EDC3,COPB1,
NUDCD2,NUB1,DUSP1,KRT15,COL1A1,C12orf10,FKBP4,RIC8A,SCPEP1,ID3,GBF1,GPA
A1,DDX4,SSU72,PRPH,PPP2R5B,CCNB2,EIF2B1,CAV1,BAI1,GINS2,SIK2,RORC,HAUS2,
BHLHE40,CASP8,HAUS4,SPSB2,PIGK,HAUS8,HMGXB3,RCOR3,LMNB1,KPNA2,S100A7
,MGRN1,HAUS3,POLD1,NT5C2,HAUS5,LAMTOR2,HAUS6,ELN,POLD2,IKZF4,ALDH7A1,
CLN3,UNC45A,TRPV4,FKBP10,KPNA4,HIRIP3,B4GALT1,AGO3,STIP1,TGFB3,XRCC1,S
MARCAD1,VRK2,PCK2,RB1,UBE2Q2,LAMTOR5,TXNRD1,CRYZ,MDM4,PIH1D1,WHSC1L
1,MRPL24,DHX8,AATF,PIN1,GRM5,SLC25A6,SFN,MKRN3,GMNN,ENG,FERMT2,POLI,T
BL1XR1,UBE2U,PKP2,KANSL1,FUBP1,NF1,YWHAB,MEF2A,ATF3,MSH3,KLC2,DDAH2,M
APT,CCNH,TELO2,TNF,PTPRU,TTI1,EIF3D,CCNG2,JUNB,IMPDH2,MARCH7,ITGA5,NUP
210,PCGF3,TRIM74,RUVBL1,ATR,APP,ARNT,UTP14A,MRPL4,NOSIP,ACD,TUBB2A,ARH
GAP5,EFNB2,SMC3,DEPTOR,TPBG,MLST8,MALT1,ERCC6,BRD4,MAP3K2,CS,FRK,CLA
SP1,SPSB1,GSR,EPHA3,INADL,KYNU,STK33,LRP6,AXIN1,RASL12,PPFIA1,PLD2,ATP2A
2,TRAF7,HSPA4,MAPRE1,DDX42,ELAC2,TGFBR3,TUBB,PLIN3,ABI2,UBE2G2,UBE2B,M
DM2,PRDM16,CDC37,PPFIA3,STK3,MRPL42,PPFIA2,KRT85,KCNJ4,PPFIBP1,EPB41L5,
SEPT1,PIGU,PIGT,PTPRD,ACAT1,PFKP,UBOX5,IFT57,BMP7,RNF10,CDK7,RNF2,PPP2
R2B,MRPS5,RING1,INHBA,TAGLN,TRAIP,GNAO1,CDK12,KIF3A,PRKD2,LIN7A,CASK,G
OPC,ANKMY2,OS9,HOMER3,VDAC2,GET4,ATF2,OTUD7B,TNFRSF10D,ATP6V1E1,AGO
4,TRIM23,TRIM65,DBN1,YWHAH,RHOQ,GLRX3,EFEMP2,NLRP2,CTBP2,PIGS,RAB7A,H
SPB2,SDHB,SLU7,PFDN1,ARHGEF1,PFN1,TSSK6,CD46,HERC4,REL,WASF1,CD9,BCL2
,CDKN1A,DNMBP,CAPNS1,SGK3,CNBP,HAUS1,SUGP1,RBBP6,ATG5,AIP,CARD9,LCK,
ATIC,CFH,LDHA,SOCS6,USP21,PICALM,CASP2,RUFY1,CLK2,ATP6V1D,HIF1AN,PIAS4,
CTNNBL1,UBE2D4,SUV420H2,SMAD3,UNK,ZFYVE19,KSR1,LTBR,NRD1,SMURF2,PPID,
EIF2B5,NFIA,HDAC2,MARK3,PKN1,MKNK1,TNFSF14,C3,SP3,NUP155,CSK,CWC15,MRP
S35,SULT1A1,ECE1,COPZ1,GJB1,NEFH,CRELD2,FXR2,THRA,CLU,RBBP8,RNF7,DCAF
6,PARD6B,CHD4,MNDA,BCL2L11,PRDX3,LIMA1,PGK1,CTGF,PRKAG2,KCNJ12,SAMHD
1,PFKL,FOXH1,DACT1,TRPC1,CFTR,PAFAH1B1,MAPK9,NLRP12,RANBP2,ACTN4,ZMY
ND11,KDM2A,RNF126,KIF3B,MYOZ1,SNX5,SMEK1,DHPS,ITGA2,DPP8,DDX39A,KATNB
1,KIF2A,CLSTN1,CENPF,PHLDA1,HAX1,UBE2H,KPNA1,UGGT1,FRYL,ATP6V1B2,MCM3
AP,ZWINT,BRAP,FOXM1,CCND3,WARS,PDCD6,CCAR1,GNL2,RAN,ADSL,CAD,M6PR,T
UBA1A,CPT1A,BCOR,PTPRK 
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D. Ordered Consensus NMF clustering maps for k=2 for gene 
expression classifying panels included in the prognostic 
study 
 
 
Ordered Consensus maps for k=2. Each heatmap depicts the stability of consensus 
clustering assignment for two clusters. 
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E. Multivariate analysis results - hazard ratios and p-values for 
all assessed variables ranked according to order of 
elimination.  
All variables which failed validation are highlighted in red and final significant 
variables are highlighted in green. 
 
Variable Hazard Ratio (C.I.) p-value
EDNRB expression 
< median 1.00 (Ref) 0.972
≥ median 0.98 (0.44 – 2.23)
Beulet signature
Cluster A 1.00 (Ref)
Cluster B 1.52 (0.78 – 2.96) 0.211
Cluster C 0.95 (0.40 – 2.30) 0.915
12 Amplification 1.00 (0.46 – 1.91) 0.882
BAP1 non-syn mutation 1.08 (0.56 – 2.09) 0.819
4p  Deletion 1.13 (0.54 – 2.37) 0.737
Lane signature
Indolent 1.00 (Ref) 0.748
Aggressive 1.13 (0.54 – 2.38)
22q Deletion 1.24 (0. 58 – 2.67) 0.578
8q  Amplification 1.27 (0.59 – 2.68) 0.536
TGFβ signature
Low expression score 1.00 (Ref) 0.415
High expression score 1.25 (0.72 – 2.18)
TP53 non-syn mutation 1.67 (0.54 – 5.19) 0.368
Furhmann Grade
G1/G2 1.00 (Ref)
G3 1.45 (0.77 – 2.70) 0.243
G4 1.87 (0.87 – 4.02) 0.107
9p Deletion 1.35 (0.82 – 2.23) 0.232
20q focal Amplification 0.69 (0.40 – 1.20) 0.194
Zhao signature
Cluster 1 (good) 1.00 (Ref) 0.246
Cluster 2 (poor) 1.51 (0.75 – 3.00)
Kosari signature
Non - aggressive 1.00 (Ref) 0.137
Aggressive 0.62 (0.32 – 1.16)
TSPAN7 expression
< 33 percentile 1.00 (Ref) 0.341
≥ 33 percentile 0.76 (0.43 – 1.34)
Tumour stage
Stage I   1.00 (Ref)
Stage II   3.48 (1.20 – 10.06) 0.022
Stage III   4.61 (1.93 – 11.00) <0.001
Stage IV 18.01 (7.89 – 41.12) <0.001
Chrom 19 deletion 4.18 (1.27 – 13.69) 0.018
ccA subgroup 1.00 (Ref)
ccB subgroup 2.99 (1.87 – 4.80) <0.001
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F. Multivariate analysis with ClearCode34 signature 
 
 
Variable Hazard Ratio (C.I.) p-value
Tumour stage
Stage I   1.00 (Ref)   
Stage II   3.92 (1.36 – 11.32) 0.012
Stage III   4.86 (2.51 – 13.90) <0.001
Stage IV 19.32 (8.44 – 44.21) <0.001
ClearCode34
ccA subgroup   1.00 (Ref) <0.001
ccB subgroup   2.23 (1.39 – 3.60)
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G. Consensus NMF clustering analysis for multiregion biopsy 
dataset. 
 
A. Consensus NMF clustering matrix for multi-region biopsy dataset for two clusters 
(obtained from http://genepattern.broadinstitute.org/), B. Heatmap shows 
consensus NMF clustering analysis for the multi-region biopsy dataset using gene 
expression data of 107 ccA/ccB signature genes. Tumour regions assigned to the 
ccA or ccB prognostic subgroups is indicated by coloured bars at the top of the 
heatmap.  
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H. MSigDB Overrepresentation analysis for ccA vs. Normal 
Kidney 
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I. MSigDB Overrepresentation analysis for ccB vs Normal 
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